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This dissertation proposes a family of algorithms for deriving signatures of mutually 
associated features, to which we refer as attractor metafeatures, or simply attractors. Specifically, 
we present multi-cancer attractor derivation algorithms, identifying correlated features in 
signatures from multiple biological data sets in one analysis, as well as the groups of samples or 
cells that exclusively express these signatures. Our results demonstrate that these signatures can 
be used, in proper combinations, as biomarkers that predict a patient’s survival rate, based on the 
transcriptome of the tumor sample. They can also be used as features to analyze the composition 
of the tumor.   
Through analyzing large data sets of 18 cancer types and three high-throughput platforms 
from The Cancer Genome Atlas (TCGA) PanCanAtlas Project and multiple single-cell RNA-seq 
data sets, we identified novel cancer attractor signatures and elucidated the identity of the cells 
that express these signatures. Using these signatures, we developed a prognostic biomarker for 
breast cancer called the Breast Cancer Attractor Metagenes (BCAM) biomarker as well as a 
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Chapter 1 Introduction 
1.1 Background 
Cancer remains one of the major causes of death in the world [1] but lacks universally 
effective diagnostic and therapeutic regimens. Cancer consists of a group of diseases that may 
affect any body part, characterized by the abnormal growth of a group of cells that may invade 
adjacent tissues and metastasize to other organs. Despite the progress in the development of 
therapeutic regimens and diagnostic tools in the last two decades, knowledge of the details of the 
biological mechanisms in cancer to aid in developing diagnostic tools and therapeutic agents is 
still limited. 
The lack of knowledge about biological mechanisms is partially due to the diversity of this 
family of diseases. Knowledge of how the cause of the disease aligns with changes in the 
genome [2] would make it possible to shed light on the biological mechanisms by analyzing 
alterations in the genome of a tumor cell. The characteristics of the family of diseases may differ 
from one organ of origin to another, from one patient to another, even in the same tissue, because 
of its evolutionary nature [3-9]. Many cell subpopulations and underlying biological process are 
involved in the interactional process of the formation of cancer, or oncogenesis, and the 
progression of cancer [10, 11]. Such biological processes involve numerous molecular 
components. 
Such complexity not only obstructs the development of precise tools for diagnosis and the 
discovery of the “universal cure” to the disease, but also hinders the reconstruction of the 
biological mechanism, because conventional research techniques of molecular cell biology are 
only suited for study of one component of the cell at a time, using a small batch of samples. 
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Furthermore, the assessment of the efficacy of a new regimen relies on extensive clinical studies 
and a trial-and-error methodology. 
Recent breakthroughs of high-throughput cell biology technologies enable scientists to 
capture the molecular characteristics of components across the whole genome and many 
pathologic tissues in tractable time and budget. This opportunity provides the ability to study the 
disease by simultaneously analyzing the association of all such molecular characteristics with 
clinical phenotypes and the association of all molecular components with each other, using a set 
of samples that is large enough to ensure sufficient statistical power for analysis. With such 
holistic information about the disease, biologists may be able to model the heterogeneity of the 
disease and reconstruct the underlying biological mechanisms, eventually developing an 
effective diagnosis and treatment regimen with high precision. 
High-Throughput Cell Biology Technologies 
In a biological system, the “central dogma” dictates transfer of genetic information from one 
type of biomolecule containing a biological sequence to another type of biomolecule [12-14]. 
Genetic information is stored in sequences of deoxyribonucleic acid (DNA), which are 
“transcribed” into the corresponding sequences of ribonucleic acid (RNA). The sequences of 
some RNAs are “translated” into the sequences of amino acids. 
In the 1970s, researchers proposed many commercialized technologies for qualitative and 
quantitative characterization of specific biological sequences, some of which remain in wide use 
in cell-biology research. For qualitative methods, the southern blot [15] and the northern blot 
[16] detect specific DNA and RNA sequences in a biological sample. Because a single-stranded 
nucleic acid sequence binds to its complementary counterpart, these methods detect the presence 
of a target sequence using a labeled sequence that is complementary to the target, called the 
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hybridization probe. Later, researchers proposed quantitative reverse transcription PCR 
(RT-qPCR) as a more sensitive alternative to the northern blot [17], suggesting the western blot 
[18] to detect specific protein sequences, exploiting the binding specificity of the antibody to the 
corresponding proteins. For qualitative analysis, Sanger et al. introduced the sequencing method, 
or the chain-termination method, to determine the DNA sequence [19]. The method incorporates 
a special type of labeled nucleotides that can temporarily cease the synthesis of a DNA sequence 
from a template, allowing observations of the order of the nucleotides of the sequence. 
The drawback of these techniques is that they are suited only for interrogating one or a few 
targets in one experiment. Due to the large number of molecular components involved in the 
biological process, modeling the pathogenic process of a complicated disease such as cancer was 
unattainable at the time. 
Researchers developed the multiplex automated versions of these methods in the 1990s and 
the concept of interrogating a large number of targets in one experiment became practical. By 
fixing various DNA hybridization probes onto many microscopic spots on a plane, the 
microarrays massively quantified DNA [20] and later the RNA sequences by incorporating 
reverse transcription. Using bisulfite conversion, which is a procedure that converts the 
unmethylated cytosine residues in the DNA sequence to uracil, the microarrays can quantify 
DNA methylation levels across the entire genome [21]; by incorporating the chromatin 
immunoprecipitation (ChIP) techniques, scientists can use the microarrays to study the 
interactions of the DNA sequence and proteins [22]. Thus, quantifying all DNA, the “genome,” 
all RNA, or the transcriptome, and the DNA methylation levels of the genome, the methylome, 
in a sample became practical for biomedical research, and the field of study using these objects is 
referenced as omics. 
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The massive automation of Sanger sequencing was the cornerstone of the effort to map the 
human genome [23]. Modern high-throughput sequencing systems identify, for each person, the 
exact sequence of the whole human genome and its single nucleotide polymorphisms (SNPs) and 
copy number alterations (CNAs) by comparison with a reference genome. High-throughput 
sequencing methods allow the incorporation of techniques that transform information into DNA 
sequences. The method can be extended to quantify all RNAs by incorporating reverse 
transcription, called RNA-seq [24], to profile DNA methylation levels by incorporating bisulfite 
conversion, called bisulfite sequencing [25], or to investigate DNA-protein interactions using 
ChIP techniques, called ChIP-seq [26]. Recently, high-throughput sequencing methods to 
analyze the sequences in a single cell, such as scDNA-seq [3, 6, 27, 28], scRNA-seq [29-31], and 
scBS-seq [32], became available because the technical difficulty of sequencing using the low 
input of DNA and RNA was overcome. Biomolecular techniques used in single-cell sequencing 
methods were developed specifically for the particular circumstances required to study single 
cells with an extremely limited amount of input. Therefore, the properties of such data are 
different from those of their “bulk” counterparts. 
For the study of many proteins in a sample, biologists proposed several methods such as the 
reverse-phase protein assay (RPPA) [33] and mass spectrometry (MS)-based methods [34, 35]. 
Because the availability of these high-throughput technologies has encouraged efforts on 
profiling and studying new biological samples of all species and health conditions, massive 
amounts of data have been generated. To help archive and share these data, scientists set up 
several database repositories for public access. For the omics data sets of all types of biological 
samples, such repositories are the Gene Expression Omnibus (GEO) [36], the Sequence Read 
Archive (SRA) [37], the database of Genotypes and Phenotypes (dbGaP) of the National Center 
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for Biotechnology Information [38], and ArrayExpress of the European Bioinformatics Institute 
of the European Molecular Biology Laboratory (EMBL-EBI) [39]. For the omics data sets of 
human cancer samples, The Cancer Genome Atlas (TCGA) [40-48], The International Cancer 
Genome Consortium (ICGC) [49], and the American Association of Cancer Research (AACR) 
Project Genomics, Evidence, Neoplasia, Information, Exchange (GENIE) [50] are projects 
dedicated to share data for all types of cancer. 
The data sets generated using high-throughput technologies typically can be presented as a 
matrix, in which the rows and the columns conventionally represent the molecular components 
or the “features,” such as genes, and the samples (or cells) profiled in the study, or the 
“observations,” respectively. The value of each element in the matrix represents the quantity or 
the presence of a molecular component in the particular sample and the distribution of values 
reflects the biological property of the samples. Thus, one can formulate the analysis of biological 
data into a machine-learning framework. In the context of cancer research, using unsupervised 
machine-learning techniques one can discover the features and samples that share similar 
patterns in a data set, such as the functional modules of the biological components or subtypes of 
the disease. If the data set is annotated with the clinical phenotypes of patients, the association of 
biological components with the phenotypes can be clarified and modeled using supervised 
machine-learning techniques [51]. 
Distinct challenges accompany the analysis of these emerging large data sets, such as 
excessive computational complexity. Furthermore, the number of features is typically much 
larger than the number of samples, which affects the reliability of conventional statistical 
methods. The values in the matrix are noisy, due to the stochastic data-capturing nature of the 
technologies, and can be affected by variations, such as batch effects. Each type of data also has 
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its own distinct property. For example, the matrix of an RNA-seq data set is typically sparse and 
suffers from overdispersion, i.e., variance larger than expected [52]. These concerns need to be 
addressed during the analysis and to be considered during the development of new methods for 
high-throughput data analysis. 
1.2 Prior Work on Cancer Signature Identification 
Cancerous cells display several molecular traits that are different from those normal cells of 
the same type. Certain molecular measurements aligned with the pathogenic states of cancer, 
such as the level of a specific protein in blood and the activity of a set of genes in tumor samples. 
These measurements can be developed as indicators of the pathogenic process and predictors of 
the benefit of therapeutic treatments, called “biomarkers.” A type of cancer may be stratified into 
multiple subgroups based on the characteristics of the cells. These subgroups of types are called 
subtypes, and may influence the response to a treatment and the prognosis of the patient. The 
validity of a biomarker may be specific to a particular subtype of cancer. 
Clinical practitioners have introduced biomarkers and subtyping systems to help evaluate the 
benefit of treatment for a patient. For example, for patients in the early stage of certain subtypes 
of breast cancer, some available and commercialized genomic tests are the OncotypeDX test [6], 
Prosigna assay (PAM50) [7], and the MammaPrint test [8]. 
Despite the diversity of pathological manifestations in various types and subtypes and the 
markers that indicate the pathogenic states for each of them, Douglas Hanahan and Robert 
Weinberg proposed that cancer has general unifying capabilities, or “cancer hallmarks” [6]. It is 
reasonable to hypothesize that: 1) some traits of the molecular components are represented by 
particular patterns detectable in biomolecular data sets containing measurements derived from 
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cancer samples; and 2) the molecular components with similar patterns of the traits are involved 
in the same biological process, which may also relate to the pathogenic process. 
Therefore, a discovery path for such universal traits and toward the development of the 
corresponding multi-cancer biomarkers for diagnosis, prognosis, and treatment-response 
prediction can build on computational analysis of the large high-throughput data sets coming 
from biopsies of numerous patients and from many different cancer types. 
Clustering Analysis 
Clustering analysis is a family of unsupervised learning methods that organize the unlabeled 
items in a data set into multiple groups by a similarity metric. Among the clustering methods, 
hierarchical clustering and centroid-based clustering methods have been in wide use in the 
research on cancer signatures. 
Hierarchical clustering algorithms may assign the items into clusters by successively 
partitioning or merging them, according to a similarity measure, often in the development of heat 
maps, which are visualization tools for a matrix of biological data, with the potential to identify 
correlated features as biological signatures and groups of samples as subtypes. For single-cell 
data sets, researchers use such algorithms to identify the populations of cells [9, 53, 54]. The 
signatures found using hierarchical clustering analysis facilitated the development of 
commercialized cancer biomarkers, such as MammaPrint [55]. Hierarchical clustering is an 
intuitive and deterministic method used in helping visualize high-throughput data for presenting 
the modules of correlated molecular components as signatures and similar samples as subtypes. 
Centroid-based clustering methods assume a centroid of each cluster in the data and partition 
the items into these clusters by their similarity with centroids, and refine partitioning in an 
iterative process. The k-means algorithm [56] is a popular realization of a centroid-based method 
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that partitions the items into k clusters. In an iterative process, the algorithm assigns the items to 
the cluster with the nearest mean and updates the centroid of each cluster until it satisfies a 
stopping criterion. A closely related method is called k-medoids, which uses data points instead 
of the mean of the points as the centers and minimizes the sum of distances of the data points to 
their medoids by swapping a medoid with a non-medoid at each iteration. Researchers used a 
realization of the method, PAM, to identify a set of fifty genes that classify breast cancer tumors 
into four subtypes, called PAM50. Parker et al. used the gene set in PAM50 in a commercialized 
biomarker product to evaluate the risk of distant recurrence of breast cancer patients [57]. 
Researchers not only apply clustering analysis to gene expression data, but also to mutation data 
[58, 59], copy number variation (CNV) data [60], and DNA methylation data [61]. To address 
the properties of the emerging single-cell data sets, scientists have proposed multiple novel 
approaches, introduced in Chapter 5. 
An obvious limitation of centroid-based methods is that they require a predefined set of 
initial points. A solution is to randomly select the initial points and repeat the algorithm multiple 
times, leading to a nondeterministic result. To cluster the items without selecting initial points, 
researchers proposed a variation of density-based clustering methods, called DBSCAN. The 
method clusters the items by their density in the space. It has been used to cluster the cell 
populations of the melanoma scRNA-seq data set [62]. A drawback of the method is that it is 
difficult to select an appropriate parameter and assumes similar densities around the groups in a 
data set, which may not always be the case in the biological data. 
The possibilities of identifying coexpression signatures across multiple data sets was 
explored with clustering methods. A method called the cluster-of-clusters assignment (COCA) 
was applied to the data of six omics platforms of 3,527 samples from 12 cancer types of the 
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TCGA data sets [59] identifying a set of cross-tumor-type molecular signatures and classification 
of subtypes. To cluster the features and the samples across data sets, the COCA algorithm 
incorporates the information of platform-specific clusters as a set of binary vectors so the method 
re-clusters them based on these vectors. The documented cancer signatures were then introduced 
to analyze the characteristics of subtypes. Although the method incorporated normalization steps, 
it does not address the distinctiveness of the tissues of origin. Therefore, the subtypes it found 
were approximately consistent with their tissues of origin. The result suggested that some known 
signatures can be found in the samples from different tissues of origin, but the method was not 
designed to identify novel universal signatures. 
As a closely related effort, a clustering method, called CoINcIDE , clusters cancer samples 
across multiple data sets [63]. It evaluates the similarities of each pair of clusters found in each 
data set and assigns weighted edges between the pairs that are close; thus, it finds “metaclusters” 
as subtypes. As a different approach to analyze multiple data sets, researchers have proposed 
methods that model each data set using a mixture model and integrate the data sets using the 
other model for integrative clustering [64, 65]. Because these methods assume structural 
similarity in the data sets [66], they are not applicable to data sets with dramatic differences, such 
as data sets from different types of cancer. 
A different approach is to capture the characteristics of the data sets using mathematical 
models to perform cross-data-set clustering. For example, iCluster [64] uses a joint variable 
model to model multiple data sets and to perform integrative clustering across multiple data sets 
and data types. Multiple Dataset Integration (MDI) employs the Dirichlet-multinomial allocation 
(DMA) mixture model to model multiple data sets [65]. 
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Dimensionality Reduction 
Principal-component analysis (PCA) has been the most popular method to reduce the number 
of dimensions, visualizing the similarities of genes or samples in a data set, making the cancer 
signatures and subtypes observable. PCA projects values through linear transformation to the 
orthogonal planes that maximize the variance of the projection, “explaining” variations in the 
data [67]. A related method is independent-component analysis (ICA), which poses component 
analysis into a task of matrix factorization in which the data matrix is the product of a mixing 
matrix and a set of hidden variables that can be used to identify cancer signatures [68]. 
The t distributed stochastic-neighbor-embedding (t-SNE) method has been gaining popularity 
to address problems of dimensionality reduction. t-SNE minimizes divergence between: 1) the 
original data in which the similarity of a pair of points is defined as a distribution in high-
dimensional space; and 2) a low-dimensional space in which the similarity is defined as, for 
example, a t distribution [69]. t-SNE does not assume linearity in the relationship of data points, 
so it typically outperforms PCA on biological data. In contrast to PCA, t-SNE is not a 
deterministic method and its computational complexity is far larger than that of PCA. Because it 
does not produce a transformation from the original data space to the projected plane, it cannot 
be easily used to process the incoming data. For the analysis of single-cell transcriptome data 
[62], t-SNE is applied on PCA-transformed data so the computational complexity is tractable, 
while including as many dimensions as possible in the analysis. 
A closely related family of methods identifying sets of the similar genes and samples is 
matrix factorization, performed by decomposing a matrix into two or more matrices. 
Nonnegative matrix factorization (NMF) is one of its most widely used variations. It decomposes 
a nonnegative data matrix into two nonnegative matrices that represent signatures as the 
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weighted sum of genes and the levels of signatures in the samples. Matric factorization is 
suitable for analyzing RNA-seq data, because the measurement is the count of molecules. NMF 
has been used in many studies identifying cancer signatures [70]. The drawback of NMF is that it 
is ill-posed, allowing nonunique solutions from the factorization. Furthermore, the values in the 
decomposed matrices do not necessarily represent the significance of the signature, so the 
decomposition cannot be immediately interpreted as cancer signatures [71]. 
Attractor Signatures 
Modules of highly correlated genes, defining a co-expression signature, are assumed to 
represent a particular biological process. One of the most popular methods is weighted gene co-
expression network analysis (WGCNA), which constructs the set of the correlated genes in a 
data set by connecting the genes using the weights based on a similarity function [72]. 
Researchers also have proposed several regulatory network reconstruction methods that 
leverage mutual information (MI) or the tree-based method to capture nonlinear interactions 
between genes [73-75]. Since single-cell sequencing technology has become available, 
researchers also have introduced methods that analyze biological network, using single-cell 
gene-expression data [76]. 
The co-expression signature identification methods mentioned above assume a set of 
mathematical constraints, such as mutual exclusivity or orthogonality, and ideal biological 
premises on input data. However, in actual biological systems, such assumptions may not 
represent reality, for example, matrix factorization methods may not accurately capture 
co-expression events with biological significances. Thus, an algorithm without any constraints 
should be devised to identify the signatures as surrogates of the biological processes.  
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We proposed an unsupervised iterative algorithm that identifies signatures called “attractor 
metagenes” (more generally “attractor metafeatures”) [77] without using such assumptions on 
the input data. To understand such an algorithm, we can start with a hypothetical case. For 
example, we found a cluster of correlated genes in a gene expression data set. Thus, we would 
like to scrutinize them as a coexpression event and try to “sharpen” the coexpression to find out 
the gene at the “heart” (core) of the underlying co-expression.  
Given that the phenotype is absent, we can repeatedly apply an unsupervised approach, 
described as follows: We can define a metagene from the average expression levels of all genes 
within the cluster of correlated genes, and rank all the individual genes of the data set in terms of 
their association with that metagene. Then we substitute an equal number of the top-ranked 
genes for genes from the cluster of correlated genes. Several of the original genes may stay at the 
top of the list and the rest will be replaced. This process “attracts” some other genes that are 
more strongly correlated with the cluster.  
We can then define a new metagene by the average expression levels of the genes in the new 
cluster of correlated genes. Then we rank all the genes again in terms of their association with 
that new metagene, and so on. It is intuitive to expect that this iterative process will eventually 
converge to a cluster of correlated genes that contains precisely the genes that are most 
associated with the metagene of this cluster. We can think of this particular cluster defined by the 
convergence of this iterative process as an “attractor.” 
The above description demonstrates a simplified realization of the attractor derivation 
method. Rather than the average of a particular number of gene expression values from a cluster, 
we define an attractor metagene as the weighted average of all genes where each individual gene 
has a nonnegative weight, i.e. the  attractor derivation algorithm iterates a process that computes 
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the associations of a vector with all the features in the matrix, and uses a function of these 
associations as weights to update the vector as a weighted average of all the features of the 
matrix, called the “metafeature.” After a sufficient number of iterations, the process converges to 
a precise “attractor metafeature” to which we simply refer to as an “attractor.” A ranked set of 
genes specifies each attractor. Their “score,” which measures the strength of their membership in 
the underlying coexpression, ranks the genes. Therefore, the top-ranked genes of an attractor 
point to the core (“heart”) of coexpression in the corresponding signature, which is different 
from classifying features into mutually exclusive groups. This method finds multiple attractors 
that can be mapped to biomolecular events in a high-throughput data set. In multiple cancer data 
sets, from many different cancer types the method identified a set of attractors that are nearly 
identical in composition [77]. Using the data sets of the TCGA Pan-Cancer Project and the 
attractor method, we identified 18 attractors in very similar composition of the top-ranked 
features [78]. 
Many of our attractor metagenes were associated with clinical phenotypes, consistent with 
the hypothesis that they can be used as cancer signatures. For gene-expression-based attractors, 
we identified the mitotic chromosomal instability attractor (CIN) associated with the 
proliferation of tumor, which is many caused by chromosomal instability in the tumor cells; the 
mesenchymal attractor (MES) indicating stromal infiltration and mesenchymal transition, 
associated with invasiveness; the leukocyte-related attractor (LYM), representing immune 
infiltration; and the endothelial attractor (END) representing endothelial cells in the sample. For 
the DNA-methylation-based attractors, we found the negatively associated M+ and M- attractors, 
highly correlated with LYM, consisting of sites over- and under-methylated in the infiltrating 
immune cells [78]. 
14 
The attractor metagenes have been proven to be quantitative surrogates that measure multiple 
clinical characteristics of cancer, incorporated as features of the winning model for breast cancer 
survival which was developed by us. It outperformed all other models in the Sage 
Bionetworks/DREAM Breast Cancer Prognosis Challenge [79, 80] aimed to evaluate the 
accuracy of computational models to predict breast cancer patients’ survival time using clinical 
information, a gene-expression profile, and a copy-number profile. 
Given the knowledge of the existence of cancer attractors, we have interest in identifying 
universal multi-cancer attractor signatures from data sets consisting of multiple cancer types. 
However, the tissue of origin of tumors also affects gene-expression profiles. Simply 
normalizing and concatenating multiple data sets into one large matrix, the pattern identifying 
algorithms may identify co-expression patterns that are irrelevant to the disease. We present a 
novel “consensus” attractor derivation algorithm that identifies attractors that represents the same 
co-expression event in multiple data sets without normalizing and concatenating the data sets in 
one instance. 
1.3 Contributions of the Thesis 
We present the development of several attractor derivation methods as powerful tools for 
identifying signatures with biological significance at the bulk and the single-cell level from 
different cancer types and data sets including the “consensus” version. With the understanding of 
the biological significance of the attractor signatures and the experience in the prognostic model 
development challenges, we developed predictive models for cancer using combinations of the 
attractor signatures, which demonstrate their clinical significance. Because we discovered that 
several attractors from single-cell data sets represent specific cell subpopulations, thus can serve 
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as the features for analyzing the heterogeneity of a sample, we developed a software platform for 
analyzing the cell populations using the single cell RNA-seq data. 
In this study, we refined the attractor algorithm that we had previously co-developed, which 
were contributed to and analyzed in the collaborative efforts on The Cancer Genome Atlas Pan-
Cancer analysis project [47, 59], and produced a method that systematically identifies attractor 
signatures across multiple data sets, robust to the bias formed by data-set-specific effects. One 
novelty of this consensus attractor algorithm is that it is designed to point accurately to few genes 
that are at the heart of the underlying biological mechanism, while filtering out tissue-specific 
signals. This method provides an opportunity for us to understand the biology and target 
potential driver genes, regardless of cancer types. The resulting multicancer signature is called 
the “consensus attractor.” In a collaborative project, we also proposed a genome-wide method to 
identify cotransmitted genomic variants, based on the attractor paradigm, called the “attractor 
metaSNP” [81]. We describe these methods in Chapter 2. 
We identified multiple consensus-attractor signatures using the TCGA PanCanAtlas Data 
Freeze 1.3.1 data sets and statistically confirmed their existence in cancer-type-specific data sets. 
Other novel aspects of our work include the development of a method to analyze methylation 
data using 450K array probes, a new version of genomically colocalized attractors identifying 
amplicons, as well as other CNVs and locally coregulated attractors, pointing to the top-ranked 
genes in each case. In addition to the multicancer signatures previously identified in general form 
[77, 82], we also identified the corresponding biological processes and analyzed their clinical 
significance, such as the prognostic values of attractors discovered in this study. The immune-
related consensus-attractor signatures were included in analysis of the TCGA PanCanAtlas 
PanImmune project [83]. By applying the consensus-attractor derivation method on large single-
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cell RNA-seq data sets, we discovered multiple novel attractors that represent specific tumor 
subclones and nontumor cells in the microenvironment. We present the results and discoveries in 
Chapter 3. 
We distilled a linear model that predicts the prognosis of a breast cancer patient from a large 
breast cancer data set using a cross-validation-based feature selection and regression model-
fitting approach, presented in Chapter 4. The model consists of the CIN, MES, and LYM-
attractor metagenes and the FGD3-SUSD3 metagene (which we had discovered as the most 
protective feature during the challenge), dubbed the Breast Cancer Attractor Metagenes (BCAM) 
biomarker, validated using multiple independent breast cancer data sets, proven to be more 
accurate than other methods. Using these methodologies, we also identified a protein attractor 
signature associated with the response to therapy in the acute myeloid leukemia patients [84].  
The attractors found using single-cell data may not only serve as markers for cell-type 
identification, but also clarify several mechanisms of tumor pathogenesis. Based on this, we 
developed a platform (“ASCOT”) to identify single-cell attractors and cell populations that can 
be used to process a new single-cell data set. In Chapter 5, we describe the derivation of the 
single-cell transcriptome attractor metafeatures and the development of the cell-classification 
platform to analyze the tumor and its microenvironment. 
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Chapter 2 Derivation of the Attractor Metafeatures 
2.1 Introduction 
The attractor-derivation algorithm is an unsupervised, iterative transformation process, used 
to identify attractor metafeatures such as the coexpression signatures in individual 
high-throughput cancer data sets. Such signatures, in proper combination, had significant 
association with cancer phenotypes and were empirically observed as similar across data sets 
from multiple cancer types [77-79, 85].  
However, it is difficult to tell if coexpression patterns in some cancer data sets genuinely 
form a “pancancer” signature, or even a pattern that exists only in certain cancer types, or a 
technical artifact without setting criteria for filtering results. The approaches that integrate 
multiple data sets assume that they are similar to each other, such that one computational model 
can be used to analyze multiple heterogeneous data sets. If the sizes of the data sets are diverse, a 
simple integration may result in bias in the signatures toward the patterns in the large data sets. 
In this chapter, we describe the attractor-derivation methods, including the consensus version, 
addressing such concerns. 
2.2 Definitions 
Each data set containing n features (expression or methylation values) in m samples is 
presented as a real-numbered n×m matrix G with rows 𝐠1, 𝐠2, … 𝐠𝑛 as the features of the data set. 
If there are 𝑝 data sets with the same 𝑛 features involved in an experiment, the matrices are 
denoted as 𝐆1, 𝐆2, …𝐆𝑝, and feature 𝑖 of data set 𝑗 is denoted as 𝐠𝑗i. 
We define a metafeature 𝐦 as the weighted average of the n features 𝐠1, 𝐠2, … 𝐠𝑛 using a 1×n 
weight vector 𝐰 as the weights, which presents the association of an arbitrary real-valued 1×m 
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vector with 𝐠1, 𝐠2, … 𝐠𝑛. To derive 𝐰, we used an association metric 𝐽(𝐱, 𝐲) based on MI for the 
least requirement on the assumption, defined as a function of two vectors whose domain is a 
closed set in ℝ, and the range is a closed set in [0, 1]. In the context of high-throughput data 
analysis, the two vectors 𝐱 and 𝐲 are rows of the matrix such that they are two real-valued 1×m 
vectors. The association metric is the mutual information 𝐼 using the B-spline algorithm 
proposed by Daub et al. (2004) [86]. The range is normalized to [0, 1] using the larger entropy of 
the two input vectors. We require that if the Pearson correlation coefficient 𝜎 of 𝐱 and 𝐲 is 
negative, the resulting value is 0, such that the algorithm will not recruit the features with an 
opposite pattern to the metafeature; α is the exponent of I with a value > 1. We set α using the 
criterion for the selection [77]: 
𝐽(𝐱, 𝐲) = {
𝐼(𝐱; 𝐲)𝛼 if 𝜎(𝐱, 𝐲) ≥ 0
0 if 𝜎(𝐱, 𝐲) < 0.
 
We define a function 𝑓(𝐱) that scales the elements in vector 𝐱 as follows, such that the sum of 





To evaluate a measure of the difference of two vectors, we define a function 𝑑(𝐱, 𝐲) as the 
maximum of the absolute differences between each of the highest 20 values. 
Derivation of the Attractor Metafeatures Using a Single Data Set 
Derivation of an attractor is an iterative process that starts from a “seed” metafeature, 
repeated until convergence. The process is outlined as follows and the pseudocode is Algorithm 
2.1. 
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Starting with an arbitrary real-numbered 1×m vector 𝐦s, which is typically a feature of the 
data set, 𝐠𝑖, the weight vector 𝐰 is computed as the association of  𝐦swith all the features 
𝐠1, 𝐠2, … 𝐠𝑛 that are normalized using function 𝑓(𝐱): 
𝐰 = 𝑓(𝐽(𝐠1, 𝐦s), 𝐽(𝐠2, 𝐦s), …  𝐽(𝐠𝑛, 𝐦s)). 
The metafeature is evaluated as a vector of the weighted sum of 𝐠1, 𝐠2, … 𝐠𝑛 or the dot product 
of 𝐰 and 𝐆. 
𝐦 = 𝐰𝐆 
Then each iteration updates metafeature 𝐦 using a new 𝐰, evaluated using the preceding 𝐦 and 
repeated until the process converges; that is, the difference of two 𝐰 at consecutive iterations 
monotonically approach 0. 
𝐰 = 𝑓(𝐽(𝐠1, 𝐦), 𝐽(𝐠2, 𝐦), …  𝐽(𝐠𝑛, 𝐦)) 
We define the condition of convergence to an attractor metafeature (referred to as “attractor”) as 
the difference of the weights in two consecutive iterations 𝑑(𝐰′ − 𝐰) < 10−7. 
Each attractor metafeature can be represented by a ranked listing of the features having the 
highest normalized mutual information with the attractor metafeature. We refer to these values of 
normalized mutual information 𝐽(𝐠𝑖, 𝐦) as the scores of individual features of metafeature 𝐦. 
Compared with our previous version of attractor-derivation algorithm [77], the improved 
algorithm allows any arbitrary real-numbered 1×m vector as seed 𝐦𝑠, does not require a weight 
vector as input, and the condition of convergence is defined using the top-ranked elements of the 
weight vectors of two consecutive iterations instead of using the metafeatures of two consecutive 
iterations so the range of the differences is independent of gene-expression levels. 
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Algorithm 2.1  
Require: Data matrix 𝐆 with feature vectors 𝐠1, 𝐠2, … 𝐠𝑛 
Require: Feature vector of the seed vector 𝐦𝐬 
Require: 𝜖: Threshold for convergence 
Require: K: Maximum number of iteration 
Require: 𝐽(𝐱, 𝐲): The function of the association metric 
Require: 𝑓(𝐱): The function to normalize the associations 
Require: 𝑑(𝐱, 𝐲): The function that evaluates the differences between two vectors 
𝛿 ← ∞ 
𝑘 ← 0 
𝐰 ← 𝑓( [ 𝐽(𝐠1, 𝐦𝐬), 𝐽(𝐠2, 𝐦𝐬), …  𝐽(𝐠𝑛 , 𝐦𝐬) ] ) 
𝐦 ← 𝐰𝐆 
while 𝛿 > 𝜖 and 𝑘 < K do 
𝐰′ ← 𝑓( [ 𝐽(𝐠1, 𝐦), 𝐽(𝐠2, 𝐦), …  𝐽(𝐠𝑛, 𝐦) ] ) 
𝛿 ← 𝑑(𝐰′, 𝐰) 
𝐰 ← 𝐰′ 
𝐦 ← 𝐰𝐆 
𝑘 ← 𝑘 + 1 
end while 




Consensus-Attractor Derivation Algorithm 
To identify attractors shared across multiple cancer types, we developed a one-pass 
“consensus” algorithm that simultaneously considers the data matrices of all data sets involved in 
the experiment. This consensus method replaces the method we proposed in previous research 
projects [77] which were based on comparing results from individual data sets. We also 
empirically found that the simple method of applying the above-described algorithms by 
concatenating all data matrices (each reflecting the qualities of a different tissue) into one matrix 
often misses or misrepresents important attractors, which is consistent with the need to develop a 
special algorithm. 
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The consensus-attractor algorithm is an iterative transformation of metafeatures, where each 
iteration defines a new metafeature in a similar manner. In each iteration, however, the 
association measure of each feature with the immediately preceding metafeature is now 
summarized as a consensus weight vector 𝐰𝒄 from the corresponding weight vectors taken from 
each individual data set using a consensus summarization function 𝑐(𝛀) where 𝐰1, 𝐰2 … 𝐰𝑝 ∈
𝛀, such that the associations of the metafeature with all features are evaluated using information 
from all data sets. When the process converges, the consensus attractor can thus be identified 
without a post hoc analysis on the attractors found using the individual data sets. 
The consensus algorithm is outlined as follows. Given 𝑝 data sets with the same set of 
features 𝐆1, 𝐆2, …𝐆𝑝 called set 𝚪, the process is started using the s
th feature as seed metafeature 
for each data set, such that the weight vector for each data set is evaluated using the association 
metric and the normalization function. For data set 𝑗, the weight vector is computed as follows. 
w𝑗 = 𝑓([𝐽(g𝑗1 , m𝑗s), 𝐽(g𝑗2 , m𝑗s), … , 𝐽(g𝑗𝑛 , m𝑗s)]) 
The 𝑝 weight vectors are summarized as a consensus weight vector 𝐰𝒄 using function 𝑐, which 
identifies the 50% weighted percentile of a set of values in which the weights are proportional to 
the number of samples included in the individual data sets. The metafeature of each data is then 
evaluated using 𝐰𝒄. For data set 𝑗, a metafeature is computed as follows. 
m𝑗 = w𝑐G𝑗 
This iterative process is then repeated until the convergence condition is met, that is, the 




Require: Data matrices 𝐆1, 𝐆2, …𝐆𝑝 ∈  𝚪 with n rows 
Require: Feature vector of the seed vector index 𝑠 
Require: 𝜖: Threshold for convergence 
Require: K: Maximum number of iterations 
Require: 𝐽(𝐱, 𝐲): The function of the association metric 
Require: 𝑓(𝐱): The function to normalize the associations 
Require: 𝑑(𝐱, 𝐲): The function that evaluates the differences between the two vectors 
Require: 𝑐(𝛀): The function to summarize weighted vectors 
𝛿 ← ∞ 
𝑘 ← 0 
for each 𝐆𝑗 ∈  𝚪 
𝐦𝑗s ← 𝐠𝑗s 
w𝑗 ← 𝑓 ([𝐽 (g𝑗1
, m𝑗s) , 𝐽 (g𝑗2
, m𝑗s) , … , 𝐽 (g𝑗𝑛
, m𝑗s)]) 
end for 
w𝑐 ← 𝑐(w1, w2, … , w𝑝) 
for each 𝐆𝑗 ∈  𝚪 
m𝑗 ← w𝑐G𝑗  
end for 
while 𝛿 > 𝜖 and 𝑘 < K do 
for each 𝐆𝑗 ∈  𝚪 
𝒘𝒋
′ ← 𝑓 ([𝐽 (g
𝑗1
, m𝑗) , 𝐽 (g𝑗2






′ , … , 𝒘𝒑
′ ) 
𝛿 ← 𝑑(𝒘𝒄
′ , w𝑐) 
w𝑐 ← 𝒘𝒄
′  
for each 𝐆𝑗 ∈  𝚪 
m𝑗 ← w𝑐G𝑗  
end for 
𝑘 ← 𝑘 + 1 
end while 




Because the paradigm of the consensus algorithm is flexible, we similarly defined the 
consensus algorithm for the derivation of the specialized attractors as genomically localized 
attractors and methylation attractors, described in the next sections. In each case, for each 
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iteration we used as an association measure the weighted median of the individual association 
measures of all data sets, using the same parameters in each case. 
Derivation of the Genomically Localized Attractors 
To explore the amplicons [77, 87, 88] and other genomically localized coexpression events in 
the transcriptomic data, we developed a specialized attractor algorithm that considered the 
genomic proximities of the genes. The procedure of the algorithm consists of two steps. 
In the first step, the objective is to identify genomic regions with local coexpression events. 
For each gene included in the expression matrix, we refer to the set of its genomically 
neighboring genes on its chromosome (up to 25 from each side) as the “neighborhood” of the 
gene; therefore, each neighborhood consists of no more than 51 genes. Using each gene as seed, 
we identified the corresponding attractor by considering only the genes in its neighborhood with 
exponent 𝛼 = 2. We discarded from consideration neighborhoods that did not lead to an attractor 
with the fifth score higher than 0.5. For each of the remaining neighborhoods, we refer to the 
(minimum of five) genes whose scores are higher than 0.5 as the “essential genes” of the 
neighborhood. Any pair of neighborhoods sharing essential genes were merged, replaced with a 
newly defined neighborhood containing the union of their sets of essential genes. When the 
merging process is completed, the finally defined neighborhoods contain disjointed sets of 
essential genes, although it is possible that some neighborhoods will overlap genomically with 
each other. In the second step, we applied the general-attractor-finding algorithm with 𝛼 = 2 to 
each neighborhood without using any heuristics because the computational complexity is 
manageable. For each neighborhood, we retained only one attractor, the one with the highest 
fifth score. 
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Derivation of Attractors Using the Data Set with Surjectively Mapped Features 
Due the nature of the biological traits, certain high-throughput platforms “surjectively” map 
multiple “probes” to one gene, which is at the level of our interest in the study. The Illumina 
HumanMethylation450 DNA methylation microarray is such a data set in the TCGA data sets. 
The original attractor-derivation method is not appropriate to these arrays, because each gene 
may have multiple measurements of levels at different methylation probes. These probes may 
highly correlate with each other, which leads to attractors that are biased to the probes of a single 
gene. Thus, we developed a “probe selection” attractor algorithm that addresses the issue when 
probes cannot be summarized to a gene using a known approach. 
The probe-selection-attractor algorithm uses only one probe per gene for each metafeature. 
The algorithm computes the associations between a metafeature and all the probes; then discards, 
for each gene, all probes except the one with the highest weight, and only these weights are used 
for the evaluation of the metagene. It is possible, though rare, that the selected probe for a gene 
may be different from one from the previous iteration. We found that this algorithm has nice 
convergence properties and we defined the convergence criterion as the maximum of the 
absolute differences between each of the top 20 association values of the genes in two 
consecutive iterations being less than 10−4. 
Because of the excessively high number of probes in the 450K array platform, we searched 
each data set using a two-step procedure comprising the scanning step and refinement step. In the 
scanning step, we applied the probe-selection-attractor-finding algorithm to the data sets that 
consist of the 37,179 probes, identified using the following rules: We first considered the set to 
be all probes located in a gene and existing in the HumanMethylation27 array and the 
HumanMethylation450 array. If a gene included in the resulting set contained less than two 
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probes, then we augmented the set of probes, aiming to have each gene represented by at least 
two probes, if available. We did that by assigning new probes among those in the 
HumanMethylation450 set, selecting those with the highest median of standard deviations across 
all data sets. We applied the probe-selection algorithm using the above-described probes as seeds 
and used the rank list of the resulting attractors as the input of the next step. The condition of 
convergence was reduced to 10−3 to alleviate complexity, as there is no need for extremely 
accurate final results at this stage because the refinement step will use more stringent criteria. 
In the refinement step, we ran the probe-selection-attractor-finding algorithm on the 
HumanMethylation450 array data sets. We used as seed the sample-wise mean of the ten probes 
with the highest scores of each attractor identified in the scanning step. The condition of 
convergence was set to 10−4 as a compromise between accuracy and complexity. On the very 
rare occasions when this condition was not sufficiently stringent for full convergence, we 
consider two attractors to be the same if the ranked lists of their top 20 probes were identical. We 
retained the converged attractors for which the tenth highest score was higher than 0.5 to 
guarantee each attractor contained at least ten highly comethylated probes. 
We observed that some attractors would result by the presence of very few (typically one) 
outlier samples, corresponding to measurements apparently in error. To filter out these attractors, 
we represented each attractor by the average of the methylation levels of its ten highest-scoring 
probes and eliminated the attractors when the value of absolute skewness of the distribution of 
those levels was higher than three. In the iterative evaluation of each metafeature, the probe-
selection algorithm ignored probes not associated with genes and probes not top-ranked in each 
gene. After the algorithm converged, to identify any such additional high-ranked probes, we 
included all 450K probes in the final ranking. 
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Derivation of SNP Attractors 
As a joint study with Dr. Abdulkadir Elmas and Prof. Xiaodong Wang, we explored the 
application of the attractor-derivation method on the analysis of the single-point variants in the 
whole genome. The resulting method is called the “attractor metaSNP” algorithm [81]. 
A set of the alleles at multiple genomic loci may align in a nonrandom manner, called 
linkage disequilibrium (LD). The presence of certain LD associates with particular diseases. 
Therefore, accurate and efficient discovery of LD patterns that represent the genomic diversity of 
a population is of importance for genome-wide association research. Due to the length of the 
human genome, the task of LD pattern and discovery is not trivial. Because an LD pattern of a 
population comprises multiple SNPs that carry similar information about the diversity, it is 
desirable to identify a representative SNP, or tag SNP, to locate these loci of genomic sites. 
Unlike other platforms whose readouts are continuous values, a SNP profile is presented with 
a trilevel value at each SNP. Thus, the meta-SNP is defined as a weighted average of these 
trilevel values of SNPs. Although the meta-SNP cannot be regarded as a virtual SNP due to its 
continuous nature, it presents the high-LD haplotype block of a group of SNPs. Thus, an attractor 
meta-SNP can be a proxy that encodes the allelic variations in the region. A tag SNP can be 
selected from the top-ranked SNPs of the attractor using the association metric. Therefore, the 
SNP tagging task for a genomic region can be formulated into an attractor-derivation process, 
that is, using all the SNPs of this region as seeds, the attractor-derivation algorithm presented in 
previous section, Algorithm 2.1 finds a set of distinct attractor meta-SNPs that represent all the 
blocks of the linked variations in that region. Here 𝛼 of the association metric 𝐽 is set as 5 [81]. 
For the genome-wide analysis, we developed a two-step method to balance the precision of 
SNP tagging and computational complexity. In the first step, we scanned all SNPs of the genome 
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as seeds by applying the attractor-derivation method on each of the sliding windows consisting 
of only 101 SNPs, which are the SNP at the center, and 50 SNPs on both sides of the seed SNP. 
At this step, α of the association metric J was set as 2 to detect SNPs with a low degree of LD. 
For each seed SNP, if the fifth largest weight of its converged attractor was larger than 0.5, 
the SNP was retained as the seed in the second step. 
In the second step, we limited the computation of the associations and the weighted averages 
in the 10,001-SNP genomic region of each seed identified in Step 1 using 𝛼 = 5 to identify 
distinctive attractors. We selected the top-ranked SNP in weight of an attractor as the tag SNP. In 
the case that multiple SNPs shared an identical largest weight, we selected the SNP that was 
spatially closest to the median of SNPs. To rank the tag SNPs, we defined the strength of a tag 
SNP as the unnormalized mutual information of the tenth top-ranked SNP and the attractor meta-
SNP. This method was applied on the human SNP data sets to derive the tag SNPs [81]. 
Selection of the Parameters 
For the individual data sets, we empirically set 𝛼 as 5 to maximize the tenth largest score of 
an attractor for the data sets generated using “bulk” technologies [77]. For the data sets generated 
using single-cell technologies, we found that 𝛼 should be lowered to 4. We retained the 
converged attractors for which the 𝑘-th highest score was higher than 0.5, setting 𝑘 = 10 for 
gene-expression attractors and 𝑘 = 3 for miRNA attractors. This process guaranteed that each 
gene-expression attractor contained at least ten highly co-expressed genes, and each miRNA 
attractor contained at least three highly co-expressed genes. We required the top-ranked gene for 
each valid attractor to be the same as the seed from which the attractor was generated. To limit 
the computational complexity of the search, we interrupted the attractor-finding process when 
the second highest score at the first iteration was less than 0.5, or when the score of the seed did 
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not remain highest ranked after the first 10 iterations. We also filtered out any attractors with 
more than five of the top ten features from chromosome X or chromosome Y as gender-related. 
Using the conditions described above, a scan results in a set of 𝑞 converged attractors in 
𝐰1, 𝐰2 … 𝐰𝑞 ∈ 𝛀. 
To validate the selection of the consensus-attractor derivation method, we conducted an 
experiment to examine the effect of the selection of exponent 𝛼. We performed ten consensus-
attractor derivation processes on 18 gene expression data sets from the TCGA PanCanAtlas data 
sets described in Chapter 3 (Table 3.1), using the ten genes associated with mitosis (Table 3.2), 
changing the exponent 𝛼 from zero to ten in 40 steps. The mean duration for a consensus-
attractor derivation process using one seed to reach convergence was 3.56 minutes on a 
workstation equipped with an Intel i7-4790 3.60 GHz CPU and 32 GB memory.  
The results of this experiment suggest that the consensus-attractor derivation algorithm is 
robust to the selection of exponent 𝛼. The strength of an attractor, defined as the tenth score of a 
converged attractor [77] is stable in Figure 2.1A, where the ordinary curve is the median of the 
strengths of the ten attractors at the exponent and the dashed curves are the maximum and 
minimum of the strengths. The number of distinct attractors remains 1 with regard to 𝛼 from 2 to 
9 (Figure 2.1B), which presents that the consensus-attractor derivation method does not falsely 
divide the co-expressed genes associated with known biological processes into multiple sets 
when 𝛼 is changed. Therefore, we set 𝛼 = 5 for consistency with the selection for the attractor-




We conducted the same experiment that determines the parameter for the consensus method 
using single-cell gene-expression data sets which are described in Chapter 3 (Table 3.3) and 
mitosis genes from Table 3.4, were defined using scRNA-seq data sets, although they are almost 
identical to bulk mitosis genes. The mean duration for an attractor to achieve convergence is 2.06 
minutes. The result of the experiment presents that the strength of an attractor, defined as the 
fifth largest score of the converged attractor for the weaker association in the scRNA-seq data, 
decreases dramatically from 𝛼 = 4 (Figure 2.2A) and the number of distinct attractors increases 
from 𝛼 = 4 (Figure 2.2B). Thus, for the scRNA-seq data, we set 𝛼 = 4 for the consensus-








Figure 2.1 (A) Strength and (B) number of attractors against exponent 𝜶 for the consensus-
attractor derivation method in TCGA bulk data sets. 
 
 
Figure 2.2 (A) Strength and (B) number of attractors against exponent 𝜶 for the consensus-




Summarization of the Derived Attractors 
To perform a genome-wide study on transcriptomes in the data sets, we typically started the 
attractor-derivation algorithm using all the 𝑛 features as seeds so the data set was “scanned” for 
all possible attractors. As we discussed previously [77], initial attractors using different seeds 
may converge at the same weight vector 𝐰, indicating a need for a procedure that identifies such 
duplications. We propose a method that compares the top-ranked N features of the attractors by 
the indices and decide if the two attractors can be categorized as one attractor. All attractors in 𝛀 
are processed by the algorithm, and the resulting set of the attractors is 𝚲. If an incoming 
attractor is different from all attractors that are in 𝚲, the new attractor is included as a new 
member of 𝚲. The pseudocode of the algorithm is Algorithm 2.3. Compared with the previous 
method [77], the method based only on the indices resolves the problem that when two attractors 
converge to the same 𝐰 from different paths, the processes are stopped when their 𝐰 and 𝐦 
remain different. In such cases, resulting attractors may not be considered the same using the 
previous method. For the experiment with multiple data sets, because the consensus-attractor 
derivation algorithm incorporates information from all data sets during the attractor-derivation 
process, it does not require a hierarchical clustering routine to create the “attractor clusters” from 
attractors with similar top-ranked genes from different data sets; thus, a virtual attractor can be 
inferred from the members of a cluster, which requires the assignment of arbitrary thresholds 
[77]. By contrast, consensus attractors are summarized using the same summarization algorithm 
as general attractors. 
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Algorithm 2.3  
Require: Weights of the converged attractors 𝐰1, 𝐰2 … 𝐰𝑞 ∈ 𝛀 
Require: N: number of the features used in the evaluation 
Require: 𝑠𝑜𝑟𝑡_𝑖𝑛𝑑𝑒𝑥(𝐰, N): The function that sorts 𝐰 in descending order and returns the indices of the top N 
sorted elements. 
𝚲 ← ∅ 
for each 𝐰i ∈ 𝛀 
𝐯 ← sort_index(𝐰i, N) 
if 𝚲 ≠ ∅ and 𝐯 ∉ 𝚲 then 
𝚲 ← 𝚲 ∪ 𝐯 
else 




Evaluation of the Significance of Multicancer Attractors in Individual Data Sets 
Once consensus (multicancer) attractors were identified, we determined whether each was 
present in each of the individual cancer types by evaluating the corresponding statistical 
significance. We used the hypergeometric test of the number of overlapped features with scores 
larger than 0.5 of the consensus attractor and the attractor in the individual data set. The size of 
the sampling population was the number of all features of the data set. 
2.3 Implementation 
Parallelization of the Algorithm 
Because the number of features n is invariant for a particular data type, the bottleneck of the 
algorithm is the evaluation of the associations, which is affected by the number of samples m, 
and the upper bound of the complexity depends on the condition of convergence. Because the 
scanning for all correlated patterns using a data set with 𝑛 features can be divided into 𝑛 
attractor-derivation tasks, the process can be intuitively parallelized onto 𝑢 processing units, 
where 𝑢 ≤ 𝑛. The parallelization of the attractor-derivation algorithms was parallelized to be 
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executed on the clustered computing environment that is compatible with the Sun Grid system, 
which automatically allocates 𝑛 tasks to the worker nodes of the cluster computer. 
We deployed the program on the on-demand web service provided by Amazon called 
Amazon Elastic Compute Cloud (EC2) using a cluster-computing toolkit StarCluster 
(http://web.mit.edu/stardev/cluster/). We launch the on-demand StarCluster using the Amazon 
Machine Image (AMI) with a preinstalled operating system and StarCluster (ami-3393a45a) on 
20 m1.medium instances, such that multiple tasks with different running times are distributed on 
one working node to limit the number of idle nodes during the run. 
We also implemented the algorithms for local workstations with multiple cores using the R 
package doMC [89] to allocate tasks to the designated processors. Because doMC used the fork-
system call, the parallelized version of the implementation cannot be executed on Windows. The 
program was executed on Ubuntu 14.04 LTS on a Dell Precision T7610 workstation with Dual 
Intel Xeon Processor E5-2637 v2 (Four Core HT, 3.5 GHz) and 256 GB memory. 
The attractor-derivation algorithms were mainly performed on the Amazon EC2 clusters. For 
scanning using the methylation data sets, we performed Step 2 locally due to the size of the data. 
The genomically localized algorithm is not parallelized because the complexity is much lower 
than other variations of attractor-derivation approaches. 
2.4 Comparison with Previous Work 
To validate the consensus algorithm, we compared the performance of the consensus-
attractor derivation algorithm with the previous attractor method by applying algorithms on the 
12 RNA-seq data sets of TCGA PanCan12 Data Freeze [47, 78] and analyzing the numbers of 
attractors discovered by the algorithms. 
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As presented in Table A.1, the consensus-attractor derivation method identified all seven 
gene-expression signatures that had been previously found using a combination of the attractor 
algorithm for an individual data set and hierarchical clustering, as in Table A.2, which is 
available under synapse ID syn1895985. In addition to known gene-expression attractors, the 
consensus-attractor derivation algorithm identified two novel attractors from the same data set. 
For derivation of the WDR38 signature, because we eliminated gene WDR38 from data sets 
COAD and READ, we applied the consensus-derivation algorithm on the ten TCGA data sets 
with the gene. The top-ranked gene of the resulting attractor found using WDR38 as seed is 
ZMYND10. 
Comparison with Other Approaches 
We compared the attractor-derivation method for individual data sets with K means, PCA, 
and hierarchical clustering quantitatively [77] and with ISA and ICA qualitatively [71]. For the 
clustering methods that accept multiple data sets as input, because CoCA [59], CoINcIDE [63], 
and iCluster [64] identify tumor subtypes across data sets, but the attractor-finding algorithm 
identifies co-expressed genes, they are not directly comparable. MDI [65] was developed to 
identify clusters of coregulated genes in multiple data sets, which is close to the aim of the 
consensus-attractor derivation algorithm, although inherently, the attractor-derivation method is 
not a clustering algorithm. Because MDI uses Gibbs sampling to estimate Dirichlet models, the 
output is not deterministic. However, the attractor-finding algorithm produces deterministic 
results. Because the output MDI and the consensus-attractor derivation algorithm relate 
qualitatively, we quantitatively compare their performances when capturing the coexpression 
events in the multiple data set. 
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Performances were assessed using six synthetic gene-expression data sets provided in the 
MDI software package. These data sets have 100 genes in seven patterns derived from the time-
series gene expression of the budding yeast S. cerevisiae. Because five of the six data sets were 
derived from one of the six data sets, we compared the performances of the two methods using 
the similarity of clustering results withthat data set. We evaluated accuracy using the adjusted 
Rand index (ARI) [90, 91] in the R package mclust [92, 93], which is an objective metric of the 
similarity of two clustering results. 
We applied the consensus-attractor method (Algorithm 2.2) on the six synthetic data sets 
with 𝛼 = 5, 𝜖 = 10−5, and 𝑘 = 3. We sorted the consensus attractors using the third largest 
score. From the attractor with the highest rank, we assigned the genes with scores > 0.5, > 0.4, > 
0.3 to a cluster. Because the membership of attractors is not exclusive, a gene that is a member of 
two attractors was assigned to the cluster of the attractor with the higher rank. The attractor 
algorithm identified seven attractors, consistent with the design of the synthetic data sets. The 
resulting ARIs are 0.32, 0.36, and 0.33, respectively. 
For the MDI approach, we performed MDI.m with the default 10,000 MCMC sampling 
iterations and generated consensus clustering using GenerateClusteringPartition.m with one data 
type and the fraction of samples from the beginning of the method’s sampling iterations that will 
be eliminated (“burn-in”) to reduce the dependence on the initial point = 0.3, 0.5, 0.7, 0.9. The 
resulting ARIs were 0.25, 0.25, 0.34, 0.34. For computational complexity, the consensus-
attractor algorithm took 23.11 seconds to scan all 100 genes in the six data sets; MDI with 
10,000 MCMC samplings took 14,171.58 seconds. The results suggested the consensus-attractor 
method and MDI achieve comparable accuracies when identifying patterns in multiple gene-
expression data sets. However, the amount of computational complexity of the consensus-
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attractor-finding algorithm is much lower than MDI, which is critical for an analysis using 
common human-gene-expression data sets, which typically have from 20,000 to 60,000 features. 
Therefore, the consensus-attractor algorithm performed equally well or better than MDI and 
outperformed MDI on complexity. 
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Chapter 3 Attractor Biological Signatures 
3.1 Introduction 
The availability of such data sets from 33 cancer types of TCGA provides an opportunity for 
thorough data mining, so that such common patterns can be computationally discovered and 
defined with high accuracy. 
3.2 Multicancer Signatures 
The availability of increasingly richer biomolecular data sets from many cancer types 
provides an unprecedented opportunity for computational data mining in search of patterns 
(“signatures”) reflecting general cancer-associated mechanisms. Using the attractor-derivation 
algorithms, we discovered such patterns by analyzing a collection of data sets containing values 
from mRNA and microRNA expression, as well as DNA methylation from multiple cancers. In 
addition to the gene signatures that link to multiple oncogenic biological processes in each data 
type, the method also identified signatures across data type, e.g., the expression and the DNA-
methylation signatures that are associated with infiltrating lymphocytes in solid cancer types. 
The membership of many of these signatures points to particular biological mechanisms related 
to cancer progression, suggesting they represent important attributes of cancer in need of being 
elucidated for potential applications in diagnostic, prognostic, and therapeutic products pertinent 
to multiple cancer types.  
The TCGA PanCanAtlas Data Set 
We analyzed data sets with more than 200 samples of the TCGA PanCanAtlas Data Freeze 
1.3.1 (Table 3.1). For each platform, we used all data sets containing at least 200 samples and 
created expression/methylation matrices including the intersection of features in all data sets. For 
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each data set, we downloaded from Synapse repository syn:3241074 the EB++ Adjusted 
Illumina HiSeq 2000 RNA Sequencing Version 2 analysis (IlluminaHiSeq_RNASeqV2) profiles 
of gene-expression levels and the Illumina HiSeq 2000 miRNA Sequencing 
(IlluminaHiSeq_miRNASeq) of miRNA-expression levels, as well as Illumina Infinium 
HumanMethylation450 BeadChip array profiles (HumanMethylation450). We used the provided 
mRNA-expression data sets summarized to the gene level. The methylation data sets contain 
multiple probes per gene.  
For mRNA- and miRNA-expression data sets, we removed genes with more than 50% zeros 
or missing values, as well as the samples with more than 50% zeros or missing values. All 
remaining zeros and missing values were imputed using the 𝑘-nearest-neighbor imputation 
method in Bioconductor’s impute package [94, 95] with 𝑘 = 10. We log-transformed the 
resulting values using the log2+1 function and normalized them using the quantile normalization 
method of Bioconductor’s limma package [96]. 
For DNA-methylation data sets, we removed any probes and samples with more than 50% 
missing values, imputed the remaining missing values using the 𝑘-nearest neighbor imputation 
method with k = 10 and normalized the resulting values using the beta-mixture quantile 
normalization method [97]. 
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Table 3.1 List of the TCGA Data Sets Analyzed in This Study 
Cancer Type Gene Expression miRNA Expression DNA Methylation 
Bladder Urothelial Carcinoma (BLCA) 408 410 416 
Breast Invasive Carcinoma (BRCA) 1092 756 771 
Cervical Squamous Cell Carcinoma and Endocervical 
Adenocarcinoma (CESC) 
305 308 308 
Colon Adenocarcinoma (COAD) 443 214 296 
Head and Neck Squamous Cell Carcinoma (HNSC) 517 485 525 
Kidney Renal Clear Cell Carcinoma (KIRC) 516 241 315 
Kidney Renal Papillary Cell Carcinoma (KIRP) 286 287 272 
Low Grade Glioma (LGG) 532 528 532 
Liver Hepatocellular Carcinoma (LIHC)  371 372 377 
Lung Adenocarcinoma (LUAD) 512 450 461 
Lung Squamous Cell Carcinoma (LUSC) 488 336 364 
Ovarian Serous Cystadenocarcinoma (OV) 307 476 
 
Prostate Adenocarcinoma (PRAD) 495 492 496 
Sarcoma (SARC) 259 260 261 
Cutaneous Melanoma (SKCM) 472 450 473 
Stomach Adenocarcinoma (STAD) 401 378 393 
Thyroid Cancer (THCA) 509 510 511 
Uterine Corpus Endometrial Carcinoma (UCEC) 529 399 422 
 
Results 
Here we report the results of discovering attractor-molecular signatures on the TCGA 
PanCanAtlas Data Freeze 1.3.1 data sets, including all cancer-type-specific and consensus-
attractor signatures. In addition to the consensus-attractor algorithm, novel aspects include the 
development of a method to analyze methylation data using 450K array probes, a new version of 
genomically colocalized attractors identifying amplicons and other CNVs, and locally 
coregulated attractors, pointing to the top-ranked genes in each case. Among many presented 
signatures, three highly aligned with each other: the expression, hypermethylation, and 
hypomethylation signatures of the core of infiltrating lymphocytes shared by solid cancer types. 
40 
Some signatures presented in this paper connect with known functions, including the ones 
that are used to derive the gene-programs of cancer in the TCGA Pan-Cancer analysis project 
[59], some with novel functions, and some with yet-unknown functions. We contributed the 
immune-related consensus-attractor signatures to the TCGA PanCanAtlas PanImmune project. 
Because these patterns cannot be due to chance, presenting the full set of all these signatures 
(cancer-type-specific as well as multicancer) to the research community, resulting from thorough 
data mining of the TCGA data sets provides useful information from which researchers can 
generate biological hypotheses, validating information about the nature of cancer.  
Consensus Multicancer-Attractor Signatures of Bulk Samples 
Multicancer-attractor signatures discovered using the TCGA data sets appear in the complete list 
appears in Appendix B. We observed that the MiRNA identified coexpression events as triplets 
from the algorithm; we required only three top-ranked entries larger than 0.5 for miRNA-
attractor signatures. We confirmed the consistency of consensus attractors and the attractors 
discovered in individual data sets and we evaluated the significance of overlapping top-ranked 
features of consensus attractors and attractors in individual cancer data sets (Appendix C).  
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Table 3.2 List of Consensus-Attractor Signatures in the TCGA PanCanAtlas Data Sets 
Leukocyte CD53, SASH3, IL10RA, NCKAP1L, LCP2, ITGAL, CCR5, CD4, MYO1F, 
ARHGAP30 
Mitosis TPX2, KIF4A, NCAPH, KIF2C, BUB1, MCM10, SGOL1, CENPA, MELK, HJURP 
MES COL1A2, COL3A1, COL5A1, SPARC, COL6A3, COL1A1, COL5A2, FBN1, VCAN, 
THBS2 
END CXorf36, TIE1, CD34, CDH5, CLEC14A, ARHGEF15, ROBO4, ESAM, ELTD1, 
CD93 
IFIT IFIT3, IFI44L, IFIT1, RSAD2, MX1, IFI44, OAS2, CMPK2, IFI6, IFIT2 
CCNT1 CCNT1, ASXL2, DDI2, TAOK1, UHMK1, REST, LATS1, RAPGEF6, GTF2A1, 
NCOA2 
NDUFB7 NDUFB7, GADD45GIP1, C11orf83, ATP5D, NDUFA11, TCEB2, NDUFA13, 
TRAPPC5, SSNA1, MRPL55 
PILRB PILRB, AHSA2, CCNL2, LOC91316, ZNF767, TTLL3, AGAP4, LENG8, WASH7P, 
AGAP6 
DNA Methylation 
M+  VPS13D (cg00384847), IL22RA1 (cg09152089), BMF (cg17809595), PRSS8 
(cg13439730), MTMR11 (cg24620905), MPL (cg18856478), NUAK2 (cg05699921), 
TNKS1BP1 (cg12603560), DDR1 (cg16215084), INPP5J (cg27324619) 
M-  CORO1A (cg02358862), SLA2 (cg12504877), PTPN6 (cg21249754), STK16 
(cg08098128), C5orf56 (cg21171858), PTPRCAP (cg10542975), SKI (cg01852476), 
IGFLR1 (cg16927606), TBC1D20 (cg06119477), GRK6 (cg19459094) 
PIP5K1P1  PIP5K1P1 (cg07136949), GLRX2 (cg09182724), PPIE (cg13171016), ZBTB49 
(cg10735211), ZNF248 (cg17187559), PRDM2 (cg19283112), INPP5A (cg22918356), 
HOOK3 (cg22561380), CPEB3 (cg10967735), UBTD2 (cg05970768) 
WDR36  WDR6 (cg13651693), TBC1D5 (cg22375856), SKIV2L2 (cg17831554), SCAPER 
(cg26804004), FGFR1OP2 (cg23196781), CD2AP (cg15629447), SEC23A 
(cg18127619), SENP6 (cg02720600), MAT2B (cg23426792), SOS1 (cg16149437) 
RPL14  RPL14 (cg05489143), CCNL1 (cg02399570), ZNF143 (cg14037413), METTL13 
(cg03762505), OTUB1 (cg19233923), ORMDL3 (cg09155575), SNX3 (cg18493069), 
EFCAB2 (cg05210886), ZNF224 (cg26649251), ATL2 (cg14036868) 
SNORD116 SNORD116-12 (cg19708133), SNORD116-15 (cg19183867), SNORD116-23 
(cg17727579), SNORD116-28 (cg10786226), SNORD116-24 (cg03363417), 
SNORD116-4 (cg11063170), SNORD116-18 (cg02625244), SNORD116-1 
(cg03381111), SNORD116-13 (cg01699028), SNORD116-11 (cg14182820) 
ABCE1 ABCE1 (ch.4.2662600F), GTF2A1 (ch.14.1251344R), CEP120 (ch.5.2235120R), 
KTN1 (ch.14.679957F), CCDC88A (ch.2.1294774R), TRAPPC11 (ch.4.3383604F), 
ORC5 (ch.7.2226368R), DIAPH3 (ch.13.865492R), PIGF (ch.2.1116759R), INTS6 
(ch.13.721274R) 
LINC00937 LINC00937 (cg01865312), USP6 (cg08742106), CSH1 (cg23935447), TBC1D3C 
(cg23350580), RFPL2 (cg04376820), TBC1D3P1 (cg14503521), TBC1D3P2 
(cg18573745), COL11A2 (cg18624108), ASB10 (cg13645954), SCN4A (cg25601446) 
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RAB1A RAB1A (cg2292569), RICTOR (cg07148370), FKBP14 (cg23492432), 
LOC100188947 (cg05934333), MLH1 (cg16863190), RWDD4 (cg13674088), RDH11 
(cg10166090), CCDC34 (cg02888748), ZNF283 (cg14023449), UBE2D3 
(cg09095080) 
CDKN1C CDKN1C (cg08206623), IVNS1ABP (cg07920855), FTL (cg12026095), RIC8B 
(cg26979339), WDR6 (cg13003239), SCLY (cg22352273), RAB11FIP3 
(cg17524151), NUCKS1 (cg01947301), CCSAP (cg23274123), BNIP2 (cg17502267) 
miRNA Expression 
DLK1-DIO3 hsa-mir-127, hsa-mir-379, hsa-mir-134, hsa-mir-382, hsa-mir-758, hsa-mir-654, hsa-
mir-370, hsa-mir-409, hsa-mir-493, hsa-mir-431 
miR-199a/214 hsa-mir-199a-2, hsa-mir-199a-1, hsa-mir-199b, hsa-mir-214 
chrXq27.3 hsa-mir-514-1, hsa-mir-514-2, hsa-mir-514-3, hsa-mir-508 
miR-451/144/486  hsa-mir-451, hsa-mir-144, hsa-mir-486 
miR-99a/let-7c/miR-125b hsa-mir-99a, hsa-let-7c, hsa-mir-125b-2 
miR-200 hsa-mir-200b, hsa-mir-200a, hsa-mir-429 
Let-7a hsa-let-7a-1, hsa-let-7a-3, hsa-let-7a-2 
miR-194/192 hsa-mir-194-2, hsa-mir-194-1, hsa-mir-192 
miR-17/92 hsa-mir-20a, hsa-mir-17, hsa-mir-92a-1 
 
 
Leukocyte-Attractor Signature and M+/M- Methylation-Attractor Signatures 
The leukocyte-attractor signature aligns with leukocyte abundance in the tumorsample. The 
top five identified genes, prominent in all types are CD53, SASH3 (aka SLY), IL10RA, 
NCKAP1L, LCP2 (aka SLP-76). We discovered a similar form of the attractor using the TCGA 
PanCan12 data set called LYM because we hypothesized that the strong coexpression of the top-
ranked genes was mostly due to the varying relative amounts of some activated lymphocytes that 
infiltrate cancer samples [78]. By identifying this signature in single-cell transcriptomes, the cells 
from solid tumors, in Chapter 5 we elucidate that the signature forms through relative amounts of 
leukocytes. The signature was predictive of patients’ outcomes in multiple cancer types [79, 85]. 
Expression of the signature aligns with improvedoutcomes in multiple cancer types (Appendix 
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E). In Chapter 4, we discuss the integration of this signature into a biomarker for breast cancer 
prognosis. 
Figure 3.1A demonstrates strong coexpression, as well as the very large range of values 
among the solid nonimmune-related cancer types. Color-coded three-way scatter plots use genes 
CD53 (horizontal), SASH3 (vertical), IL10RA (color coded from blue to red). Dots at the upper 
right corner of each scatter plot represent patients with high lymphocyte infiltration. The 
observation is consistent with the hypothesis that this core signature plays a key role in cancer. 
The strong pancancer coexpression of core genes suggests the presence of a particular mixture of 
leukocytes subpopulation. The unified combined biological role and pathways of these genes is 
still yet to be clarified. 
We have presented that the LYM-attractor signature strongly correlates with the methylation-
attractor signatures M+ and M-, which indicates that a population of cells expressing LYM exists 
and the DNA-methylation patterns represented as M+ and M- represent the overmethylated and 
undermethylated sites of those immune cells (Figure 3.1B) . We considered the possibilities that 
those genes are expressed by tumor cells or infiltrating cells. Based on the attractor signatures 
discovered in single-cell transcriptomes (Table 3.4), we clarified that the leukocytes, including 
the lymphocytes, express the previous LYM signature. Therefore, the leukocyte-attractor 
signature overrides the previous LYM signature. To ensure consistency, we also reference the 
signature as LYM in the following chapters. 
In addition, the newly discovered single-cell-attractor signatures provethe leukocyte-attractor 
signature results from a mixture of subpopulations of leukocytes. The most prominent attractor 
signatures exclusively represent T lymphocytes, B lymphocytes, and macrophages as 
demonstrated in the next section and Chapter 5. 
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Mitosis-Attractor Signature 
We identified the signature using multiple data sets of individual cancer types and the TCGA 
PanCan12 data set and reported that it is associated with tumor grade  and a patient’s survival 
[77] in many cancer types. In particular, we showed that it is predictive of survival in breast 
cancer [79, 85]. Because a significant number of genes [71] are among the list of genes that 
characterize aneuploidy in tumor samples, called CIN70, also associated with poor outcomes in 
multiple cancer data sets and reflecting genomic instability [98], wereferenced the signature as 
the mitotic chromosomal-instability (CIN) signature. These genes can be found in the cancer-
marker product [99] to address the proliferation of the tumor. 
Using single-cell transcriptomes, we discovered the signature and observed its expression not 
only in tumor cells but also in normal cells undergoing mitosis. When we took a deeper look at 
the mechanism of formation of the signature, we found that the top-ranked genes of the attractor 
are the genes expressed at the mitotic-spindle checkpoint (TPX2, BUB1, DLGAP5) [100] and at 
the G2/M DNA-damage checkpoint (TPX2, BUB1, KIF2C, CDCA8, HJURP, DLGAP5) [62]. A 
defective spindle checkpoint relates to increased chromosomal instability in breast cancer cell 
lines [101]. The G2/M DNA-damage checkpoint also aligns with genomic instability and cancer 
incidence [102, 103]. 
The G2/M checkpoint ensures that chromosomes replicated correctly and DNA damage 
repaired before mitosis and the mitotic spindle checkpoint ensures that all chromosomes attach to 
the spindle before proceeding to the next step. Both checkpoints are essential for guaranteeing 
genome stability. We found that normal cells in the same form also express the signature. 
Because the checkpoints are essential for all cells, the signature represents the activity of mitosis; 
thus, we reference it as the mitosis-attractor signature. 
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We observed that expression of the signature aligns with poor outcomes in most TCGA 
cancer types (Appendix E). We demonstrate the incorporation of the signature into a prognostic 
marker for breast cancer in Chapter 4. 
 
Figure 3.1 Scatter plots of(A) CD53, SASH3, IL10RA in 18 TCGA data sets, (B) Leukocyte, 




The signature is enriched in the genes that encode the collagens and the genes associated 
with epithelial mesenchymal transition and invasiveness (SPARC, FBN1, THBS2, VCAN). We 
speculated that the MES signature highly aligns with the cancer-associated fibroblasts because 
the MES signature has been reported to align with the fibroblast infiltration level predicted by a 
tool called ESTIMATE [104] in the 12 TCGA cancer types. In this study, the discovery of the 
cell population that expresses the MES genes, described in the next section, clarified that cancer-
associated fibroblasts express the signature. The discovery also indicates that the cancer-
associated fibroblasts may secrete the MES-correlated signatures including the miRNA set (hsa-
mir-199a-2, hsa-mir-199a-1, hsa-mir-199b, hsa-mir-214) and the DLK1-DIO3 miRNA cluster 
[78], signaling the tumor cells and modulating the tumor microenvironment. However, we also 
discovered that the tumor cells express a single-cell-attractor signature that is close to the 
fibroblast attractor which implies that transdifferentiated cancer cells may express some genes. 
Reportedly, the signature aligns with breast cancer patients’ outcomes [79, 85], validated in this 
study (Appendix E). We discuss the role of the signature as a prognostic biomarker for breast 
cancer in Chapter 4. 
END-Attractor Signature 
The endothelial markers (CDH5, TIE1) and the gene that is associated with antiangiogenesis 
(ROBO4) characterize the signature [105]. Previously, we found a similar signature, called the 
END-attractor signature, in the bulk RNA-seq data and hypothesize that it is a candidate for the 
marker of endothelial cells. The signature is protective in multiple cancer types [78] and is a 
protective component in the prognostic biomarker for breast cancer [85]. We reported that the 
END and MES positively align with each other [82], and assumed that the existence of the 
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attractors indicates that the two attractors were expressed by fibroblast cells and endothelial cells 
in the tumor microenvironment. The results of the analysis using single-cell transcriptomes 
reveal the single-cell versions of the END- and the MES-attractor signatures, demonstrated in the 
next section. The correlation of the two signatures may be formed by the coexistence of the two 
cell populations infiltrated into the tumor. 
IFIT-Attractor Signature 
The top-ranked genes of the attractor induce in response to interferons. They are up-regulated 
in the ovarian cancer progenitor cells in response to interferon IFNA [106] and in response to 
treatment with recombinant IFNB1 in the blood of multiple sclerosis patients [107]. Thus, 
researchers may predict the level of signature in the response to interferon-based therapy. 
Chr8q24.3 Genomically Localized Attractor Signature 
The genomically localized attractor located on chr8q24.3 [77] is one of the strongest such 
attractors. It has been found in multiple types of cancers and confirmed as an amplicon , found 
among breast cancer amplicomes [108], and is predictive of the relapse in ER-positive breast 
cancer [109]. 
Immune-Response-Associated Genomically Localized Attractor Signatures 
Using the attractor-derivation algorithm for genomically localized coexpression events 
described in Chapter 2, we discovered 51 genomically localized signatures (Appendix B). Here 
we report the signatures that aligned with the immune response. The GIMAP signature 
(GIMAP4, GIMAP5, GIMAP6, GIMAP8, GIMAP7, GIMAP1) consists of genes in the family of 
the GTPase of the immunity-associated protein (GIMAP). They are expressed by the immune 
cells and associated with multiple immunological mechanisms and diseases [110]. 
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The HLA signature consists of genes that encode major histocompatibility-complex (MHC) 
class II proteins (HLA-DRB1, HLA-DMB, HLA-DMA, HLA-DOA, HLA-DQA1, HLA-DQB1, 
HLA-DRB5). The family of proteins are present on antigen-presenting cells involved in the 
activation of immune response. The genes belonging to the signaling lymphocytic activation 
molecule family characterize the SLAMF signature (SLAMF6, SLAMF7, CD48, LY9, SLAMF1, 
ARHGAP30, SLAMF8, CD84), which modulates the functions of T lymphocytes [111]. The 
leukocyte immunoglobulin-like receptors (LILRB4, LILRB2, LAIR1, LILRB1, LILRB, LILRA6, 
OSCAR, LILRA5) enrich the LILR signature, which aligns with the modulation of the functions 
of immune cells [112]. T lymphocytes markers characterize the CD3 signature (CD3E, CD3D, 
IL10RA, AMICA1, CD3G), which represents the population of T lymphocytes in the sample. A 
similar version of the signature uses single-cell transcriptomes, presented in the next section. 
We found that these genomically localized attractors possess not only functional significance 
but also clinical significance. We found that the GIMAP, HLA, and SLAMF signatures align 
with optimistic outcomes in most large TCGA PanCan data sets (Appendix E). The association is 
even more consistent than the leukocyte signature, although these genomically localized 
signatures positively associate with the leukocyte signature. 
PILRB-, CCNT1-, and NDUFB7-Attractor Signatures 
The PILRB signature emerged using the TCGA PanCan12 data sets [78]. We discovered the 
CCNT1- and the NDUFB7-attractor signatures in this study. Their underlying biological 
meanings are not yet known. 
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SNORD-116 Methylation-Attractor Signature 
The top-ranked probes of this attractor are located in genomic locus 15q11, which encodes a 
cluster of small nucleolar RNAs (snoRNAs) called SNORD-116 [113]. The loss of the paternal 
allele results in Prader–Willi syndrome and the loss of the maternal allele results in Angleman 
syndrome [114]. A subtype of multiple myeloma expressed SNORD115 and SNORD116 
characterize the molecular subtypes of multiple myeloma [115]. 
CDKN1C Methylation-Attractor Signature 
Five of the top probes of the attractor CDKN1C (cg08206623), FTL (cg12026095), WDR6 
(cg13003239), SCLY (cg22352273), NUCKS1 (cg01947301) are among the genes that the brain 
tissue from patients with Alzheimer’s disease up-regulates [116]. NUCKS1 (cg01947301), 
BNIP2 (cg17502267), RAB11FIP3 (cg17524151) are among the genes that a specific type of 
ovarian tumor down-regulates [117]. The biological meaning of this attractor for cancer requires 
further investigation. 
PIP5K1P1-, WDR36-, RPL14-, ABCE1-, LINC00937-, and RAB1A-Methylation-Attractor 
Signatures 
The top-ranked probes of these attractors are not located in specific genomic regions. Their 
biological meanings remain unclear. 
DLK1-DIO3-Attractor Signature 
The noncoding RNAs that resides in the genomic region chr14q32 characterizes the DLK1-
DIO3 attractor signature, positively associated with the MES-attractor signature [82]. 
Researchers reported the microRNAs in the region align with multiple types of cancer and other 
diseases [118] and noncoding RNAs in the region are potential biomarkers for the promotion of 
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liver tumor [119]. The loss of these noncoding RNAs aligns with less potential neural 
differentiation in human embryonic stem cells [120], which may be relevant to the 
transdifferentiation for tumor cells to gain invasiveness. Understanding of the regulatory 
mechanisms of these RNAs can potentially contribute to the discovery of therapeutic targets. 
miR-199a/214-Attractor Signature 
This attractor signature is regulated by the epithelial-mesenchymal-transition-associated 
transcription factor TWIST1 during the development of neural cells [121] and forms a self-
regulatory network in testicular germ-cell tumor [122]. 
miR-514/508-Attractor Signature 
The miRNAs of the attractor reside in chrXq27.3 [78]. The function of this attractor signature 
remains unknown. 
miR-451/144/486-Attractor Signature 
miR-144 and miR-451 are essential for equilibrium of the erythroid (red blood cells) [123] 
and align with promotion of tumor-cell proliferation in insulinomas [124]. The miR-451 may be 
useful in diagnosis, predicting prognosis of cancer [125] and inhibition of tumor growth [126]. 
miR-99a/let-7c/miR-125b-Attractor Signature 
The miRNAs of this signature align with the progression and generation of the stem-cell-like 
mammosphere of cholangiocarcinoma [127] and is able to predict the outcome of patients with 
certain types of mesothelioma [128]. 
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miR200-Attractor Signature 
The three miRNAs of the attractor signature are in the miR-200b-429 cluster and align with 
the recurrence and overall survival of ovarian cancer [129]. 
let-7a-Attractor Signature 
The let-7a miRNA is a tumor suppressor [130] that reverts growth in a type of lymphoma 
cells [131] and prostate cancer cells [132]. However, the hypermethylation of let-7a-3 aligns 
with favorable prognoses in epithelial ovarian cancer [133]. 
miR-194/192-Attractor Signature 
The three correlated miRNAs align with the progression of renal-cell cancers [134, 135]. 
miR-17/92-Attractor Signature 
The miRNAs of this attractor signature are in a widely-studied and highly-conserved miRNA 
cluster: the miR-17/92 cluster. They are involved in development, aging, tumor formation, and 
multiple diseases [136, 137]. In addition to oncogenetic properties, these miRNAs are also 
important in the development of B lymphocytes and lung [138]. 
Interrelationships and Association with Phenotypes 
We evaluated the associations of the consensus-attractor signatures using the median MI of 
each signature in the cancer types. Appendix E presents the interrelationships of the consensus-
attractor signatures in the TCGA data sets in which the mir-199 and the DLK1-DIO3 miRNA 
cluster correlate with the MES attractor signature. The leukocyte attractor signature corelate with 
the methylation-attractor signatures M+ and M-. The immune-response-associated genomically 
localized attractors positively correlate with the leukocyte attractor signature. 
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To elucidate the clinical implications of the consensus-attractor signatures, we evaluated the 
association of each signature and the overall survival of patients in each cancer type using the 
concordance index (CI), which is an objective measure to evaluate the consistency of the ranks 
of expression levels of a feature and the censored overall survival durations of patients, further 
described in Chapter 4. We focused the analysis on gene-expression signatures because of the 
availability of data. Appendix E presents the CI of the consensus-attractor signatures in each 
cancer type in which a signature with a CI > 0.5 is colored in red and called “inducing” because 
the higher expression of the signature aligns with shorter survival; a signature with a CI < 0.5, 
colored blue, is called “protective.” 
From the table, one can observe that the leukocyte (LYM)-attractor signature is protective in 
most TCGA data sets, which is consistent with previous publications. As discussed above, LYM 
aligns with immune-response-associated genomically localized attractors. Therefore, these 
signatures (GIMAP, HLA, SLAMF, LILR, CD3E) are also protective in most cancer types, some 
of which are more predictive than the leukocyte signature. The exception to this family of 
signature’s protective association with survival occurred in the lower glioma (LGG), which 
suggests that the immune response has a different implication in such a tumor. The CIN 
checkpoint signature is inducing in most cancer types. The exceptions occurred in colon 
adenocarcinoma (COAD) and stomach adenocarcinoma (STAD), both of which are gastric 
cancers. However, although the Chr8q24.3-attractor signature is also inducing in most cancer 
types, the exception is in the lower glioma data set. MES is also inducing in many cancer types, 
but is protective in the prostate adenocarcinoma (PRAD) data set. The exceptions imply that the 
tumors have a biological mechanism that is distinct from other tumors, requiring further 
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investigation. The END and the IFIT signatures have mixed associations with patients’ survival. 
The predictivity of other signatures is not obvious. 
3.3 Single-Cell-Attractor Signatures 
By applying the attractor algorithm and the consensus-attractor algorithm on the single-cell 
transcriptome data sets of the tumor samples (Table 3.3), we identified a novel set of attractors 
(Table 3.4). Columns of expression matrix now are cells rather than bulk samples that are 
mixtures of cell types, so resolution is enhanced because of the sharply defined cell 
subpopulations. Some of these attractors are nearly identical to the pancancer-attractor signatures 
we identified using bulk data, which clarifies the function of certain attractors. Some bulk-
expression-based attractor metagenes are now “decomposed” into higher resolution signatures 
representing cell subpopulations, which could not be identified by bulk data alone. 
In single-cell data sets, the LYM attractor forms through the exclusive expression of these 
genes byleukocytes. Therefore, the coexpression of LYM forms by immune-cell infiltration. The 
novel attractors that specifically represent the populations of T lymphocytes, B lymphocytes, and 
macrophages emerge using single-cell data sets as well. The mesenchymal MES attractor 
decomposed into a purely fibroblast-associated signature and versions in tumor cells, strongly 
associated with tumor invasiveness, cell stemness, and the epithelial-to-mesenchymal transition. 
Thus, we refer to it as a stem-like attractor signature. The mitosis attractor exists not only in 
tumor cells but also in lymphocytes in similar form. Therefore, the set of genes may not only 
relate to chromosomal instability in tumor cells but to general mitosis in lymphocytes. The 
overexpression of this signature in lymphocytes indicates the lymphocytes undergo mitotic 
clonal expansion in response to the antigen. The consensus-attractor single-cell signatures found 
in nonbrain tumor data sets appears in Table 3.4 accompanied by the full list with the scores in 
54 
Appendix D. The expression of single-cell consensus attractors is exclusively expressed by 
specific subsets of cells in the scRNA-seq data sets of melanoma [62], breast cancer [53], 
colorectal cancer [139], oligodendroglioma [9] (Appendix F). 
Table 3.3 List of the scRNA-seq Data Sets Used in the Derivation of the Single-Cell Consensus 
Attractors 
GEO Accession Number Reference Number of Cells Normalization Description 
GSE72056 [62] 4558 TPM Human metastatic melanoma tumor samples 
GSE75688 [53] 549 TPM Human breast cancer samples 
GSE81861 [139] 590 FPKM Human colorectal tumor samples 
GSE70630 [9] 4347 TPM IDH1/2-mutant oligodendroglioma tumor 
samples 
 
Table 3.4 List of the Consensus Attractors in the scRNA-seq Data Sets 
T Lymphocyte CD2, CD3D, CD3E, CD3G, FYB, ITM2A, CD96, TIGIT, IL2RG, ITK 
B Lymphocyte MS4A1, CD79A, CD22, PAX5, CD79B, IRF8, BANK1, CD19, VPREB3, WDFY4 
Macrophage/Monocyte CSF1R, CD163, CD14, LILRB4, FCGR1A, MSR1, C1QA, HCK, C1QC, VSIG4 
Fibroblast COL3A1, LUM, ISLR, COL5A1, DCN, CDH11, THY1, BGN, FBN1, MFAP4 
Endothelium ECSCR, VWF, TM4SF18, PLVAP, ELTD1, RAMP2, LDB2, ROBO4, MYCT1, SDPR 
Mitosis AURKB, ASPM, BIRC5, TOP2A, PBK, CDCA8, KIF2C, CKAP2L, TPX2, NCAPG 
Stem-like SPARC, AEBP1, CALD1, CAV1, FSTL1, DLC1, CTSK, TIMP3, NNMT, NID1 
 
T Lymphocyte-Attractor Signature 
The T-cell marker (CD2) and cytotoxicity (NKG7, CCL5, CD8A, GZMA, CCL4, CST7), 
enriche the top-ranked genes of the attractor (Appendix D), which indicates the existence of T 
lymphocytes in the sample. The cytotoxic T lymphocyte recognizes antigens through its receptor 
and destroys cells with antigens, such as tumor cells. The presence of tumor-infiltrating cytotoxic 
T lymphocytes yields optimistic outcomes in patients with ovarian [140, 141] and colorectal 
cancer [142]. 
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The tumor-infiltrating lymphocytes has been used in clinical trials as adoptive cell-transfer 
therapy for melanoma [143] and was predictive of response to the treatment [144].  
B-Lymphocyte-Attractor Signature 
Genes that are mostly expressed by the B lymphocytes (MS4A1, BANK1, CD79A, BCL11A, 
CD19, CD22) characterize the attractor. As part of the adaptive immune system, B lymphocytes 
produce antibodies to destroy tumor cells. However, B lymphocytes may play opposite roles 
where they can stimulate an immune response against cancer cells but can suppress the immune 
response by inhibiting activity of the T lymphocytes during chemotherapy [145, 146]. Tumor-
infiltrating B lymphocytes align with improved outcome [147] and improve survival 
cooperatively with tumor-infiltrating T lymphocytes [148]. The following section discusses the 
differential expression of CIN checkpoint genes in the subpopulation of B lymphocyte. 
Macrophage-Attractor Signature 
The genes expressed by the mononuclear phagocytes including the macrophages and the 
monocytes (CSF1R, CD163, CD14, FCGR1A) enrich the top-ranked genes of the attractor. 
Unlike lymphocytes, macrophages attack cancer cells through the phagocytosis process, that is, 
consuming and digesting objects that are foreign to the body. They can modulate inflammation 
in the tissue.  
Tumor infiltrating macrophages promote cancer initiation and progression [149]. Targeting 
them may benefit the response to chemotherapy [150]. Also they may play a role in the 
maintenance of cancer stem cells [151]. Because cell populations distinctly express these 
immune-response-related signatures, the composition of immune-cell populations predicted 
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using these signatures or the very signatures may develop as markers of the efficacy of the 
immunotherapy and the prognosis of the cancer patient. 
Endothelium-Attractor Signature 
As presented in Table 3.4, the endothelial cells (CDH5, CALCRL, ECSCR, VWF) expressthe 
endothelial-cell-attractor signature, while ROBO4 stabilizes the vascular network by inhibiting 
angiogenesis [105]. 
Using the scRNA-seq data, we elucidate that the endothelial cells in the tumor 
microenvironment exclusively produce the END-attractor signature. Endothelial cells form the 
angiogenic blood vessels to support the progression of tumor and modulate the immune 
response, perhaps related to metastasis [152]. 
Fibroblast-Attractor Signature 
The genes expressed by the cancer-associated fibroblast (COL1A1, DCN, THY1) characterize 
the fibroblast attractor. The attractor is similar to the MES-attractor signature but the fibroblast 
genes are ranked at the top, suggesting that the attractor is likely to be expressed by fibroblasts in 
the tumor. 
Mitosis-Attractor Signature 
The top-ranked genes of the attractor are the genes expressed at the DNA damage checkpoint 
(AURKB, BIRC5, TOP2A, CDCA8, KIF2C, CKAP2L, TPX2) [62] as well as at mitotic spindle 
formation at the mitotic spindle checkpoint (BIRC5, TPX2, AURKB, CDC20). Both are essential 
for ensuring chromosomal stability. We found a similar form of the signature in the bulk data, 
associated with poor outcomes for cancer patients [77, 79, 85]. In contrast to the assumption that 
tumor cells exclusively express the signature, they significantly align with the progression of the 
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tumor. The attractor signature was highly expressed not only in tumor cells but also in certain 
nontumor cells, particularly in subgroups of B lymphocytes in breast tumor samples (Appendix 
F). The expression of mitosis genes in lymphocytes indicates that a subset of lymphocytes in the 
microenvironment activated and underwent mitotic clonal expansion (Figure 3.2) such that the 
cloned T cells were differentiated to attack the specific antigens and the cloned B cells were 
differentiated into plasma cells that secrete antibodies. 
 
Figure 3.2 Scatter plots of (A) the T-cell signature and (B) the B-cell signature against the 
mitosis signature. 
Stem-Like-Attractor Signature 
This attractor signature is characterized by genes related to invasiveness, cell stemness, and 
the epithelial-mesenchymal transition of tumor cells. The top-ranked genes also highly overlap 
with genes of the MES signature in the bulk data set, but lack DCN, ISLR, LUM and the genes 
that encode collagens, as presented in the previous section. 
We performed gene-set enrichment analysis of the top-ranked genes of this signature using 
MSigDB [153-156], confirming that overexpression of these genes significantly enriched gene 
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sets associated with tumor invasiveness, such as genes that are up-regulated in an invasive class 
of breast cancer; invasive ductal carcinoma, compared with the noninvasive class called ductal 
carcinoma in situ [157], up-regulated in a compendium of adult-tissue stem cells [158], up-
regulated in the mammary stem cells of mouse and human [159]; “hallmark” genes that define 
epithelial-mesenchymal transition in biological events including wound healing, fibrosis, and 
metastasis [155]; and invasiveness signature resulting from the interaction of cancer cells and the 
microenvironment [160] (Figure 3.3). 
In the melanoma data set, several top genes mix with genes expressed by melanoma cells 
(MIA, TYR, PLP1, PRAME, S100B) [62] and some are expressed in fibroblast cells, such as 
SPARC [139], but these genes were indeed expressed in tumor cells in multiple data sets, 
according to annotations provided by the original papers (Figure 3.4) and by our analysis 
framework discussed in Chapter 5. Fibroblasts also expressed some of the genes of the stem-like 
signature, but tumor cells expressed more of the signature than nontumor cells in the melanoma 
data set [62] and the breast cancer data set [53] (Figure 3.5), in which the t-test P values of the 
differences of the meta-features in the tumor cells and the nonfibroblast nontumor cells are less 
than 2.2×10-16 and 3.18×10-9, respectively. The cell types of melanoma and breast cancer were 
provided as part of the data sets. 
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Figure 3.4 Scatter plots of the stem-like signature against the fibroblast signature (A) in the 
melanoma data set and (B) in the breast cancer data set. 
 
 
Figure 3.5 Boxplots of the expression levels of the stem-like signature by type of cells in (A) the 




Chapter 4 Prognostic Cancer Biomarker 
4.1 Introduction 
Molecular cancer biomarkers derived from prognostic models have been proven to be 
valuable to risk assessment and treatment-outcome prediction, such as whether an early stage 
patient will benefit from adjuvant chemotherapy [55, 57, 99]. The Sage Bionetworks-DREAM 
Breast Cancer Prognosis Challenge [80] was a crowd-sourced research study aiming to identify 
the most accurate prognostic model for breast cancer. The challenge provided large data sets 
with molecular and clinical features for model training and testing so researchers can compare 
the performances of the models using the same standard. During the challenge, we proposed five 
models that ranked at the top of the leaderboard [79], all of which used attractor metagenes and a 
metagene of two genes located adjacent to each other at Chr9q22.31, called the FGD3–SUSD3 
metagene, which we identified as the most protective feature.  
Our winning model is an ensemble of machine-learning algorithms and empirically derived 
features designed to analyze a cohort of patients. To clarify the significance of the attractor 
metagenes and to develop a prognosis-evaluation tool based on our newly identified metagenes 
for clinical use, we developed an attractor-metagene-based model that estimates breast cancer-
specific 10-year survival rate for each patient by optimizing the prediction accuracy of the model 
toward disease-specific survival (DS) information called the BCAM biomarker [85]. 
We learned that many of the models that were submitted to the challenge were similar to 
existing biomarker products; however, we hypothesized that attractor metagenes and FGD3–
SUSD3 can improve the accuracy of existing assays. Thus, we compared our features with those 
that constitute the 21-gene Oncotype DX [99], 70-gene MammaPrint [55], and 50-gene PAM50 
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[57] assays using multiple breast cancer data sets. Our results suggest that the combination of 
features used in the BCAM model may outperform models used in these products. 
During the DREAM 9 Acute Myeloid Prediction Outcome Prediction Challenge [84], we 
applied the attractor derivation approach and the prognosis modeling on the proteomics data 
from leukemia patients and discovered a proteomic attractor metafeature which predicts the 
patients’ response to therapy, demonstrating that our approaches can be applied to multiple 
cancer types, data types, and outcome types. 
4.2 Methods 
Breast Cancer Data Sets 
We found that the number of positive lymph nodes and tumor sizes were prognostic feature 
during the breast cancer challenge [79, 80]; thus, we required the training and validation data sets 
to include probes for the transcripts of FGD3 and SUSD3, tumor size, number of positive lymph 
nodes or lymph-node status, and disease-specific survival or recurrence data. We used the 
METABRIC data set [161] as the training data set and referenced the four validation data sets as 
Loi [162], Buffa [163], Wang [164], and Miller [165], presented in Table 4.1. For the data set 
with only lymph-node status, we transformed the positive status to the number of positive lymph 
nodes as 1. We logarithmically transformed the tumor size and the lymph-node number. We 
renormalized the METABRIC data set from Sage Synapse [80]. We also renormalized the data 
sets of the Affymetrix U133A/B, and Plus2.0 microarrays using the Robust Multiarray Average 
(RMA) algorithm in the Bioconductor package affy. If multiple microarray platforms were 
provided for each patient, we combined the measurements and renormalized using RMA. 
Because the model is a combination of heterogeneous covariates, we corrected the 
distribution of genomic assays in each data set by multiplying the size and lymph-node number 
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by the ratio of the standard deviations of the genomic assays in each data set to the standard 
deviation of the genomic assays in the METABRIC data set. For survival analysis, because each 
data set uses different end points for censoring, we used the end point defined closest to disease-
specific survival available in the METABRIC data set and in the Miller data set. We used time to 
recurrence in the Loi and Wang data sets and distant-relapse-free survival in the Buffa data set. 
Table 4.1 The Breast Cancer Data Sets Analyzed in this Study 
Characteristics METABRIC [161] Loi [162] Buffa [163] Wang [164] Miller [165] 
Source Database Synapse GEO GEO GEO GEO 
Accession Number syn1710250 GSE6532 GSE22219 GSE19615 GSE3494 
Number of Patients (events) 1981 (623) 393 (139) 216 (82) 115 (14) 236 (55) 
Outcome Measure Disease-Specific Survival  Time to Recurrence 
Distant-Relapse Free 
Survival Time to Recurrence Disease-Specific Survival 
Overall Follow-up Time (days)      
Median 2632 2553.25 3650 768 3710.96 
Mean 2950.98 2574.79 2855.53 719.48 2981.09 
Range 3-9218 7.99-6146.79 144-3560 12-1056 0-4653.75 
Age at diagnosis (year)      
Mean 61.12 60.4 54.5 53.89 62.51 
Range 21.93-96.29 32-88 26-80 32-85 28-93 
T stage (mm)      
Mean 26.15 23.56 26 23.12 22.07 
Range 0-182 0-82 0-90 8-65 2-65 
N stage      
Mean 1.88  1.7   
Range 0-45  0-16   
Lymph Node Positive 1036 143 92 51 78 
Grade  
1 170 82 42 23 62 
2 775 179 87 28 121 
3 952 75 65 64 51 
Immunophenotype  
ER Positive and HER2 Negative 1402   48  
PR Positive and HER2 Negative 992   39  
ER Positive 1512 348 135 66 201 
PR Positive 1044 185  52 179 
HER2 Positive 247   36  
Triple Negative 283   28  
Treatment  
HT 1224 268 128 62  
RT 1175  184   
CT 418  55 87  
None 304 125    
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Attractor Metagenes and the Prognostic Features 
We defined a set of candidates for features to use in developing the prognostic model. The 
optimal combination of these features would optimize prognostic performance in the training 
data set. We included the attractor metagenes we had used in the top-ranked models of the 
challenge, namely CIN, MES, and LYM, and two conditioned versions: MES*, restricted to 
early stage tumors defined as lymph-node negative with tumor size less than 30 mm, and LYM*, 
restricted to samples with more than three positive lymph nodes. During our participation in the 
Sage Bionetworks-DREAM Breast Cancer Prognosis Challenge, we found [79] that MES was 
prognostic only in early stage cancers and that LYM, although protective overall, aligned with 
poor prognosis in the presence of multiple positive lymph nodes. The FGD3–SUSD3 metagene 
was also an obvious candidate feature. 
As described in Chapter 2, we discovered additional attractor metagenes from 12 different 
cancer types [78] in collaboration with the TCGA Pan-Cancer project [47], such as a multicancer 
molecular signature of endothelium: END. We also included all molecular features whose 
combination is used in existing breast cancer prognostic assays: Oncotype DX (proliferation, 
invasion, estrogen, HER2 groups, CD68, GSTM1, and BAG1 genes); PAM50 defined molecular 
subtypes (basal, luminal A, luminal B, and HER2 features); the single 70-gene MammaPrint 
feature; and the three genes ESR1, PGR, ERBB2 used in the Target-Print assay [166]. Finally, we 
included the number of positive lymph nodes and tumor size, as we had identified them in the 
challenge as two of the most prognostic clinical features. 
Feature-Selector Facility 
We designed a feature-selector facility calculating the prognostic scores of combinations of 
features, including those we had used earlier and those used in existing breast cancer biomarker 
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assays, identifying the optimal selection of features for the test. We designed the prognostic 
score, evaluated as the asymptotic average of the concordance indices [167] resulting from 
random two-fold cross-validation experiments in the METABRIC data set, displayed for each 
combination of selected features to be resistant to overfitting. The concordance index is defined 
as the number of pairs of patients with determinable and concordant rankings of predictions and 
outcomes divided by the number of all the pairs of patients with determinable rankings. Each 
experiment used the selected features as covariates to train a Cox-proportional-hazards model on 
half the data set based on random splitting, and evaluated the corresponding accuracy of the 
fitted model on the other half using the concordance index. We also repeated each experiment by 
reversing the training/validation roles of the same subsets. 
The web-based facility is hosted at www.ee.columbia.edu/~anastas/featureselector, which 
evaluates the prognostic score after selecting a specified number among the above features 
(Figure 4.1). We designed the score so it would stop increasing when overfitting occurred. The 
feature-selector facility is implemented as a web service. Since splitting the data, training the 
model, and evaluating the performance takes less than one second. To avoid frequent reloads of 
the web page, we implemented the front-end of the service using the Asynchronous JavaScript 
and XML (AJAX) technique with the jQuery library, so a user can make a request to the server 
by selecting a combination of features, and the score updates without reloading the web page. 
The back-end is implemented using R and the survival package. The front-end and the back-end 
is bridged via a script written in PHP. 
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Figure 4.1 Screenshot of the feature-selector facility. 
 
Estimation of Survival Rate 
The final BCAM score between 0 and 100 is generated as the corresponding percentile value 
from the Cox model (Table 4.2) against the METABRIC data set. The breast cancer-specific ten-
year survival rate associated with the BCAM score is found by calculating the Kaplan–Meier 
hazard ratio at ten years for the METABRIC subpopulation inside a sliding window containing 
20% of the samples (10% in each side) with the closest BCAM scores. If too few patients were 
on one side of the window, we reduced the window size so it remained symmetrical. 
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Table 4.2 The BCAM Model 
Features Description Coefficient 
CIN Average expression of CENPA, DLGAP5, MELK, BUB1, KIF2C, KIF20A, KIF4A, 
CCNA2, CCNB2, NCAPG 
0.2424  
MES* Average expression of COL5A2, VCAN, SPARC, THBS2, FBN1, COL1A2, COL5A1, FAP, 
AEBP1, CTSK, restricted to node-negative patients with tumor size less than 30 mm 
0.2676  
LYM Average expression of PTPRC, CD53, LCP2, LAPTM5, DOCK2, IL10RA, CYBB, CD48, 
ITGB2, EVI2B 
-0.2868  
LYM* LYM restricted to patients with more than three positive lymph nodes 0.5491  
FGD3-SUSD3 Average expression of FGD3 and SUSD3 -0.2026  
CD68 CD68 gene 0.1751  
Size Ln( Tumor size + 10 ) in mm 0.5167  
lymNum Ln(Number of positive lymph nodes + 1 ) 0.5563  
CXCL12 CXCL12 gene -0.2715 
DNAJB9 DNAJB9 gene -0.2914 
 
Comparison of Predictive Models 
We used the concordance index to assess the accuracy of the rankings of patients’ risk, 
defined as the relative frequency of accurate pairwise predictions of survival ranking over all 
pairs of patients for which such a determination can be achieved. To compare the performances 
of the predictive models, we estimated the distribution of the concordance index as the 
concordance index for each model on each subset of samples. Because the estimator of the index 
is asymptotically normal [167], the null distribution of the concordance index can be 
approximated by a normal distribution with a mean of 0.5 and a sampling variance of the 
concordance index when the sample size is sufficiently large. Standardized by the mean under 
the null hypothesis and estimated variance from data, the concordance index approximately 
follows a Student’s t-distribution. The difference between two estimated C-indices, after 
standardization, also approximately follows a t-distribution under the null hypothesis that the two 
concordance indices are equal. Therefore, the comparison between two concordance indices can 
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be carried out by a Student’s t test and the P value is evaluated accordingly. We estimated the 
concordance index and performed the t test using the survcomp package [168]. 
Existing Breast Cancer Prognostic Models 
We compared BCAM with four biomarkers used in other genomic assays: The 21-gene 
Oncotype DX signature [99]; the 70-gene MammaPrint signature, representing a good prognosis 
gene expression profile [55]; the 50-gene ROR-S signature, whose different expression profiles 
constitute centroids for four intrinsic PAM50 subtypes [57]; and the ROR-C signature combining 
the PAM50 subtypes with original tumor size [57]. We obtained the definition of each of the four 
groups in the 21-gene signature and the formula for combining them [99] without applying the 
cutoff thresholds, as the expression levels of the groups for the microarray values and RT-qPCR 
values were not compatible. The score of the 70-gene assay derived as described in the original 
articles [55, 169]. We obtained the centroids of intrinsic subtypes from the Bioconductor 
package genefu. We obtained the formula to combine the individual scores for the four subtypes 
and tumor size from the original article [57].  
The Response-Predicting YAP1-Based Proteomic Attractor Signature for Acute Myeloid 
Leukemia  
We hypothesized that the attractor derivation method applied on large biological data sets 
identifies signatures representing important biological processes regardless of cancer types and 
data types. Thus, we applied the attractor derivation method on the protein expression data set of 
acute myeloid leukemia (AML) patients, which was provided by the DREAM 9 Acute Myeloid 
Prediction Outcome Prediction Challenge (AML-OPC) [84]. Similar to the Sage 
Bionetworks/DREAM Breast Cancer Prognosis Challenge, AML-OPC was an open challenge 
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aimed to evaluate the accuracy of models for acute myeloid leukemia prognosis prediction, 
which used the receiver operating curve (AUROC) and the average of true positive rate and true 
negative rate to assess the predictions of therapy response. The training data set had 191 patients 
with the reverse phase protein array (RPPA) data of 231 protein expression levels from bone 
marrow biopsies, clinical phenotypes and the outcomes. 
By applying the attractor derivation method on the proteomic data setting α to 2, we 
identified only one proteomic attractor signature containing nine proteins with score greater than 
0.5. The ranked list of these proteins in the signature, which tend to be present together, is YAP1, 
SMAD6, PLAC1, PPARA, PIK3CA, CTNNA1, PIM2, NF2.pS518, and ERBB3. We observed 
that simultaneous overexpression of these proteins is strongly associated with complete 
remission after therapy (but not necessarily vice versa). Figure 4.2 shows the color-coded scatter 
plot of the two strongest attractor proteins YAP1 and SMAD6 for the 191 samples of the training 
set. Notably, among the 24 training samples with the highest YAP1 attractor value (defined by 
the average values of the above eight proteins), 23 had complete response (P = 0.002 based on 
Fisher's exact test), suggesting that this attractor is predictive to the response to the therapy and 
developed a Cox model that incorporates the YAP1 proteomic attractor signature and a few other 
RPPA features with a clinical-feature-only decision tree based model to predict response to AML 
therapy [84].  
70 
 
Figure 4.2 Scatter plot of the YAP1 and the SMAD6 proteins in the AML patients. 
 
We used a semi-parametric Cox regression model on clinical data and protein data 
separately, linearly combining their scores by heuristic optimization. We observed that the area 
under the receiver operating curve (AUROC) for therapy response prediction is equal to a 
properly defined concordance index of a hypothetical survival model in which the survival time 
is response and the censoring status is 1-response, in other words, all patients resistant to therapy 
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are considered "diseased," while all patients with complete response are censored and assumed to 
have survived longer than the time to death of the diseased patients. Thus, the CI will be based 
only on the meaningful pairwise comparisons, each of which is between a patient with complete 
response against a patient with primary resistance. 
Accordingly, we devised a Cox-based heuristic approach to optimize the feature set with 
regard to the predictive performance. The features used in each predictive model were identified 
by heuristic manual optimization by finding the Cox model achieving the highest training set 
concordance index given a number of features. Starting from a random selection of n features 
from the feature pool, we fit the n-feature Cox regression to the 191 training set samples, and 
evaluate the training set CI. We then randomly replace one of the n features by another randomly 
selected feature and compare the new CI with the previous one, thus deciding whether or not the 
new feature set replaces the previous one in the current iteration. The process is repeated until 
the feature set remains unchanged for a large number of iterations. We performed the heuristic 
feature selection procedure using a small number of features on the clinical phenotypes and the 
RPPA data separately. 
In the RPPA data we included the YAP1 attractor protein signature, as well as the average 
expression of the eight highest-ranking proteins in terms of their CI (ERG, CTSG, TGM2, 
NPM1.3542, SMAD3, BAD, GATA1, and RELA). The resulting clinical features that we used 
are: age at diagnosis, total number of myeloid blast cells (ABS.BLST), cytogenetic diploidy, Flu-
HDAC regimen. The RPPA features are: the YAP1 attractor protein signature, STMN1, and the 
resistance-inducing average of the values of the eight proteins mentioned above). 
We trained the two Cox sub-models consisting of the two feature sets on the training set 
correspondingly. Then we built another Cox model integrating the two submodels. The 
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prediction was computed using the final Cox model. With the predictions and the outcomes from 
the training set, we identified the best linear mapping of the predictions achieving the highest CI 
on the training set.  
We built a decision-tree model with adaptive boosting using the R package ada [170] on the data 
set of 360 patients after augmenting the training set with the one that was provided in [171]. The 
decision tree used all the clinical phenotypes which were available in the combined covariate 
from all patients. The prediction of the model is the average of the predictions of the Cox model 
and the adaptive boosting model. The model is available at Synapse repository syn:2699126.  
4.3 Results 
We include the logarithmic versions for the number of lymph nodes and tumor size because 
we had previously found that performance becomes consistently higher if we include these 
versions rather than the direct values. The purpose of the overall facility is to provide an estimate 
of the performance of each of the existing assays by selecting the corresponding features, as well 
as to provide insight on the relative contribution of individual features when combined with 
others, leading to the selection of an optimal biomarker. Instructive results, noted in the facility, 
identify the best selection of a given number N of features. 
Following the results of the feature selector: or N = 1, the most prognostic feature among 
those listed in the facility is the “Luminal A” feature of PAM50, which measures the degree of 
correspondence with a good prognosis subtype. However, the Luminal A feature was eliminated 
from the best choice of features when N = 2, in which case the optimal choice is the FGD3–
SUSD3 metagene combined with the number of positive lymph nodes. At N = 3, we alsothe CIN 
metagene is selected, followed in increasing order by tumor size, MES*, LYM, LYM*, CD68, 
and END, each of which increases the score, at which point (N = 9) it reaches the value of 0.741 
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(Figure 4.3). Following this selection of nine features, no additional feature increases the score. 
To further increase performance, we then implemented a heuristic optimization algorithm by 
including randomly chosen single genes in combination with some or all of the selected features, 
retaining genes with high cross-validation scores and with known roles in the cancer literature. 
We thus identified two additional genes, DNAJB9 and CXCL12, for a total number of 11 
features, increasing the score to 0.747. DNAJB9 has the property that, if included among the 
potential features, is selected as early as N = 4. The other gene, CXCL12, is selected at N = 7, 
both of which play important roles in cancer [172, 173]. 
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Figure 4.3 Scores of the optimal combinations of different numbers of the features. 
 
The resulting model, BCAM, is universally applicable to all clinical subtypes and stages of 
breast cancer and does not make any use of breast cancer molecular-subtype or hormonal-status 
information, none of which provided additional prognostic value. The BCAM test comprises 
several molecular features: the breast cancer–specific FGD3–SUSD3 metagene, four attractor 
metagenes present in multiple cancer types (CIN, MES, LYM, and END), three additional 
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individual genes (CD68, DNAJB9, and CXCL12), tumor size, and the number of positive lymph 
nodes, presented in Table 4.2. The final BCAM score between 0 and 100 is generated from the 
Cox model formula as the percentile value against the 1,981-sample METABRIC data set. 
Figure 4.4 presents the estimated breast cancer-specific ten-year survival rate as a function of the 
BCAM score. 
During the development of the biomarker, we also confirmed that the breast cancer-specific 
FGD3–SUSD3 metagene, which was the most prognostic molecular feature in METABRIC, is 
highly prognostic in all other data sets, whereas the gene most associated with the FGD3–SUSD3 
metagene in METABRIC data sets and highly associated in the other data sets in this study, the 




Figure 4.4 Estimated breast cancer-specific ten-year survival rate as a function of the BCAM 
score. 
 
We validated the FGD3-SUSD3 metagene and the model using multiple independent data 
sets. For the FGD3-SUSD3 metagene, we confirmed that it was the most prognostic molecular 
feature in the METABRIC data set and was highly prognostic in all other data sets. Figure 4.5A 
presents the Kaplan–Meier survival curves of the FGD3-SUSD3 metagene whose expression 
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level significantly aligns with survival in the five data sets. The gene most associated with the 
FGD3-SUSD3 metagene in METABRIC is ESR1, which is less prognostic than FGD3-SUSD3 in 
the five data sets, presented in Figure 4.5B. 
We compared the prognostic performance of the BCAM formula with formulas of other 
genomic assays: 21-gene (the Oncotype DX 21-gene assay), 70-gene (the MammaPrint 70-gene 
assay), ROR-S (the assay using PAM50 subtype information alone), and ROR-C (the assay using 
PAM50 subtype information and tumor size). We used other breast cancer data sets appropriate 
for evaluating prognostic values, referenced as Loi [162], Buffa [163], Wang [164], and Miller 
[165]. For each data set, we also consider the two subsets, 1) lymph-node-negative (LNN) 
patients, and 2) estrogen receptor-positive (ERP) patients (regardless of PR and HER2 status). 
Additional intersection of these sets would not lead to results of statistical significance. 
BCAM outperformed the other genomic assays in all cases in which comparisons had 
statistical significance, shown in Table 4.3, in which the cells highlighted in blue are the values 
achieving the highest score in each case. Highlighted in yellow and bold are the scores for which 
the corresponding P value of comparison with the BCAM score is less than 0.05. In most 
comparisons (except when comparing BCAM with ROR-C in the LNN subsets) BCAM makes 
use of clinical information not used in the other assays. These results demonstrate the advantage 
of integrating clinical stage with the biomolecular information into one product with enhanced 
prognostic power. 
For the YAP1 proteomic attractor signature and the response predicting model, our model 
outperformed the other models by an AUROC score of 0.8052 on a 100-patient test set, as 




Figure 4.5 Kaplan–Meier plots of (A) FGD3-SUSD3 and (B) ESR1 in breast cancer data sets. 
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Table 4.3 List of the Concordance Index Scores of Each Prognostic Assay on the Breast Cancer 
Data Sets and the Subgroups of Cases 
Data Set Set Samples Events BCAM ROR-S ROR-C OncotypeDX MammaPrint 
Buffa  
Full 216 82 0.757 0.673 0.681 0.684 0.628 
LNN 125 43 0.720 0.663 0.658 0.681 0.628 
ERP 134 49 0.725 0.710 0.677 0.727 0.647 
Loi 
Full 393 139 0.716 0.604 0.668 0.635 0.605 
LNN 250 85 0.695 0.610 0.670 0.6346 0.604 
ERP 348 117 0.714 0.605 0.677 0.640 0.606 
Wang 
Full 115 14 0.782 0.640 0.686 0.642 0.594 
LNN 64 5 0.839 0.638 0.648 0.665 0.674 
ERP 66 3 0.660 0.367 0.545 0.435 0.372 
Miller 
Full 236 55 0.764 0.639 0.726 0.643 0.636 
LNN 158 22 0.690 0.604 0.702 0.608 0.604 
ERP 201 49 0.755 0.646 0.727 0.645 0.650 
METABRIC 
Full 1981 623 0.755 0.654 0.670 0.671 0.634 
LNN 1037 333 0.718 0.637 0.648 0.650 0.641 
ERP 1526 447 0.749 0.641 0.668 0.657 0.612 
TCGA RFS 
Full 320 21 0.656 0.594 0.492 0.615 0.621 
LNN 155 8 0.639 0.562 0.508 0.621 0.594 
ERP 244 11 0.638 0.569 0.526 0.568 0.594 
 
4.4 Discussion 
The results of our analysis of the METABRIC data set led to the remarkable suggestion that 
breast cancer subtype classification, as well as estrogen/progesterone receptor and HER2 status, 
do not provide any additional prognostic information when the expression levels of the FGD3–
SUSD3 and the attractor metagenes are known and considered. This suggestion is strengthened 
by the fact that the METABRIC data set is uniquely rich and thus useful for reaching results of 
statistical significance in survival analysis. To test the suggestion using the feature-selector 
facility, for all feature combinations we found that selecting the Oncotype DX Estrogen group, or 
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any of genes ESR1 and PGR, in addition to any selected feature combination that includes 
metagenes FGD3–SUSD3 and CIN does not increase, and in most cases, decreases the score. 
However, replacing the selection of the Oncotype DX Estrogen group or any of genes ESR1 and 
PGR with FGD3–SUSD3 in any selected feature combination increases the score. 
The expression values of Her2, PR, ER, and the subtype designation correlate with the 
metagenes of BCAM and therefore are indirectly considered. They do provide vital information 
and improved understanding of breast cancer biology, which has led to effective treatments. 
However, the results of our analyses suggest that they are not necessary for a breast cancer 
biomarker product. FGD3 and SUSD3 are genomically adjacent to each other and correlate with 
ESR1 and PGR. The simultaneous silencing of FGD3 and SUSD3 strongly associates with poor 
prognosis [79]. Furthermore, a recent study identified SUSD3 as the single most predictive gene 
of response to aromatase inhibitor therapy [174]. The mechanism of cosilencing the two genes is 
not yet clear. Elements that may regulate the two genes have been found in the loci. An ESR1 
binding site has been found in the locus of FGD3 [175] and ESR1 regulates the expression of 
SUSD3 through the interaction with estradiol (E2) in the cell lines [175]. 
Using the GeneHancer [176] database, which deposits the known enhancers and target genes 
in the human genome, we identified enhancer GH09G092987, which has only FGD3, SUSD3, 
and LOC101927954 as the gene targets and resides in the locus of FGD3, which may address the 
mechanism of cosilencing FGD3 and SUSD3. Among the transcription factor binding sites in 
enhancer GH09G092987, we identified that expression levels of FOXA1 and GATA3 are the only 
two genes associated with the expression of the FGD3-SUSD3 metagene at MI = 0.20 and MI = 
0.29, respectively. FOXA1 and GATA3 mediate ER binding by shaping the enhancer accessibility 
together [177]. 
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Thus, we believe that existing breast cancer prognostic assays should be reevaluated and the 
identification of the biological mechanism responsible for FGD3–SUSD3 silencing, as well as 
the corresponding phenotypic associations, should be high priority research topics. The BCAM 
biomarker is a universal prognostic assay applicable to all breast cancer subtypes and stages, 
integrating tumor biology across stages. As evidenced by the feature-selector facility, the LYM 
and MES metagenes would not be prognostic in the absence of stage information, and the 
conditioned LYM* and MES* features add significantly to the overall prognostic power. BCAM 
is also independent of tumor grade, as the CIN metagene is a proxy for, and more prognostic 
than, grade or the expression of the MKI67 gene. 
We also observed that inclusion of gene CD68, used in the Oncotype DX assay, improves the 
prognostic performance of our model, of which we were not aware during our participation in the 
challenge. The expression of gene CD68, a marker of tumor-associated macrophages, aligns with 
worse prognosis, although it positively correlates with the protective LYM lymphocyte 
infiltration signature, and their combination improves prognostic ability. 
We previously identified and defined the CIN, MES, LYM, and END features by multicancer 
analyses as representing attributes of cancer in general [77, 78]. Although they were all found 
without any use of the METABRIC data set, their prognostic power was independently 
confirmed in METABRIC. This raises the exciting possibility that they will also prove to be 
useful in serving as “building blocks” of biomarkers in other types of cancer as well. Using the 
attractor derivation methodologies, we also identified a proteomic attractor signature and a 
model which predicts response to acute myeloid leukemia therapy during the DREAM 9 Acute 
Myeloid Prediction Outcome Prediction Challenge [84]. 
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In addition to the universal applicability to all subtypes of breast cancer and the superior 
accuracy in prognosis prediction, by analyzing the distribution of the outcome of the cases that 
received different treatment options with regard to the predicted score, we found that when the 
BCAM score of ER-negative cases is low, the probability of surviving cancer is not low without 
receiving chemotherapy (Figure 4.6), which may lead to the recommendation that certain triple 
negative and HER2-positive patients avoid chemotherapy. 
 







This study had a few limitations, one being the lack of large independent data sets that have 
outcomes and the necessary data to apply the BCAM model, such as expression levels of genes 
FGD3 and SUSD3. The four available independent data sets we used have relatively small 
sample sizes and are difficult to pool. The estimated performance of existing biomarker assays 
on platforms different from those used in the actual product implementation is only suggestive 
and cannot be used as a definitive proxy of actual performance. As a general justifying principle, 
relative gene expression is reliable across platforms and measurement techniques. For example, 
we demonstrated a high level of interplatform concordance in genes identified as differentially 
expressed by comparing three RT-PCR platforms and seven microarrays, including Illumina, 
Affymetrix, and Agilent [178]. Researchers have compared the predictions from five gene 
expression-based models, including those used in Oncotype DX, MammaPrint, and intrinsic 
subtypes [179] using Agilent microarray data in all cases. Researchers evaluated the ability of six 
genomic signatures, including Oncotype DX, MammaPrint, and PAM50-ROR, to predict relapse 
in breast cancer patients with ER+ tumors treated with adjuvant tamoxifen using only four 
Affymetrix microarray data sets, but the authors of the paper [180] acknowledged that translating 
the signatures between platforms may lead to imperfect comparisons. 
The aim of our study was to demonstrate that our results are promising and to suggest that 
they should be rigorously evaluated in the context of larger scale clinical studies in the future. 
One of the main conclusion of our work is the unexpected and remarkable suggestion that ER, 
PR, and HER2 status, or molecular subtype classification, do not provide additional prognostic 
value when the values of the FGD3–SUSD3 and attractor metagenes are considered. 
For the YAP1 proteomic attractor signature, the results suggest that high levels of the YAP1 
proteomic attractor signature is strongly associated with complete response to AML therapy. 
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Scrutinizing the membership of the signature may shed light on the details of the underlying 
biological mechanism, which appears to increase the chance of complete response to therapy by 
inducing apoptosis of cancer cells. It is already known that YAP1 triggers DNA damage-induced 
apoptosis in hematological cancers [181], and that YAP1 phosphorylation is a critical step in 
selective activation of proapoptotic genes in response to DNA damage [182], which 
demonstrates that the attractor derivation method and our approach for predictive model can be 
extended to multiple cancer types, data types, and outcome types. 
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Chapter 5 Tumor Analysis Using Single-Cell Transcriptomes 
5.1 Introduction 
Single-cell omics technologies enable the study of a tumor and its microenvironment at an 
unprecedented resolution. Accurate characterization of the single cells from a tumor data set is 
crucial for understanding the composition and interactions of its heterogeneous cell populations. 
We developed ASCOT, a user-friendly software framework for the analysis of single-cell omics 
tumor data, that reduces dimensionality, addresses zero inflation by transforming the data into 
metafeatures, and characterizes cell populations using clustering analysis based on the attractor 
methodology. The framework designates the properties of the cells and the inferred copy-number 
variation levels to the putative cell populations and visualizes the discovery using the t-SNE plot. 
Single-cell omics profiling technologies study tumors and their microenvironment at the 
single-cell level. However, experience analyzing the “bulk” omics data is not applicable due to 
the unique properties of such data. For instance, the scRNA-seq data matrix is typically sparse 
due to zero inflation distorting the distance between the cells [183]. Characterizing the 
heterogeneous cells from a tumor sample using single-cell data is challenging since flow 
cytometry is limited to the known cell markers and the number of antibodies [184]; analyzing 
unknown cell subclones is not always feasible with flow-cytometry methods. 
Researchers have proposed several methods to address these challenges through different 
strategies. RaceID [185] uses the gap statistic to determine the number of centers of the k-means 
clustering. BackSPIN [186] used a customized algorithm, sorting of points into neighborhoods 
(SPIN), to cluster the cells by ordering the distance matrices. Seurat [187] reduces the dimension 
of the data matrix using PCA and t-SNE for density clustering. SINCERA [188] iteratively 
refines the results of hierarchical clustering based on the identified cell-type-specific signatures. 
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pcaReduce [189] integrates PCA with an agglomerative clustering method. SNN-cliq [190] 
builds a shared k-nearest neighbor graph of the cells and clusters the cells by identifying the 
cliques. Single-cell consensus clustering (SC3) [191] projects the data using multiple clustering 
transformations and performs a consensus clustering on the results to integrate them. 
The methods that focus on specific issues, such as mitigating the effect of zero inflation [183, 
192-195], analysis of the differential expression [66, 196, 197], analysis of the cell fates [198] 
have also been introduced. But these methods make restrictive assumptions on the data, lack the 
facilities for analyzing tumor heterogeneity, or require considerable programming expertise. 
ASCOT addresses the issues of zero inflation, dimension reduction, and clustering by deriving 
the virtual signatures of cells using an unsupervised, iterative, attractor-derivation method [77], 
which identifies the correlated features and summarizes the features into weighted averages as 
“metafeatures” that represent the core of the coexpression mechanisms. The attractor method can 
identify the coexpression and comethylation signatures associated with tumor phenotypes and 
representing biomolecular events of multiple cancer types [77-79, 85], the building blocks of the 
best-performing model in the DREAM Breast Cancer Prognosis Challenge [79] and a breast 
cancer prognosis biomarker [85]. Thus, the attractor method is applicable to the analysis of the 
omics data other than gene expression. 
The attractor method accurately captures the cell-type-specific coexpression events in the 
data sets. Several bulk-based attractor signatures were proved to be consisting of mixtures of 
cells subpopulations, and so they were decomposed into multiple single-cell attractor signatures, 
e.g. LYM is decomposed into the signatures that represent various leukocyte subpopulations 
including T lymphocytes, B lymphocytes, and macrophages; CIN is decomposed into dividing 
cancer cells but also immune cells with clonal expansion; MES is decomposed into CAFs as well 
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as the “stem-like” signature expressed by cancer cells. The stem-like signature (SPARC, AEBP1, 
CALD1, CAV1, FSTL1, DLC1, CTSK, TIMP3, NNMT, NID1) is of particular importance because 
it is associated with tumor invasiveness, cell stemness, and epithelial-mesenchymal transition 
(Figure 3.3), which are relevant to tumor metastasis. Thus, the expression of this signature can be 
used to precisely prioritize specific subclones of a tumor, which could be critical for tailoring a 
treatment plan that minimizes the risk of metastasis. 
Since these attractor signatures are exclusively associated with specific cell types and 
biological events, they can serve as ideal features for cell type analysis. In this chapter, we 
present that the attractor derivation method captures the single-cell attractor signatures and use 
them to classify the cells without using the phenotypes or the copy numbers. 
In addition to identifying biologically significant features, the attractor method identifies cell 
subgroup signatures and transforms them into virtual “metacells,” representing the transcriptomic 
“fingerprints” of the cells. The framework catalogs the cells based on the attractor metacells. 
To automate the process of annotating the putative cell populations, ASCOT detects the 
overexpressed-marker sets in each cell population using statistical methods, infers the copy-
number variation using gene-expression data [199], and visualizes the cataloging result in a t-
SNE plot with the legend. 
We implemented a friendly graphical user interface (GUI) for the framework. The 
parameters of the workflow and the marker-gene lists are adjustable through the GUI or a 




Several algorithms are integrated into ASCOT and the scRNA-seq data sets for benchmarking. 
The framework is implemented using R [200] and the GUI is implemented using tcltk2 [201]. 
The Single-Cell Transcriptome Data Sets 
We analyzed the scRNA-seq data set of the actual tumors and the cells with   ground truth. 
The tumor data sets we analyzed in the study are listed in Table 3.3. They consist of cells from 
actual melanoma [62], breast cancer [53], and colorectal tumor samples [139] (Table 3.3). The 
single-cell data sets with gold-standard labels are listed in Table 5.1 [30, 202, 203]. The 
parameters in the following section were identified by maximizing the similarity of the clustering 
result and the annotation of data set GSE36552. 
Table 5.1 List of the Annotated scRNA-seq Data Sets Analyzed in this Study 
GEO Accession 
Number 
Reference Number of Cells Normalization Description 
GSE36552  [202] 124 RPKM Human early embryos and embryonic stem cells  
GSE38495  [30] 88 RPKM Human cell lines and circulating tumor cells 
GSE45719  [203] 317 RPKM Mouse embryo cells 
 
Preprocessing of the Data Matrix 
The workflow input consisted of a real-numbered data matrix with feature rows and cell 
columns. The matrix is log2-transformed and missing values were imputed using the 𝑘-nearest-
neighbor imputation method in the Bioconductor package impute [94, 95] with 𝑘 = 10. The 
features are sorted by standard deviation across the population. 
Identification of the Metafeatures 
Starting from the row with the largest standard deviation, the framework ranks all remaining 
rows in terms of the signed MI with the selected row. The signed MI is the mutual information of 
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two continuous vectors [86] augmented by a sign determined by the Pearson correlation 
coefficient. 
The rows that have MI > 0.35 with the selected row are retained as coexpression features and 
removed from the data matrix. The process is repeated from the row with the largest standard 
deviation in the remaining matrix until all rows have been examined. 
The processed matrix is scanned by Algorithm 2.1 and processed using Algorithm 2.3 with 
the top-ranked three features in terms of MI. In the first round of attractor scanning, the attractor-
finding algorithm is applied to the data matrix using exponent six and the top-ranked genes of 
each of the coexpression feature sets as seeds. In addition, the top-ranked genes of the single-cell 
consensus attractors can be included as seeds. The attractor metafeatures are then computed as 
the weighted mean of the attractors with at least two top-ranked features with MI > 0.3. The sum 
of each set of weights is normalized to one. The metagenes are combined as a new matrix called 
the metafeature matrix; the rows are the metagenes and the columns are the cells. 
Identification of the Cell Subpopulations 
Algorithm 2.1 is applied to the transposed metafeature matrix using all cells as seeds and is 
followed by Algorithm 2.3 with the top-ranked three cells to remove the identical converged 
attractors. An attractor with the second largest MI > 0.2 is retained to compute the attractor 
metacell using the definition as the metafeatures. 
We found that restricting the exponent within a range of five to nine yields metacell numbers 
that fall in an empirical range of the cell populations in a sample, 2–20 in the GSE36552 data set 
(Figure 5.1). To maximize the chance that we find important but elusive populations, the 
scanning is started with exponent at nine. If the resulting number of the attractor metacells is 
greater than 40, the scanning process is repeated using the exponent reduced by one. 
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To initiate the clustering process, the cells are ranked in terms of the signed MI with each 
metacell. The top-ranked cell of each metacell is used as an exemplar of the initial condition of 
the PAM algorithm in the cluster package [204, 205]. The PAM algorithm is applied to the 
metafeature matrix using the Euclidean distance. The cells are cataloged into cell populations. 
The k-means algorithm initialized using the attractor metacells is provided as an alternative 
clustering method. 
 
Figure 5.1 Relationships of the exponent for metacell discovery and the number of discovered 
metacells in the annotated scRNA-seq data set GSE36552. 
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Inference and Visualization of the Properties of the Cells 
For each cell population identified through the described process, the single-sided t test of 
each feature in the data matrix is performed on two groups of cells: the cell population of interest 
and the other the cells. Using a threshold of P < 0.0001, we identified the features significantly 
overexpressed in the cell population of interest. 
The significantly overexpressed features are compared with predefined sets of the cell-
specific marker genes and biological processes. The comparison is performed using the 
hypergeometric test. If the cell population has P < 0.0001 with a gene set, the cell population is 
labeled with the property or cell type represented by the gene set. 
The copy-number variation of each cell is inferred using the simple sum of the sliding-
window means of the values across the whole genome. The window size is 101 genes [199] and 
the expression level is capped at nine. 
The characterization of the cell populations is visualized using the t-SNE algorithm in the 
Rtsne package [206] with perplexity equal to 30. The designation of the cells and the significance 
levels of the characteristics of each cell population were output in CSV format. 
5.3 Results 
To assess ASCOT’s performance identifying the cell populations, we evaluated the accuracy 
of ASCOT on classifying cells from three scRNA-seq cell-line data sets with labels of truth [30, 
202, 203]. We evaluated accuracy using the adjusted Rand index (ARI) [90, 91], which is an 
objective metric of the similarity of two clustering results (Table 5.2). 
We compared the performances with other unsupervised clustering methods designed for 
scRNA-seq data. SC3 transforms the input gene expression matrix into multiple spaces to 
perform the k-means clustering and summarizes the consensus of the clustering result [191]. We 
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used the suggested parameters and reported the largest SC3-achieved ARI in each experiment. 
pcaReduce integrates PCA with hierarchical clustering to achieve consistent clustering structures 
[189]. We performed pcaReduce with the sampling-based merging mode and the empirically 
identified best-performing parameters 𝑛𝑏𝑡 = 20 and 𝑞 = 10. Because pcaReduce generates 
multiple clustering results, the ARI of the clustering structures found in an experiment are 
summarized using the arithmetic mean. The ARI of the three methods in the three data sets are 
shown in Table 5.2. 
Table 5.2 List of the Adjusted Rand Indices of the Single-Cell Clustering Methods 
Method GSE36552 GSE38495 GSE45719 
ASCOT 0.92 0.61 0.44 
SC3 0.92 0.47 0.45 
pcaReduce  0.57 0.56 0.41 
 
Case Studies 
We present cases demonstrating that ASCOT is useful in a clinical setting for precision 
medicine. The transcriptomes were obtained from publicly available scRNA-seq data sets of 
melanoma [62] and breast cancer [53], GSE72056 and GSE75688, respectively. 
Metastatic Melanoma 
We applied the ASCOT workflow to the cells from melanoma patient CY79 (n = 896) of data 
set GSE72056. ASCOT identified three tumor subclones without using copy-number 
information, but the tumor clones have significantly larger (t-test P < 2.2E-16) CNV levels than 
the other cell populations, as presented in the sizes of points in the t-SNE plot (Figure 5.2A), in 
which the CNV levels of the cells in Tumor Subclone 1 and Tumor Subclone 2 are higher than in 
Tumor Subclone 3 (P = 5.27E-15). The putative tumor clone also expressed a larger stem-like 
signature than the nontumor cells (P < 2.2E-16) as in Figure 5.3A. Large groups of the T and B 
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lymphocytes had significant marker overexpression (P < 2.2E-16 in both cases), consistent with 
the fact that the resection site of the tumor is an auxiliary lymph node. Although the cells’ data-
set annotation was derived using the inferred CNV and the overexpressed markers, it can be used 
as an approximation to the truth. Thus, we compared the clustering results of ASCOT and SC3 
with the provided annotation using ARI as the figure of merit. The ARI values of ASCOT and 
SC3 are 0.39 and 0.40, respectively. The low ARI values are caused by the tumor’s subclone 
division. If we combine the three tumor subclones, the ARI yielded by ASCOT becomes 0.84. 
 
Figure 5.2 t-SNE plot of the classification result of the samples from (A) melanoma patient 




Figure 5.3 Boxplots of the stem-like signatures by the type of cells in (A) the cells from patient 
CY79 and (B) the cells from patient CY84 of the melanoma data set. 
Acral Primary Melanoma 
Weapplied ASCOT to the cells from melanoma patient CY84 in data set GSE72056, in 
which the tumor cells are from a primary tumor. Because the sample size is small (n = 159), we 
use exponent 𝛼 = 5 for the attractor metacell derivation. ASCOT identified five tumor clones 
whose CNV is larger than that of the nontumor cells (P = 8.651E-10) and the tumor subclones in 
question expressed larger stem-like signature than the other tumor subclones (P = 5.461E-10) as 
shown in Figure 5.2B and Figure 5.3B. 
For the nontumor cells, ASCOT identified a diverse immune cell population. In addition to 
the B lymphocytes, and two macrophage/monocyte groups, it identified two subgroups of T 
cells. The “T-cell 1” cell group expressed the markers of the helper/regulatory T cells (P < 2.2E-
16), and the “T-cell 2” cell group expressed the cytotoxic T-cell markers (P < 2.2E-16), which 
may indicate a promising outcome contributed by T-cell infiltration. The lack of division of the 
cell subpopulations may contribute to the low similarities of ASCOT and SC3 to the provided 
annotation, 0.47 and 0.54, respectively. Combining the tumor subclones and the T-cell subgroups 
and the macrophage subgroups based on ASCOT’s output increases the ARI to 0.61. 
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Breast Cancer 
ASCOT can be applied to a data set consisting of multiple subtypes of tumors. Using 
ASCOT, we analyzed the 526 cells with annotation in the breast cancer data set, which consist of 
cells from 11 tumors clinically classified as ER-positive, ER/HER2-positive, HER2-positive, and 
triple negative subtypes. 
The results of the analysis are presented in Figure 5.4, in which we find that the putative 
tumor cells have larger CNV levels than the nontumor cells. Tumor Subclone 1 consists mainly 
of tumor cells from two ER-positive patients, which ASCOT successfully classifies as of the 
same subtype but from different patients. The few cells from the ER-negative patients in this 
group suggest the existence of intratumor heterogeneity within those ER-negative tumors. Tumor 
Subclone 2 consists of tumor cells from one ER-positive patient, which expressed high level of 
the stem-like signature. Tumor Subclones 3 and 4 consist of tumor cells from an HER2-positive 
patient and a triple negative patient, respectively. The tumor cells extracted from the lymph 
nodes are still classified into the same group with the tumor cells from the primary site. The 
tumor cells from a particular HER2-positive patient split into Tumor Subclone 5 and 6. For the 
nontumor cells, ASCOT also identified a cancer-associated fibroblast group, a macrophage 
group, two T-cell and two B-cell groups sampled from different patients. The cells of T-Cell 2 
expressed the markers of cytotoxicity, which indicates that the T cells in the group are activated 
to attack the tumor cells. The cells of B-Cell 2 overexpressed the cell-cycle marker genes, which 




Figure 5.4 t-SNE plot of the cell populations in the breast cancer data set. 
 
5.4 Discussion 
As we observed that the attractor-derivation algorithm is able to identify the signatures that 
represent specific cell populations and cell states in a multiple-tumor scRNA-seq data set in 
Chapter 3, we explored the application of the signatures to address cell heterogeneity in the 
tumor cells and developed a software framework that characterizes and identifies the cells from a 
tumor sample. We found that applying the attractor-derivation algorithm to the transposed 
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metagene matrix yields a set of metacells that characterize the properties of the cell populations. 
These metacells can be integrated with the clustering methods. Our unsupervised analysis 
framework employs the attractor algorithm to derive the attractor metafeatures and the attractor 
metacells to analyze the cellular heterogeneity in a tumor sample with a user-friendly GUI. 
Using the adjusted Rand index as the figure of merit, we presented that the framework 
outperformed or performed equally well as other cell-cataloging methods for three scRNA-seq 
data sets with ground truth. For the scRNA-seq data set of actual tumors, the framework 
identified not only the tumor subclones, but also the states of the subsets of the nontumor cells 
from individual patients’ tumor samples. Although the framework does not classify the 
malignancy of the cells using CNV, the result of cell-type identification is consistent with the 
manual CNV-based annotations. We observed multiple activation states in the lymphocyte 
populations, which may be developed as predictive markers for response to immunotherapy. 
Thus, this attractor-based framework facilitates the analysis of cell heterogeneity in the tumor 
sample using single-cell molecular data with an improved performance and a user-friendly 
interface. 
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Chapter 6 Conclusions and Future Work 
In this dissertation, we proposed a family of attractor-derivation algorithms for identifying 
the correlated biomolecular features in multiple high-throughput data sets, which may be 
biologically meaningful signatures for cancer research. These algorithms are able to identify the 
general and the genomically localized forms of the correlated patterns existing in multiple gene-
expression and DNA-methylation data sets, as well as to discover the linkage disequilibrium in 
the genomes. Chapter 2 describes the methods of deriving such attractors and comments on their 
existence. 
In Chapter 3, we applied the consensus-attractor derivation algorithms on 18 cancer types 
from the TCGA PanCanAtlas data sets and discovered not only the known multicancer-attractor 
signatures but also some novel attractor signatures whose biological meanings are yet to be 
elucidated. Using rich single-cell transcriptomic data sets, we proved the hypothesis that some of 
the consensus attractors are formed by the existence of the corresponding cell subgroups in the 
tumor. 
In Chapter 4, we demonstrated that the signatures can be integrated as a powerful predictor of 
breast cancer survival, which we call the BCAM biomarker. This biomarker outperformed 
models from the branded biomarker products. We also showed that the BCAM biomarker 
potentially identifies ER-negative patients who may achieve a high survival rate without 
chemotherapy, which is clinically valuable. 
In Chapter 5, we presented a platform, called ASCOT, for analyzing the composition of 
tumors using the attractor metafeatures in the scRNA-seq data set. Using the attractor-derivation 
algorithm, the platform performs unsupervised analysis on the cells in a data set by identifying 
the co-expressed features in the single-cell transcriptomes as the features and deriving the 
metacells as the medoids of the putative cell subgroups. The platform discovers the biologically 
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meaningful attractor signatures discussed in Chapter 3, such as the attractors of the leukocytes, T 
lymphocytes, B lymphocytes, macrophages, fibroblasts, endothelium, and the mitosis event in 
the cells. 
We demonstrated that the ASCOT platform outperformed or performed as well as existing 
single-cell clustering methods on the accuracy of cell-type identification. The platform 
statistically infers the identity of the cells through predefined cell markers and RNA-derived 
copy-number variations. Thus, the platform may be useful for studying tumor–immunological, 
tumor–endothelial, and tumor–stromal interactions. In the clinical setting, the platform could be 
used to elucidate tumor heterogeneity in a particular patient to help physicians make optimal 
patient-specific treatment decisions. 
6.1 Single-Cell Epigenomic-Attractor Signatures 
In addition to single-cell transcriptomics, the emerging single-cell multiomic technologies 
enable us to record DNA methylation, transcription factor binding, histone modification, and 
DNA accessibility at the single-cell level [207]. Although single-cell transcriptomics is a 
powerful technology for deciphering cellular heterogeneity, as we presented in Chapters 3 and 5, 
several aspects remain unexplored. We presented six DNA-methylation attractors whose 
biological meanings have not been elucidated. Applying the attractor-finding algorithm on 
single-cell DNA-methylation data sets may reveal the exact cell populations with these specific 
methylation patterns to identify the meaning of these signatures. If they are associated with 
specific subpopulations of a cell type, they may be used as signatures for tracing the “lineage” of 
these cells. We have reported that the M+ methylation attractor is associated with the leukocyte 
populations [77, 208] and the leukocyte gene-expression signature in the tumor, but their top-
ranked DNA-methylation probes are not enriched in genes related to the immune response. A 
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single-cell DNA-methylation data set can potentially reveal which cell population has the pattern 
and its biological significance. 
For the other single-cell multiomics data sets that record other biomolecular traits, one could 
identify novel signatures using the attractor-derivation method, which may shed light on the 
biological mechanisms of the tumor cells by connecting the signatures found at different layers 
of the epigenomic output. 
6.2 Reconstruction of the evolution and the development processes of the cell populations 
Cancer cells evolve into multiple subclones through genetic diversification and Darwinian 
clonal selection, which leads to resistance to the therapeutic interventions that target only one of 
the subclones in the tumor thus causing treatment failure [5]. Therefore, identifying the 
evolutionary relationships of the tumor subclones in one patient is significant for clinical 
decisions. 
Multiple mathematical approaches that reveal the evolutionary history using molecular data 
have been proposed [209]. Methods for reconstructing the phylogeny of the tumor subclones 
using somatic mutations have been presented for breast [4] and prostate cancer [7]. The CNV 
information in a bulk molecular sample is valuable for addressing intratumor heterogeneity [210] 
as well. In the ICGC-TCGA-DREAM Somatic Mutation Calling Challenge Tumor 
Heterogeneity and Evolution Challenge (https://www.synapse.org/smchet), we proposed an 
ensemble model for subclonal reconstruction, which combines the information of somatic 
mutation and copy-number variation and outperformed other models in the challenge [211]. 
In Chapter 5, we demonstrated a platform addressing tumor heterogeneity in individual 
tumor samples using scRNA-seq data and presented the possibility of reconstructing subclone 
evolutionary history. With knowledge on approaches that model tumor-subclone phylogenetic 
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relationships, a potential next step would be developing an approach that reconstructs the 
phylogenetic tree of the tumor subclones of the single cells from a patient. However, in most of 
the single-cell molecular data set, the transcriptome and the genome [212] are not both available. 
Since the platform described in Chapter 5 is able to infer the copy number from the RNA data, 
an approach that infers the phylogenetic relationships of the tumor cells using such non-single-
nucleotide genomic information would be a promising addition to the platform. With such an 
approach, we may be able to elucidate the process of formation of the tumor subclones that 
expressed intriguing attractor signatures, such as the metastasis-related signature. 
The other possible next step of research would be developing a computational method that 
models the temporal changes in the transcriptome of a cell during cell differentiation. Such 
changes can be captured by single-cell technologies [213]. Because the platform can identify the 
metafeatures that reveal the state of the cells, the cell types, and the metacells summarizing the 
characteristics of each population of cells, reducing the complexity of further analysis, it is 
promising to develop an approach that reconstructs the cells’ temporal changes in the tumor 
using the metafeatures. 
6.3 Predictive markers for precision medicine in cancer 
As discussed in Chapter 3, many of the attractor signatures are associated with specific 
clinical cancer phenotypes and cell populations. The attractor signatures can be integrated into a 
predictive marker for diagnosis and prediction of prognosis to facilitate medical decisions. In 
Chapter 4, we demonstrated such an attractor-signature-based biomarker that predicts the 
prognosis of breast cancer patients receiving the standard regimens. 
Recently, immunotherapies that employ the checkpoint-receptor blockade have shown their 
clinical efficacy in multiple cancer types. Potentially predictive biomarkers, such as using the 
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expression of PD-L1 as a marker for the PD-1 directed therapy, have been proposed with limited 
predictive value [214]. Markers of response to chimeric antigen receptor T-cell therapy have also 
been studied [215]. Given the complicated immune response in the tumor microenvironment, a 
single marker may not be sufficient to accurately predict a patient’s outcome. Thus, integrating 
multiple features into a model should allow more accurate predictions [216, 217]. As described 
in Chapter 3, we discovered attractor signatures that represent specific types of leukocytes and 
their cell states. The levels of these cell-type-specific signatures reveal the composition of a 
tumor. 
Because the many specific types of leukocytes are associated with survival, these signatures 
can be the candidate members of novel predictive biomarkers. Since we also identified signatures 
related to specific cell states, not only in the tumor cells, but also in the leukocytes, they may be 
used to develop markers predicting the efficacy of novel immunotherapies. Finally, we have 
observed signatures possibly associated with the metastatic property of the tumor cells; further 
investigation of these signatures may lead to not only markers that predict the invasiveness of 
tumor cells, but also understanding of the very mechanisms occurring in the tumor cells that 
cause the transformation. 
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Appendix A Comparison of the Consensus Attractors and the 
Attractor Clusters 
Table A.1 The Consensus Attractors in the TCGA PanCan12 Data Sets 
LYM Score CIN Score MES Score END Score PILRB Score IFIT3 Score ZMYND10 Score ASXL2 Score GADD45GIP1 Score 
SASH3 0.83 CENPA 0.76 COL1A2 0.87 TIE1 0.85 PILRB 0.69 IFIT3 0.81 ZMYND10 0.95 ASXL2 0.8 GADD45GIP1 0.68 
CD2 0.82 NCAPH 0.75 COL5A1 0.85 CDH5 0.84 ZNF767 0.65 IFIT1 0.77 90288 0.58 UHMK1 0.7 TRAPPC5 0.66 
PTPRC 0.77 CDCA8 0.74 COL3A1 0.85 CD34 0.82 LOC91316 0.64 IFI44L 0.76 LRRC46 0.53 REST 0.7 MRPS34 0.59 
CCR5 0.76 KIF23 0.74 SPARC 0.76 CXorf36 0.8 AHSA2 0.62 MX1 0.76 CASC1 0.5 CCNT1 0.64 ATP5D 0.58 
CD48 0.76 MELK 0.73 FBN1 0.75 ROBO4 0.79 CCNL2 0.6 OAS2 0.75 LRRC48 0.49 TAOK1 0.63 NDUFS8 0.58 
CD3E 0.75 KIF2C 0.72 COL1A1 0.75 CD93 0.74 PABPC1L 0.59 CMPK2 0.75 C10orf79 0.48 MGAT5 0.6 NDUFB7 0.58 
SLAMF6 0.75 HJURP 0.72 COL6A3 0.75 ARHGEF15 0.73 LENG8 0.59 RSAD2 0.73 RSPH1 0.48 DDI2 0.6 NDUFA13 0.57 
ITGAL 0.75 BUB1 0.72 COL5A2 0.75 CLEC14A 0.72 AGAP6 0.59 IFI44 0.69 DNAH7 0.45 STRN 0.59 C19orf70 0.57 
IL2RG 0.74 BUB1B 0.71 AEBP1 0.7 S1PR1 0.69 GOLGA8A 0.57 IFIT2 0.63 LRRC50 0.44 LATS1 0.59 TIMM13 0.55 
CD53 0.74 SKA1 0.71 MMP2 0.69 PLVAP 0.68 SEC31B 0.55 OAS1 0.63 WDR93 0.44 RIF1 0.57 COPE 0.55 
 
Table A.2 The Attractor Clusters in the TCGA PanCan12 Data Sets [71] 
LYM Score CIN Score MES Score END Score AHSA2 Score IFIT3 Score WDR38 Score 
SASH3 0.85 TPX2 0.78 COL3A1 0.8 CDH5 0.81 AHSA2 0.77 IFIT3 0.78 WDR38 0.68 
CD53 0.84 KIF4A 0.75 COL5A2 0.78 ROBO4 0.77 LOC91316 0.64 MX1 0.76 YSK4 0.62 
NCKAP1L 0.78 KIFC1 0.73 COL1A2 0.77 CXorf36 0.76 PILRB 0.63 OAS2 0.76 ROPN1L 0.61 
LCP2 0.78 NCAPG 0.73 THBS2 0.75 CD34 0.73 ZNF767 0.63 RSAD2 0.75 C1orf194 0.6 
IL10RA 0.78 BUB1 0.73 COL5A1 0.75 CLEC14A 0.69 TTLL3 0.61 CMPK2 0.74 MORN5 0.6 
PTPRC 0.77 NCAPH 0.73 VCAN 0.73 ARHGEF15 0.67 CCNL2 0.61 IFIT1 0.73 WDR16 0.59 
EVI2B 0.76 CDCA5 0.73 COL6A3 0.72 CD93 0.67 PABPC1L 0.61 IFI44L 0.72 RSPH4A 0.58 
BIN2 0.75 KIF2C 0.72 SPARC 0.71 LDB2 0.67 LENG8 0.6 IFI44 0.7 FAM183A 0.57 
WAS 0.74 PLK1 0.72 AEBP1 0.71 ELTD1 0.67 CHKB-CPT1B 0.59 IFI6 0.64 ZMYND10 0.56 







Table B.1 The Gene Expression Attractor Signatures 
Rank Leukocyte Score Score Score Checkpoint/CIN Score CCNT1 Score Stroma Score NDUFB7 Score PILRB Score IFIT3 Score 
1 CD53 0.84 CXorf36 0.85 TPX2 0.75 CCNT1 0.81 COL1A2 0.84 NDUFB7 0.68 PILRB 0.75 IFIT3 0.82 
2 SASH3 0.82 TIE1 0.82 KIF4A 0.74 ASXL2 0.79 COL3A1 0.84 GADD45GIP1 0.68 AHSA2 0.70 IFI44L 0.78 
3 IL10RA 0.81 CD34 0.81 NCAPH 0.73 DDI2 0.73 COL5A1 0.82 C11orf83 0.67 CCNL2 0.70 IFIT1 0.74 
4 NCKAP1L 0.80 CDH5 0.80 KIF2C 0.72 TAOK1 0.72 SPARC 0.78 ATP5D 0.67 LOC91316 0.65 RSAD2 0.73 
5 LCP2 0.78 CLEC14A 0.74 BUB1 0.72 UHMK1 0.71 COL6A3 0.75 NDUFA11 0.66 ZNF767 0.65 MX1 0.72 
6 ITGAL 0.77 ARHGEF15 0.74 MCM10 0.71 REST 0.69 COL1A1 0.75 TCEB2 0.65 TTLL3 0.64 IFI44 0.69 
7 CCR5 0.76 ROBO4 0.74 SGOL1 0.71 LATS1 0.68 COL5A2 0.73 NDUFA13 0.65 AGAP4 0.63 OAS2 0.68 
8 CD4 0.76 ESAM 0.73 CENPA 0.70 RAPGEF6 0.67 FBN1 0.68 TRAPPC5 0.64 LENG8 0.63 CMPK2 0.66 
9 MYO1F 0.75 ELTD1 0.72 MELK 0.70 GTF2A1 0.67 VCAN 0.66 SSNA1 0.63 WASH7P 0.63 IFI6 0.59 
10 ARHGAP30 0.74 CD93 0.71 HJURP 0.70 NCOA2 0.67 THBS2 0.66 MRPL55 0.62 AGAP6 0.62 IFIT2 0.58 
11 LAPTM5 0.74 MMRN2 0.71 BUB1B 0.70 LCOR 0.66 AEBP1 0.65 AURKAIP1 0.62 CDK3 0.60 DDX58 0.57 
12 FERMT3 0.74 S1PR1 0.66 NCAPG 0.69 NBEAL1 0.65 MMP2 0.63 C19orf70 0.61 CHKB-CPT1B 0.59 XAF1 0.55 
13 BIN2 0.73 LDB2 0.65 KIF23 0.69 KLHL11 0.65 PDGFRB 0.63 FDX1L 0.61 ZNF692 0.57 OAS1 0.55 
14 LAIR1 0.73 MYCT1 0.65 KIF11 0.69 PRKAR2A 0.65 CDH11 0.58 MRPS34 0.61 FAM193B 0.56 HERC6 0.54 
15 DOCK2 0.73 RHOJ 0.64 KIF15 0.68 STRN 0.64 ITGA11 0.58 ZNF593 0.61 155060 0.56 OASL 0.53 
16 PLEK 0.73 PCDH12 0.63 CDCA8 0.68 ZDHHC20 0.64 COL6A2 0.58 C9orf142 0.60 CSAD 0.55 IFIH1 0.52 
17 EVI2B 0.72 ERG 0.63 NUSAP1 0.68 DPP8 0.63 EMILIN1 0.55 MRPL53 0.60 WDR27 0.55 OAS3 0.51 
18 CD2 0.71 CYYR1 0.62 EXO1 0.67 IL6ST 0.62 FAP 0.55 MRPL41 0.60 NSUN5P2 0.54 ISG15 0.48 
19 HCLS1 0.71 BCL6B 0.62 CCNA2 0.67 MGAT5 0.61 GPR124 0.54 C16orf13 0.60 NCRNA00105 0.53 DDX60 0.47 
20 SELPLG 0.71 PLVAP 0.61 FOXM1 0.67 ANKRD36BP1 0.61 COL12A1 0.53 LSMD1 0.59 SEC31B 0.52 EPSTI1 0.45 
21 CYTH4 0.71 TEK 0.60 CCNB2 0.67 IPMK 0.61 POSTN 0.52 SCAND1 0.59 FAM156A 0.52 PARP9 0.45 
22 CD48 0.71 ACVRL1 0.58 TTK 0.67 RAD54L2 0.61 PRRX1 0.52 LSM7 0.59 GOLGA8A 0.52 STAT1 0.44 
23 WAS 0.71 VWF 0.58 KIF18B 0.67 HIPK3 0.60 BGN 0.52 RFXANK 0.59 PABPC1L 0.52 HERC5 0.42 
24 CYBB 0.71 NOTCH4 0.57 NEK2 0.67 EXOC6B 0.60 NID2 0.52 NDUFS8 0.59 MAPK8IP3 0.52 UBE2L6 0.42 
25 IL12RB1 0.70 EMCN 0.55 SKA3 0.67 RC3H2 0.59 ADAMTS2 0.52 FAM128B 0.59 NCRNA00201 0.51 IRF9 0.40 
26 HAVCR2 0.70 GPR116 0.55 CKAP2L 0.67 KIAA0754 0.59 LUM 0.51 C19orf24 0.58 APBB3 0.51 PARP14 0.40 
27 C1QA 0.70 FLT4 0.54 GTSE1 0.66 C9orf102 0.59 CTSK 0.51 C16orf42 0.58 LOC338799 0.51 USP18 0.39 
28 LILRB1 0.70 KDR 0.53 PLK1 0.66 RIF1 0.58 COL8A1 0.51 CCDC124 0.58 CROCCL1 0.50 SP110 0.39 
29 PTPRC 0.70 PECAM1 0.53 DLGAP5 0.66 SERINC5 0.57 ANTXR1 0.51 ROMO1 0.57 NSUN5P1 0.50 TRIM22 0.37 
30 C1QB 0.70 SH2D3C 0.51 SKA1 0.66 ATE1 0.57 FNDC1 0.51 DNLZ 0.57 GOLGA8B 0.50 IFI27 0.37 
31 SPI1 0.69 PTPRB 0.51 CEP55 0.66 UBXN7 0.57 DCN 0.51 SURF2 0.56 LOC100272228 0.50 RTP4 0.36 
32 ITGB2 0.69 FGD5 0.50 CDCA5 0.65 ETV3 0.56 ASPN 0.50 NUBP2 0.56 PDXDC2 0.49 SP100 0.36 
33 MS4A6A 0.69 ENG 0.50 POLQ 0.65 CLOCK 0.56 ISLR 0.50 SIRT6 0.56 HERC2P2 0.49 IFIT5 0.36 
34 FYB 0.69 CALCRL 0.49 KIFC1 0.65 C1orf58 0.56 TIMP2 0.49 ZNF524 0.56 AGER 0.48 SAMD9L 0.35 
35 SPN 0.69 JAM2 0.49 ERCC6L 0.64 FAM63B 0.56 ANGPTL2 0.49 TIMM13 0.56 LOC100131434 0.48 MX2 0.34 
36 SNX20 0.68 GJA4 0.48 CDC25C 0.64 MAP3K2 0.55 CRISPLD2 0.49 NDUFS7 0.56 ATG16L2 0.48 PARP12 0.34 
37 CD3E 0.68 HSPA12B 0.47 KIF14 0.64 MYO9A 0.55 ADAM12 0.49 MRPL23 0.55 SNRNP70 0.47 PLSCR1 0.34 
38 C1QC 0.68 AOC3 0.46 TROAP 0.64 LMTK2 0.55 MXRA5 0.49 FAM173A 0.55 GIGYF1 0.46 SAMD9 0.34 
39 ARHGAP9 0.68 ADCY4 0.46 ARHGAP11A 0.64 N4BP2 0.55 COL10A1 0.48 ANAPC11 0.55 NKTR 0.45 TAP1 0.34 












































Table B.2 The miRNA Attractor Signatures 
Rank mir199 Score mir514 Score mir127 Score mir451 Score mir99a Score mir200b Score let7a Score mir194 Score mir20a Score 
1 mir-199a-2 0.95 mir-514-1 0.81 mir-127 0.81 mir-451 0.90 mir-99a 0.88 mir-200b 0.93 let-7a-1 0.96 mir-194-2 0.97 mir-20a 0.95 
2 mir-199a-1 0.92 mir-514-2 0.80 mir-379 0.79 mir-144 0.87 let-7c 0.85 mir-200a 0.90 let-7a-3 0.95 mir-194-1 0.97 mir-17 0.76 
3 mir-199b 0.91 mir-514-3 0.79 mir-134 0.76 mir-486 0.76 mir-125b-2 0.73 mir-429 0.68 let-7a-2 0.67 mir-192 0.65 mir-92a-1 0.52 
4 mir-214 0.62 mir-508 0.60 mir-382 0.76 mir-223 0.09 mir-125b-1 0.38 mir-141 0.26 let-7f-2 0.27 mir-148b 0.06 mir-19b-2 0.49 
5 mir-136 0.38 mir-891a 0.04 mir-758 0.75 mir-16-1 0.07 mir-100 0.09 mir-200c 0.21 let-7e 0.24 mir-107 0.06 mir-19b-1 0.41 
6 mir-382 0.33 mir-184 0.03 mir-654 0.73 mir-584 0.07 mir-204 0.09 mir-183 0.10 let-7b 0.23 mir-652 0.05 mir-18a 0.35 
7 mir-154 0.32 mir-103-1 0.02 mir-370 0.73 mir-16-2 0.06 mir-218-2 0.09 mir-96 0.10 let-7g 0.16 mir-128-2 0.05 mir-93 0.35 
8 mir-127 0.31 mir-101-2 0.02 mir-409 0.72 mir-185 0.05 mir-195 0.09 mir-182 0.09 let-7f-1 0.15 mir-101-2 0.05 mir-92a-2 0.33 
9 mir-409 0.30 mir-30d 0.02 mir-493 0.67 mir-190 0.05 mir-181c 0.08 mir-375 0.09 let-7c 0.09 mir-181d 0.05 mir-15a 0.20 
10 mir-134 0.28 mir-361 0.02 mir-431 0.66 mir-363 0.05 mir-199b 0.08 mir-1266 0.08 mir-195 0.08 mir-128-1 0.05 mir-660 0.13 
11 mir-493 0.28 mir-92a-1 0.02 mir-432 0.65 mir-624 0.04 let-7a-2 0.08 mir-203 0.07 mir-98 0.08 mir-190 0.05 mir-454 0.13 
12 mir-370 0.26 mir-203 0.02 mir-337 0.59 mir-140 0.04 mir-143 0.07 mir-93 0.05 mir-152 0.08 mir-32 0.05 mir-106a 0.13 
13 mir-379 0.26 mir-664 0.02 mir-410 0.58 mir-139 0.04 mir-199a-2 0.07 mir-135b 0.04 mir-410 0.07 mir-185 0.05 mir-181b-2 0.13 
14 mir-337 0.25 mir-30c-2 0.02 mir-485 0.56 mir-126 0.04 mir-199a-1 0.07 mir-7-1 0.04 mir-128-2 0.07 mir-19b-1 0.04 mir-103-2 0.10 
15 mir-381 0.24 mir-375 0.02 mir-381 0.56 mir-942 0.04 mir-497 0.07 mir-148b 0.04 mir-151 0.07 mir-15a 0.04 mir-301a 0.09 
16 mir-145 0.23 mir-374a 0.02 mir-369 0.55 mir-1976 0.03 mir-139 0.07 mir-24-1 0.04 mir-185 0.07 mir-30d 0.04 mir-16-2 0.09 
17 mir-758 0.23 mir-340 0.02 mir-889 0.54 mir-18a 0.03 mir-152 0.07 mir-181d 0.04 mir-340 0.06 mir-942 0.04 mir-362 0.09 
18 mir-369 0.22 let-7f-1 0.02 mir-487b 0.54 mir-15a 0.03 mir-23b 0.06 mir-27b 0.04 mir-193a 0.06 mir-101-1 0.04 mir-576 0.09 
19 mir-889 0.22 mir-34c 0.02 mir-495 0.53 mir-378 0.03 mir-214 0.06 mir-181c 0.04 mir-125b-2 0.06 let-7f-1 0.04 mir-103-1 0.09 
20 mir-654 0.21 mir-103-2 0.02 mir-154 0.53 mir-425 0.03 mir-370 0.06 mir-671 0.04 mir-132 0.05 mir-532 0.04 mir-219-1 0.07 
21 mir-487b 0.20 mir-20a 0.02 mir-411 0.52 mir-133a-1 0.03 mir-127 0.06 mir-219-1 0.04 mir-2110 0.05 mir-660 0.04 mir-335 0.07 
22 mir-377 0.20 mir-660 0.02 mir-377 0.51 mir-484 0.03 mir-101-1 0.06 mir-23b 0.04 mir-26a-2 0.05 mir-219-1 0.04 mir-101-2 0.07 
23 mir-411 0.19 mir-532 0.02 mir-136 0.50 mir-15b 0.03 let-7a-1 0.06 mir-335 0.03 mir-128-1 0.05 mir-200c 0.04 mir-181d 0.07 
24 mir-539 0.19 mir-362 0.02 mir-323 0.46 mir-107 0.03 let-7a-3 0.06 mir-194-2 0.03 mir-411 0.05 mir-20a 0.04 mir-20b 0.06 
25 mir-495 0.19 mir-129-1 0.02 mir-299 0.43 mir-29c 0.03 mir-27b 0.05 mir-1287 0.03 mir-100 0.05 mir-378 0.04 mir-1307 0.06 
26 mir-485 0.18 mir-200c 0.02 mir-496 0.41 mir-20b 0.03 let-7b 0.05 mir-1301 0.03 let-7i 0.05 mir-181c 0.04 mir-423 0.06 
27 mir-125b-1 0.18 mir-204 0.01 mir-487a 0.38 mir-142 0.03 mir-136 0.05 mir-1976 0.03 mir-23a 0.05 mir-200a 0.04 mir-30c-2 0.06 
28 mir-299 0.18 mir-181b-2 0.01 mir-543 0.35 mir-106a 0.03 mir-411 0.05 mir-1180 0.03 mir-107 0.05 mir-200b 0.04 mir-532 0.05 
29 mir-432 0.16 mir-129-2 0.01 mir-539 0.33 mir-145 0.03 mir-432 0.05 mir-194-1 0.03 mir-381 0.05 mir-340 0.03 mir-301b 0.05 
30 mir-410 0.16 mir-224 0.01 mir-199a-1 0.32 mir-652 0.02 mir-101-2 0.05 mir-128-2 0.03 mir-140 0.04 mir-659 0.03 mir-96 0.05 
31 mir-431 0.16 mir-30a 0.01 mir-199a-2 0.32 mir-143 0.02 mir-181d 0.05 mir-301a 0.03 mir-379 0.04 mir-141 0.03 mir-210 0.05 
32 mir-708 0.15 mir-29b-1 0.01 mir-199b 0.31 mir-29a 0.02 mir-337 0.05 mir-224 0.03 mir-101-2 0.04 mir-96 0.03 mir-942 0.05 
33 mir-487a 0.13 mir-34a 0.01 mir-433 0.31 mir-25 0.02 mir-26a-2 0.05 mir-30d 0.03 mir-382 0.04 mir-361 0.03 mir-106b 0.05 
34 mir-323 0.13 mir-320a 0.01 mir-214 0.27 mir-338 0.02 mir-487b 0.05 mir-30c-2 0.03 mir-181d 0.04 mir-30c-1 0.03 mir-30d 0.05 
35 mir-100 0.12 mir-501 0.01 mir-494 0.22 mir-32 0.02 mir-132 0.05 mir-769 0.03 mir-23b 0.04 mir-106a 0.03 mir-25 0.05 
36 mir-143 0.12 mir-93 0.01 mir-412 0.16 mir-150 0.02 mir-410 0.05 mir-192 0.03 mir-181b-1 0.04 mir-92a-1 0.03 mir-130a 0.05 
37 mir-496 0.11 mir-452 0.01 mir-145 0.12 mir-29b-1 0.02 let-7i 0.05 mir-17 0.03 mir-212 0.04 mir-29c 0.03 mir-338 0.04 
38 mir-152 0.10 mir-584 0.01 mir-100 0.11 mir-194-1 0.02 mir-382 0.05 mir-15a 0.03 mir-99a 0.04 mir-1468 0.03 mir-425 0.04 
39 mir-99a 0.10 mir-1248 0.01 mir-542 0.11 mir-18b 0.02 mir-150 0.04 mir-107 0.03 mir-497 0.04 let-7a-1 0.03 mir-181c 0.04 
40 mir-497 0.10 mir-140 0.01 mir-152 0.11 mir-24-2 0.02 mir-130a 0.04 mir-151 0.02 mir-181c 0.04 mir-576 0.03 mir-503 0.04 
 
Table B.3 The Genomically Localized Gene-Expression Attractors 
Rank GIMAP4 Score HLA Score SLAMF Score ATP5D Score LILR Score NUBP2 Score COPE Score AURKAIP1 Score GPS1 Score SHARPIN Score HIST1H4H Score SSNA1 Score GADD45GIP1 Score MRPL2 Score POLR2I Score 
1 GIMAP4 0.86 HLA-DPA1 0.86 SLAMF6 0.83 ATP5D 0.73 LILRB4 0.79 NUBP2 0.72 COPE 0.72 AURKAIP1 0.69 GPS1 0.72 SHARPIN 0.73 HIST1H4H 0.72 SSNA1 0.77 GADD45GIP1 0.79 MRPL2 0.73 POLR2I 0.78 
2 GIMAP5 0.84 HLA-DRA 0.86 SLAMF7 0.79 NDUFS7 0.71 LILRB2 0.78 MRPS34 0.69 CCDC124 0.71 UBE2J2 0.67 MRPL12 0.69 ADCK5 0.67 HIST1H2BC 0.70 C9orf142 0.73 NDUFB7 0.72 POLR1C 0.69 LIN37 0.70 
3 GIMAP6 0.83 HLA-DPB1 0.85 CD48 0.77 TIMM13 0.70 LAIR1 0.75 TCEB2 0.68 RFXANK 0.68 GLTPD1 0.66 ANAPC11 0.67 TIGD5 0.66 HIST1H2BD 0.65 MRPL41 0.73 C19orf53 0.66 MRPL14 0.67 COX6B1 0.69 
4 GIMAP8 0.80 HLA-DRB1 0.80 LY9 0.75 NDUFA11 0.67 LILRB1 0.74 NDUFB10 0.67 NDUFA13 0.67 PUSL1 0.65 STRA13 0.64 CYHR1 0.64 HIST1H1C 0.64 EDF1 0.69 C19orf43 0.64 MRPS18A 0.62 SDHAF1 0.62 
5 GIMAP7 0.80 HLA-DMB 0.77 SLAMF1 0.73 C19orf70 0.66 LILRB3 0.66 GFER 0.66 DDX49 0.64 ATAD3A 0.64 DUS1L 0.64 HSF1 0.64 HIST1H2AC 0.63 PHPT1 0.63 WDR83 0.62 MEA1 0.61 ALKBH6 0.61 
6 GIMAP1 0.68 HLA-DMA 0.75 ARHGAP30 0.62 SIRT6 0.65 LILRA6 0.58 FAM173A 0.65 PGLS 0.60 CPSF3L 0.59 RFNG 0.63 VPS28 0.62 HIST1H2BK 0.57 DNLZ 0.61 TRMT1 0.56 TOMM6 0.60 RBM42 0.59 
7   HLA-DOA 0.73 SLAMF8 0.58 C19orf24 0.65 OSCAR 0.51 NARFL 0.65 TMEM161A 0.57 C1orf159 0.59 LRRC45 0.62 EXOSC4 0.61 HIST1H3D 0.53 C9orf37 0.47 RAD23A 0.52 BYSL 0.51 PSENEN 0.54 
8   HLA-DQA1 0.73 CD84 0.47 ALKBH7 0.64 LILRA5 0.43 STUB1 0.65 FKBP8 0.55 C1orf86 0.58 ASPSCR1 0.57 PPP1R16A 0.60 HIST1H2BE 0.52 ARRDC1 0.41 CCDC130 0.49 KLHDC3 0.49 TBCB 0.54 
9   HLA-DQB1 0.64   MAP2K2 0.64   MRPL28 0.64 UBA52 0.55 DVL1 0.57 SIRT7 0.55 FBXL6 0.59 HIST1H2AE 0.44 PMPCA 0.40 STX10 0.47   TMEM147 0.53 
10   HLA-DRB5 0.63   CLPP 0.63   C16orf13 0.62 LSM4 0.54 NOC2L 0.54 C17orf89 0.52 GLI4 0.57   MRPS2 0.39 DHPS 0.46   U2AF1L4 0.51 
11       LSM7 0.63   NTHL1 0.61 C19orf60 0.54 MIB2 0.50 CCDC137 0.49 MAF1 0.57   NDOR1 0.38 FARSA 0.45     
12       CDC34 0.59   MLST8 0.61 NR2C2AP 0.45 ATAD3B 0.48 CHMP6 0.47 PUF60 0.57     DCAF15 0.38     
13       UQCR11 0.58   FAM195A 0.60 ARMC6 0.45   AZI1 0.46 ZC3H3 0.56           
14       SGTA 0.57   TBL3 0.60 SSBP4 0.42   PCYT2 0.46 PYCRL 0.55           
15       RPS15 0.56   RPUSD1 0.58     DCXR 0.45 COMMD5 0.54           
16       DOHH 0.56   ZNF205 0.58     C17orf70 0.41 GPAA1 0.54           
17       C19orf25 0.55   E4F1 0.57     HGS 0.41 MFSD3 0.54           
18       RNF126 0.55   MPG 0.56       DGAT1 0.49           
19       WDR18 0.54   FLYWCH2 0.55       EEF1D 0.49           






21       CCDC94 0.52   TELO2 0.51       LRRC14 0.47           
22       POLR2E 0.52   PGP 0.49       SCRIB 0.46           
23       MBD3 0.51   NME3 0.49       ZNF517 0.42           
24       PLEKHJ1 0.51   PIGQ 0.48       ZNF696 0.39           
25       THOP1 0.51   THOC6 0.46                   
26       SLC39A3 0.50   RHOT2 0.46                   
27       ADAT3 0.50                       
28       POLRMT 0.49                       
29       NCLN 0.48                       
30       MPND 0.47                       
31       RPL36 0.46                       
32       MED16 0.44                       
33       APBA3 0.43                       
34       FZR1 0.34                       
 
Rank SIGLEC Score BUD31 Score ZNF28 Score PIN1 Score DPM2 Score ZNHIT1 Score ZNF225 Score CLTC Score PSMB6 Score ZNF579 Score INO80E Score SSSCA1 Score ZNF134 Score CYTH4 Score ZNF420 Score 
1 SIGLEC9 0.77 BUD31 0.75 ZNF28 0.69 PIN1 0.67 DPM2 0.66 ZNHIT1 0.73 ZNF225 0.68 CLTC 0.70 PSMB6 0.79 ZNF579 0.78 INO80E 0.70 SSSCA1 0.67 ZNF134 0.60 CYTH4 0.78 ZNF420 0.69 
2 SIGLEC7 0.72 ATP5J2 0.74 ZNF468 0.64 FDX1L 0.66 PTGES2 0.66 POLR2J 0.68 ZNF45 0.66 MED13 0.64 MED11 0.65 HSPBP1 0.71 ZNF688 0.62 ZFPL1 0.66 ZNF551 0.60 NCF4 0.71 ZNF569 0.56 
3 FPR3 0.66 SHFM1 0.66 ZNF813 0.61 MRPL4 0.66 ENDOG 0.62 ALKBH4 0.64 ZNF235 0.60 APPBP2 0.63 SPAG7 0.61 ZNF787 0.65 BCL7C 0.58 BRMS1 0.61 ZNF304 0.59 RAC2 0.67 ZNF568 0.56 
4 SIGLEC5 0.63 COPS6 0.63 ZNF611 0.60 ELOF1 0.59 ZDHHC12 0.59 POP7 0.61 ZNF227 0.59 USP32 0.60 RNASEK 0.59 ZNF444 0.59 PHKG2 0.57 BAD 0.57 ZNF417 0.58 IL2RB 0.62 ZNF585A 0.55 
5 CD33 0.61 PDAP1 0.60 ZNF845 0.59 PPAN 0.59 PTRH1 0.59 MOSPD3 0.58 ZNF230 0.58 INTS2 0.58 SLC25A11 0.58 ZNF580 0.57 ZNF668 0.57 DRAP1 0.56 ZNF776 0.56 CSF2RB 0.55 ZNF585B 0.55 
6 SIGLEC10 0.59 CPSF4 0.57 ZNF765 0.55 EIF3G 0.59 URM1 0.53 FIS1 0.49 ZNF234 0.56 DCAF7 0.47 C17orf49 0.55 ZNF524 0.55 PRR14 0.53 RNASEH2C 0.56 ZNF543 0.54 APOL3 0.47 ZNF570 0.54 
7 SIGLEC14 0.57 ARPC1A 0.38 ZNF701 0.55 QTRT1 0.57 COQ4 0.53 PRKRIP1 0.46 ZNF223 0.53   RNF167 0.46 FIZ1 0.52 TBC1D10B 0.51 NUDT22 0.55 ZNF17 0.52   ZNF461 0.54 
8 FPR1 0.54   ZNF525 0.50 ZNF653 0.54 C9orf114 0.51 GNB2 0.45 ZNF180 0.52   DERL2 0.44 SUV420H2 0.52 CD2BP2 0.51 FKBP2 0.55 ZNF550 0.48   ZFP30 0.51 
9       ECSIT 0.48 WDR34 0.49 LRWD1 0.44 ZNF222 0.51     ZNF628 0.51 PPP4C 0.51 SAC3D1 0.54 ZNF548 0.47   ZNF790 0.51 
10       ATG4D 0.46 C9orf16 0.46 SLC12A9 0.35 ZNF284 0.49     RPL28 0.51 ARMC5 0.47 FAU 0.53 ZNF549 0.45   ZNF260 0.47 
11       TMED1 0.44 FPGS 0.44 TSC22D4 0.31       EPN1 0.50 ZNF768 0.41 CCS 0.52 ZNF772 0.44   ZNF527 0.46 
12       CDC37 0.43   LRCH4 0.23       NAT14 0.48 FBRS 0.41 TRPT1 0.49 ZNF773 0.41   ZNF566 0.44 
13                       COX8A 0.48       
14                       CCDC85B 0.47       
15                       YIF1A 0.47       
16                       FIBP 0.46       
17                       BANF1 0.46       
18                       ZDHHC24 0.45       
19                       PRDX5 0.44       
20                       SART1 0.44       
21                       TMEM134 0.43       
22                       PPP1CA 0.42       
23                       RPS6KB2 0.40       
24                       DNAJC4 0.39       
 
Rank NOSIP Score TEX264 Score SLC25A46 Score TIMM50 Score MXD3 Score BAG4 Score APRT Score MRPL51 Score YME1L1 Score KRIT1 Score CD3E Score ARHGAP5 Score BUB1B Score MRPL38 Score TATDN1 Score 
1 NOSIP 0.69 TEX264 0.72 SLC25A46 0.64 TIMM50 0.74 MXD3 0.72 BAG4 0.72 APRT 0.73 MRPL51 0.75 YME1L1 0.75 KRIT1 0.73 CD3E 0.87 ARHGAP5 0.71 BUB1B 0.81 MRPL38 0.81 TATDN1 0.69 
2 PTOV1 0.66 NPRL2 0.66 PJA2 0.59 MRPS12 0.70 PRELID1 0.71 WHSC1L1 0.66 TRAPPC2L 0.64 MLF2 0.63 WAC 0.58 PEX1 0.65 CD3D 0.83 HECTD1 0.70 NUSAP1 0.80 ICT1 0.76 NSMCE2 0.68 
3 PNKP 0.62 TUSC2 0.63 TMED7 0.57 EIF3K 0.64 NHP2 0.66 DDHD2 0.56 CTU2 0.60 EMG1 0.60 ABI1 0.57 ANKIB1 0.63 IL10RA 0.65 HEATR5A 0.61 OIP5 0.75 MRPS7 0.61 NDUFB9 0.61 
4 IRF3 0.57 TMEM115 0.54 APC 0.55 YIF1B 0.58 HIGD2A 0.55 ERLIN2 0.52 COX4I1 0.57 TPI1 0.51 RAB18 0.57 CCDC132 0.61 AMICA1 0.61 G2E3 0.52 RAD51 0.69 SAP30BP 0.52 C8orf76 0.58 
5 MED25 0.53 CYB561D2 0.53 MAN2A1 0.52 PSMD8 0.52 RAB24 0.52 ASH2L 0.51 KLHDC4 0.51 PHB2 0.51 ACBD5 0.54 AKAP9 0.59 CD3G 0.60 STRN3 0.51 CASC5 0.52 TSEN54 0.52 WDYHV1 0.54 
6 AKT1S1 0.49 IFRD2 0.45 DMXL1 0.51 RPS16 0.50 DDX41 0.45 PROSC 0.42 SPATA2L 0.50 NOP2 0.47               
7 SCAF1 0.49   SRFBP1 0.44 SARS2 0.49     CHMP1A 0.49 USP5 0.44               
8     CSNK1G3 0.43 FBL 0.48     RPL13 0.47                 
9     DTWD2 0.41 NFKBIB 0.47     MVD 0.45                 
10       PAF1 0.42                       
 
Rank FCGR Score ABCE1 Score PSMD4 Score MT1 Score C11orf83 Score ZNF615 Score                   
1 FCGR2A 0.77 ABCE1 0.67 PSMD4 0.78 MT1E 0.65 C11orf83 0.79 ZNF615 0.76                   
2 FCGR3A 0.72 NAA15 0.66 PSMB4 0.74 MT2A 0.59 C11orf48 0.70 ZNF614 0.66                   
3 FCER1G 0.71 
SMARC
A5 
0.63 SCNM1 0.74 MT1X 0.56 WDR74 0.66 ZNF613 0.54                   
4 FCGR2B 0.68 OTUD4 0.57 VPS72 0.69 MT1M 0.54 TMEM223 0.51 ZNF432 0.53                   








Table B.4 The DNA Methylation Attractor Signatures 
Rank chrX1 Score PIP5K1P1 Score RAB1A Score M- Score WDR36 Score M+ Score 
1 OTUD5-X-48699524 0.95 PIP5K1P1-6-7931671 0.81 RAB1A-2-65193932 0.82 CORO1A-16-30104712 0.74 WDR36-5-110492626 0.73 VPS13D-1-12213926 0.72 
2 ATP6AP1-X-153310085 0.95 GLRX2-1-191342263 0.80 RICTOR-5-38985420 0.77 SLA2-20-34691984 0.74 TBC1D5-3-17276680 0.72 IL22RA1-1-24342151 0.72 
3 SLC25A14-X-129301519 0.94 PPIE-1-39991641 0.79 FKBP14-7-30020022 0.76 PTPN6-12-6930467 0.73 SKIV2L2-5-54720446 0.71 BMF-15-38183205 0.71 
4 WDR45-X-48845035 0.94 ZBTB49-4-4361823 0.79 LOC100188947-10-93362493 0.76 STK16-2-219820709 0.73 SCAPER-15-74942483 0.71 PRSS8-16-31054500 0.70 
5 BCORL1-X-128945703 0.93 ZNF248-10-38186583 0.77 RWDD4-4-184799210 0.75 C5orf56-5-131820724 0.73 FGFR1OP2-12-27009049 0.70 MTMR11-1-148175405 0.70 
6 TSPYL2-X-53128511 0.93 PRDM2-1-13948140 0.77 MLH1-3-37067197 0.75 PTPRCAP-11-66961672 0.73 CD2AP-6-47702154 0.70 MPL-1-43586945 0.70 
7 SLC10A3-X-153372326 0.93 INPP5A-10-134346813 0.76 RDH11-14-67232677 0.74 SKI-1-2221923 0.72 SEC23A-14-38581517 0.69 NUAK2-1-203553550 0.69 
8 FAM199X-X-103297947 0.93 HOOK3-8-42948932 0.76 CCDC34-11-27338241 0.73 IGFLR1-19-40925164 0.72 SENP6-6-76482177 0.69 TNKS1BP1-11-56846646 0.69 
9 MSL3-X-11686289 0.93 CPEB3-10-93966067 0.76 ZNF283-19-49034674 0.73 TBC1D20-20-366893 0.72 MAT2B-5-162878633 0.69 DDR1-6-30961927 0.69 
10 PGK1-X-77246106 0.93 UBTD2-5-171615221 0.75 UBE2D3-4-104006551 0.73 GRK6-5-176789451 0.71 SOS1-2-39098682 0.69 INPP5J-22-29848860 0.68 
11 DOCK11-X-117513939 0.93 GTF3C5-9-134896341 0.74 EXOC4-7-132787874 0.73 SIPA1-11-65164310 0.71 MBD5-2-148932354 0.69 ERP27-12-14973319 0.67 
12 RPL10-X-153279694 0.93 KIF23-15-67514347 0.73 ICA1L-2-203348478 0.73 C16orf54-16-29664452 0.71 CUL3-2-225071605 0.69 ACLY-17-37329405 0.66 
13 ELK1-X-47395114 0.93 PFN1P2-1-143324003 0.72 SEPT11-4-78136907 0.73 CAPZB-1-19676519 0.71 TTC14-3-181811039 0.68 OVOL1-11-65317339 0.66 
14 PGRMC1-X-118254330 0.92 TMEM222-1-27524676 0.72 NDUFS4-5-52907829 0.72 UHRF1-19-4867783 0.71 SNX13-7-17798239 0.67 CDH1-16-67329970 0.66 
15 FAM104B-X-55204421 0.92 PPP2R5A-1-210549427 0.72 SPG11-15-42739186 0.72 TESC-12-115985830 0.71 VPS13B-8-100366924 0.67 SLC44A2-19-10597448 0.66 
16 ACSL4-X-108863405 0.92 CANX-5-179057948 0.71 HNRNPLL-2-38685080 0.72 PKN1-19-14411855 0.70 DYRK1A-21-37713986 0.67 ERRFI1-1-8007780 0.66 
17 FAM3A-X-153397861 0.92 ZNF827-4-147077015 0.70 MAPK14-6-36117579 0.72 PRKRIP1-7-101853857 0.70 SLC10A7-4-147584058 0.67 SIX5-19-50962540 0.66 
18 CLCN5-X-49573824 0.92 FAM46A-6-82519375 0.70 EAPP-14-34075825 0.72 KLHL6-3-184755939 0.69 METTL15-11-28147398 0.67 PBX1-1-162847793 0.66 
19 SNX12-X-70204905 0.92 MAP1LC3B2-12-115498101 0.70 C22orf39-22-17808934 0.72 OSM-22-28993881 0.69 BAZ2B-2-159884719 0.67 GUCA2A-1-42403992 0.66 
20 IRAK1-X-152938312 0.92 NDUFA4L2-12-55920677 0.69 PIK3CB-3-139962082 0.72 ACAP1-17-7180947 0.69 ABCE1-4-146250741 0.67 NR2F6-19-17215961 0.66 
21 HDAC6-X-48544909 0.92 BTN3A2-6-26478602 0.69 RUFY2-10-69775440 0.72 TNFAIP8L2-1-149395922 0.69 TANK-2-161772271 0.67 FAM129B-9-129368977 0.65 
22 FAM58A-X-152517793 0.92 ATXN1-6-16869864 0.69 LARS2-3-45442291 0.71 BIN2-12-50004379 0.68 PHTF2-7-77307513 0.67 GGT1-22-23309964 0.65 
23 EFNB1-X-67965634 0.92 SRPK2-7-104672344 0.69 NR1I2-3-120980726 0.71 FAM78A-9-133141340 0.68 IMPG2-3-102522062 0.67 ERBB3-12-54759072 0.65 
24 LAGE3-X-153360293 0.92 ANP32AP1-15-33316765 0.68 RNF8-6-37446585 0.71 FAM107B-10-14741821 0.68 PCCA-13-99612378 0.67 SPI1-11-47333561 0.65 
25 TSR2-X-54483777 0.92 ZFAND5-9-74169401 0.68 MAD1L1-7-1912973 0.71 FNBP1-9-131843329 0.68 ZBTB41-1-195391501 0.67 HRCT1-9-35896148 0.65 
26 UTP14A-X-128867825 0.92 CADPS2-7-122108647 0.67 TAF9-5-68697106 0.71 TMC6-17-73629362 0.68 TOPBP1-3-134858358 0.66 GNG7-19-2476231 0.65 
27 RBM3-X-48317832 0.92 ZNF709-19-12484422 0.67 VCPIP1-8-67709192 0.71 ZNF668-16-30983343 0.68 TTBK2-15-40998140 0.66 LPP-3-189353623 0.65 
28 CUL4B-X-119579241 0.92 ATAD2-8-124477924 0.67 TRIP4-15-62470208 0.71 ARRB2-17-4565071 0.68 GCA-2-162926626 0.66 CAPN13-2-30883783 0.64 
29 FAM120C-X-54225873 0.92 COBL-7-51351583 0.67 SMAP1-6-71526244 0.71 ARHGEF3-3-56764150 0.68 QSER1-11-32907637 0.66 TSPAN1-1-46421719 0.64 
30 RAP2C-X-131179963 0.92 SELT-3-151812148 0.66 DPH6-15-33627168 0.70 RAPGEF1-9-133444070 0.68 ABI1-10-27099752 0.66 ROCK2-2-11400270 0.64 
31 XIAP-X-122821572 0.92 BAG6-6-31728038 0.66 RFK-9-78197126 0.70 SNX11-17-43545701 0.68 EFCAB7-1-63775422 0.66 SH3GLB2-9-130828900 0.64 
32 AIFM1-X-129127589 0.92 HMGN1-21-39643000 0.66 POLQ-3-122744933 0.70 CD6-11-60495759 0.68 TRMT1L-1-183380568 0.66 SNRPE-1-202096513 0.64 
33 RLIM-X-73750811 0.91 NR4A3-9-101622515 0.66 ADAM10-15-56676565 0.70 PLEKHA7-11-16791376 0.68 TM9SF3-10-98276991 0.65 RTKN-2-74521580 0.64 
34 WDR44-X-117364274 0.91 ZNRF1-16-73590259 0.66 NEU1-6-31934923 0.70 MYO1G-7-44985374 0.68 VRK1-14-96396226 0.65 C11orf52-11-111294703 0.64 
35 PDK3-X-24393399 0.91 MDP1-14-23755199 0.65 RPUSD4-11-125577562 0.70 KCTD5-16-2677341 0.68 HNRNPH3-10-69772173 0.65 SEPT9-17-72795427 0.64 
36 MECP2-X-153015790 0.91 RPL27-17-38404013 0.65 SNX19-11-130268934 0.70 MYCBP2-13-76796408 0.68 POC5-5-75013776 0.65 IL17RC-3-9934128 0.64 
37 PHF16-X-46656797 0.91 TUBGCP3-13-112188126 0.65 ZMYND11-10-215064 0.70 DEDD2-19-47398193 0.68 FAM73A-1-78113167 0.65 RAB25-1-154297468 0.64 
38 UBL4A-X-153367854 0.91 DDOST-1-20860445 0.65 CRIM1-2-36492164 0.69 RBM28-7-127747744 0.67 FAM208A-3-56688690 0.65 PLXNB1-3-48446905 0.64 
39 ZDHHC9-X-128805259 0.91 FTX-X-73242246 0.64 MYLIP-6-16255648 0.69 RFTN1-3-16354967 0.67 HS2ST1-1-87322468 0.64 KDM2A-11-66772695 0.63 
40 HTATSF1-X-135407646 0.91 CRSP8P-5-79683370 0.64 SLC35A1-6-88243787 0.69 UXS1-2-106143207 0.67 ZNF280D-15-54710771 0.64 XYLT1-16-17306106 0.63 
41 PORCN-X-48252174 0.91 TXNRD1-12-103183436 0.64 MYH10-17-8318726 0.69 CD37-19-54530589 0.67 CHEK1-11-125004731 0.64 MMP15-16-56618974 0.63 
42 PRDX4-X-23595643 0.91 NF1-17-26696770 0.63 GTF2F2-13-44608931 0.69 EP400-12-131117031 0.66 ARID1B-6-157327397 0.64 CLDN15-7-100662276 0.63 
43 EMD-X-153261019 0.91 TKT-3-53265245 0.63 POLR1C-6-43597182 0.69 AGO2-8-141653902 0.66 PPIP5K2-5-102493331 0.64 CCDC12-3-46993690 0.63 
44 SLC9A6-X-134895205 0.91 RNF185-22-29886314 0.63 FBXW7-4-153572726 0.68 ZFHX3-16-71512751 0.66 DNAJC13-3-133665293 0.64 STARD10-11-72169819 0.63 
45 ZBTB33-X-119269569 0.91 HSPA1L-6-31887577 0.63 NCK2-2-105867507 0.68 ANKRD11-16-88029889 0.66 SYNJ1-21-32939309 0.64 TPCN1-12-112168772 0.63 
46 PHF6-X-133335020 0.91 ZBTB24-6-109910796 0.62 LSM2-6-31879625 0.68 BID-22-16597141 0.66 PTK2-8-141925583 0.64 SPTB-14-64298580 0.63 
47 DKC1-X-153644203 0.90 BMS1P4-10-75158248 0.62 PLXNC1-12-93182762 0.68 HNRNPM-19-8458601 0.66 CCNG1-5-162804372 0.64 ESRP2-16-66826796 0.63 
48 HDAC8-X-71709426 0.90 EFTUD1-15-80338141 0.62 NCOR2-12-123467795 0.68 GAS8-16-88620256 0.66 UBR3-2-170514400 0.64 JUP-17-37196949 0.63 
49 AMMECR1-X-109447803 0.90 PIGH-14-67136219 0.61 SVIL-10-29787155 0.67 FERMT3-11-63730422 0.66 NDUFA5-7-122968474 0.63 LOC338799-12-120719552 0.63 














Rank chrX2 Score CDKN1C Score RPL14 Score ABCE1 Score SNORD116 Score LINC00937 Score 
1 YIPF6-X-67639710 0.75 CDKN1C-11-2863910 0.77 RPL14-3-40473644 0.84 ABCE1-4-146257520 0.77 SNORD116-12-15-22872809 0.84 LINC00937-12-8430983 0.60 
2 XIST-X-72987919 0.72 IVNS1ABP-1-183553258 0.73 CCNL1-3-158359890 0.80 GTF2A1-14-80733567 0.73 SNORD116-15-15-22876994 0.78 USP6-17-4972706 0.56 
3 TBC1D25-X-48305013 0.70 FTL-19-54160273 0.71 ZNF143-11-9439170 0.72 CEP120-5-122749549 0.71 SNORD116-23-15-22887863 0.77 CSH1-17-59326107 0.56 
4 GPRASP1-X-101795720 0.69 RIC8B-12-105692283 0.70 METTL13-1-170017549 0.72 KTN1-14-55213545 0.71 SNORD116-28-15-22900910 0.74 TBC1D3C-17-31616188 0.54 
5 MBNL3-X-131371376 0.67 WDR6-3-49019631 0.69 OTUB1-11-63510174 0.71 CCDC88A-2-55451824 0.70 SNORD116-24-15-22890177 0.73 RFPL2-22-30920246 0.54 
6 NDUFB11-X-46886736 0.66 SCLY-2-238634203 0.68 ORMDL3-17-35337563 0.71 TRAPPC11-4-184844850 0.65 SNORD116-4-15-22855718 0.70 TBC1D3P1-DHX40P1-17-55451352 0.54 
7 FAM199X-X-103301791 0.66 RAB11FIP3-16-415495 0.68 SNX3-6-108689316 0.68 ORC5-7-103622833 0.64 SNORD116-18-15-22880540 0.70 TBC1D3P2-17-57709088 0.52 
8 WDR45-X-48822604 0.66 NUCKS1-1-203985523 0.64 EFCAB2-1-243199839 0.65 DIAPH3-13-59441691 0.63 SNORD116-1-15-22847664 0.70 COL11A2-6-33256790 0.51 
9 GDPD2-X-69558143 0.65 CCSAP-1-227545240 0.63 ZNF224-19-49290404 0.65 PIGF-2-46670996 0.62 SNORD116-13-15-22873990 0.65 ASB10-7-150516036 0.51 
10 AMMECR1-X-109450863 0.65 BNIP2-15-57768531 0.62 ATL2-2-38457946 0.62 INTS6-13-50853414 0.61 SNORD116-11-15-22870744 0.59 SCN4A-17-59387030 0.50 
11 ARMCX5-X-101743833 0.64 PRDM4-12-106678659 0.62 RPL24-3-102888242 0.62 MMRN1-4-91042153 0.53 SNORD116-8-15-22865483 0.58 CXCR1-2-218738251 0.50 
12 LAS1L-X-64649347 0.64 NPLOC4-17-77214612 0.59 CSGALNACT2-10-42954218 0.61 SPDYA-2-28897967 0.53 IPW-15-22912027 0.57 POM121L10P-22-23384907 0.50 
13 BCORL1-X-129017684 0.64 MSTO1-1-153846588 0.59 SPRED2-2-65512087 0.59 USP14-18-189302 0.52 SNORD116-29-15-22902018 0.56 CCDC13-3-42725458 0.50 
14 BCOR-X-39894185 0.59 PCYOX1-2-70338884 0.58 CYFIP1-15-20444588 0.59 TFEC-7-115371126 0.50 SNORD116-10-15-22870206 0.53 NOTCH4-6-32290930 0.49 
15 IGBP1-X-69302657 0.59 TULP3-12-2870043 0.57 RUFY1-5-178909842 0.59 DAZL-3-16617999 0.48 SNORD116-22-15-22886242 0.52 RGPD3-2-106452438 0.49 
16 MTMR1-X-149681498 0.58 MAP2K1-15-64466154 0.57 KMT2E-AS1-7-104440362 0.57 USP53-4-120425551 0.46 SNORD116-2-15-22850304 0.49 KNCN-1-46790659 0.49 
17 MED12-X-70257645 0.58 FAM76A-1-27924964 0.56 LENG1-19-59355340 0.57 SLC7A11-4-139383230 0.45 SNORD116-26-15-22895581 0.45 TPRX1-19-52999739 0.49 
18 TSPYL2-X-53130863 0.57 DCLRE1C-10-15035705 0.55 KDM8-16-27122782 0.57 ATXN10-22-44492831 0.45 PWAR1-15-22931226 0.36 PRAMEF1-1-12774269 0.48 
19 OTUD5-X-48664552 0.57 EHMT2-6-31974051 0.53 SGK1-6-134538034 0.56 MED13L-12-115158659 0.44 PWAR5-15-22781514 0.35 GH1-17-59350029 0.48 
20 ARMCX4-X-100629559 0.56 SART1-11-65485588 0.53 COX6A1-12-119360281 0.54 JMJD1C-10-64699174 0.44 SNORD116-21-15-22884468 0.30 EPX-17-53624409 0.48 
21 SPIN3-X-57034540 0.56 WHSC1L1-8-38358574 0.52 CEP164-11-116703634 0.52 TMEM135-11-86462105 0.43 SNORD115-7-15-22977485 0.19 PDE4DIP-1-143563404 0.48 
22 FAM120C-X-54113838 0.56 REXO2-11-113815267 0.52 SEPT7-7-35808103 0.52 PICALM-11-85430730 0.43 SNORD115-10-15-22983780 0.19 ZNF232-17-4964420 0.47 
23 PJA1-X-68299650 0.55 DAXX-6-33398714 0.50 C1GALT1-7-7188575 0.52 FANCL-2-58321387 0.43 SNORD115-39-15-23037461 0.18 TRIM50-7-72364873 0.47 
24 LOC286467-X-130757779 0.54 MPI-15-72969508 0.50 CDK5-7-150385869 0.52 TWF1-12-42486791 0.42 SNORD115-44-15-23045658 0.18 RFPL3-22-31083939 0.47 
25 TAB3-X-30786865 0.54 MARCKSL1-1-32574620 0.49 SUPT16H-14-20921794 0.52 ZC3H13-13-45525166 0.41 SNORD115-37-15-23034181 0.18 VRTN-14-73893121 0.47 
26 ZNF75D-X-134255227 0.54 CHD8-14-20975341 0.48 IL27RA-19-14003353 0.51 UFL1-6-97076162 0.41 SNORD115-40-15-23039207 0.17 LRRC37BP1-17-25927131 0.47 
27 POLA1-X-24922811 0.53 CDPF1-22-45024567 0.48 UQCRB-8-97317018 0.50 ATXN7L3B-12-73217556 0.40 SNORD115-14-15-22991165 0.17 TBC1D29-17-25911769 0.47 
28 MAGIX-X-48905932 0.52 EPC2-2-149118918 0.48 CEP350-1-178190356 0.50 MSANTD2-11-124142218 0.39 SNORD115-8-15-22980269 0.16 CAMTA1-1-7646684 0.47 
29 PHF8-X-53981612 0.52 DAG1-3-49482389 0.47 AP2S1-19-52045601 0.49 CCDC169-13-35755174 0.39 SNORD115-13-15-22989496 0.16 PGA4-11-60754428 0.47 
30 ELK1-X-47380945 0.52 CCDC85C-14-99140309 0.47 RTTN-18-66023882 0.49 SMEK2-2-55697308 0.39 SNORD115-16-15-22995245 0.16 SFTPB-2-85748871 0.46 
31 PPP1R2P9-X-42522441 0.52 C5orf28-5-43520482 0.47 MRPS14-1-173258991 0.49 PPP1R8-1-28049349 0.38 SNORD115-4-15-22972169 0.15 TNXB-6-32137426 0.46 
32 LAMP2-X-119455542 0.52 TMEM135-11-86426309 0.46 PPP3CA-4-102488448 0.48 ABCD2-12-38300228 0.37 SNORD115-38-15-23035917 0.15 PPY2-17-23598398 0.46 
33 IRAK1-X-152930154 0.51 LMBR1L-12-47790908 0.46 NCEH1-3-173911120 0.48 BRWD1-21-39488712 0.35 FAM90A8P-8-7634567 0.15 C3orf22-3-127760710 0.46 
34 PGK1-X-77268485 0.51 FAM168A-11-72986904 0.46 SRSF10-1-24179450 0.48 LINC00938-12-44408141 0.35 PWRN1-15-22354274 0.14 GGTLC1-20-23918162 0.46 
35 EBP-X-48271819 0.50 EZR-6-159159462 0.46 METTL21D-14-49652968 0.48 ANKEF1-20-9974324 0.35 SNORD115-6-15-22976708 0.14 RHO-3-130728962 0.46 
36 CLCN5-X-49741743 0.49 MLF2-12-6733229 0.45 DHX15-4-24194379 0.47 ETAA1-2-67477795 0.35 CECR7-22-15898499 0.14 DMRTB1-1-53705165 0.46 
37 RPS4Y2-Y-21327301 0.49 UNG-12-108019774 0.45 SRSF7-2-38831461 0.47 NEB-2-152184645 0.34 SNORD115-2-15-22968054 0.14 ECE2-3-185478156 0.46 
38 ARAF-X-47315977 0.49 PSMB8-6-32920258 0.44 NUFIP2-17-24645559 0.47 HSPA13-21-14677857 0.34 SNORD115-48-15-23065721 0.14 IGFN1-1-199462670 0.46 
39 VSIG1-X-107173925 0.49 PPP2CA-5-133589993 0.44 PIAS3-1-144286944 0.46 CBWD1-9-169409 0.33 ZNF716-7-57513755 0.14 CLPS-6-35872936 0.45 
40 FAM50A-X-153328646 0.49 UBTF-17-39651237 0.42 SRRT-7-100311247 0.46 SRPK2-7-104697051 0.33 SNORD115-35-15-23030352 0.13 MYH11-16-15785007 0.45 
41 PLXNA3-X-153350725 0.48 PRORSD1P-2-55363027 0.42 MAP3K7-6-91353911 0.46 WDR82-3-52266209 0.33 HTR5A-7-154495563 0.13 SLC25A3P1-1-53678407 0.45 
42 TRMT2B-X-100151633 0.48 OSGEPL1-2-190335508 0.42 PRKAB2-1-145110095 0.46 STEAP1B-7-22507885 0.32 PRAMEF4-1-12861767 0.13 CD300LG-17-39294975 0.45 
43 PIR-X-15419112 0.47 ANKFY1-17-4114065 0.41 ZDHHC5-11-57191518 0.45 ANKRD28-3-15814631 0.32 PTPRN2-7-157318937 0.13 OCM2-7-97458059 0.45 
44 PHKA2-AS1-X-18818301 0.47 DLGAP4-20-34523252 0.41 HDGFRP2-19-4423059 0.45 LPHN2-1-82038557 0.32 SNORD115-41-15-23041680 0.13 SCGB1C1-11-184509 0.45 
45 FGD1-X-54489097 0.46 SMNDC1-10-112054732 0.41 TAF5-10-105117622 0.45 LOC646762-7-29692096 0.32 GUSBP10-7-57253007 0.13 TMEM119-12-107509877 0.45 
46 ZNF185-X-151864347 0.46 ARF4-3-57558733 0.41 CCDC42B-12-112075307 0.45 MAST4-5-65966638 0.32 SNRPN-15-22647666 0.13 TBC1D28-17-18488624 0.45 
47 FTX-X-73242093 0.46 RING1-6-33284271 0.40 HMG20A-15-75500317 0.44 EPHA6-3-98014696 0.31 SNORD115-45-15-23060779 0.13 C2orf78-2-73863798 0.44 
48 PLS3-X-114782384 0.46 FOXJ2-12-8076291 0.39 UCHL3-13-75022425 0.44 BAZ2B-2-160181308 0.31 ZNF717-3-75917600 0.12 ADAM33-20-3598247 0.44 
49 NLGN3-X-70307397 0.46 NEO1-15-71132421 0.39 HEATR6-17-55511126 0.44 MSMO1-4-166467524 0.31 TRIM51-11-55409886 0.12 COL13A1-10-71253682 0.44 







Table C.1 Significance of Consistency of the Gene-Expression Attractors 
P-Value BLCA BRCA CESC COAD HNSC KIRC KIRP LGG LIHC LUAD LUSC OV PRAD SARC SKCM STAD THCA UCEC 
LYM 9.26E-229 3.49E-158 2.53E-294 5.00E-163 9.41E-274 1.61E-174 2.42E-228 4.54E-155 2.73E-247 3.07E-193 5.62E-227 6.96E-245 3.02E-209 1.74E-194 2.00E-214 1.39E-227 1.37E-264 1.45E-238 
END 1 8.30E-62 1 0.01334 1 2.28E-64 1 2.54E-47 1 1 0.33995 1 1 8.66E-41 6.76E-46 1 2.94E-46 2.78E-52 
CIN 9.88E-183 8.45E-206 1 1 2.38E-72 1.65E-177 1.97E-158 3.58E-182 2.27E-194 3.53E-204 6.03E-162 4.22E-160 3.17E-191 3.38E-203 1 8.03E-161 6.39E-110 7.13E-139 
CCNT1 1.94E-91 1.91E-98 5.91E-89 1 2.00E-112 7.63E-81 2.1E-101 2.86E-92 5.04E-73 3.26E-71 1 0.044565 3.65E-91 4.89E-115 0.026192 1 1.57E-100 5.01E-75 
MES 3.62E-66 5.98E-63 2.59E-59 2.98E-60 2.10E-75 3.96E-08 5.55E-28 0.03758 3.83E-46 1.77E-64 1.83E-66 9.45E-47 4.09E-18 1 6.50E-35 0.304755 1 1 
NDUFB7 7.07E-66 3.45E-112 2.07E-86 0.000147 6.55E-101 9.68E-62 2.21E-104 2.55E-98 4.33E-65 1.68E-07 0.001029 1.38E-15 2.61E-119 1 2.82E-75 1 8.71E-98 1 
PILRB 1.45E-40 1 1 1.47E-54 6.55E-50 1.63E-55 5.07E-48 3.69E-38 1 6.76E-74 3.92E-64 1 2.99E-50 1 1 4.47E-10 9.95E-48 2.23E-49 
IFIT3 1 2.36E-50 1 1 9.88E-47 1 1 1 1 5.64E-33 1.14E-41 1.13E-48 1.02E-37 1 1 1.45E-31 1 2.52E-42 
 
Table C.2 Significance of Consistency of the DNA Methylation Attractors 
P-Value BLCA BRCA CESC COAD HNSC KIRC KIRP LGG LIHC LUAD LUSC PRAD SARC SKCM STAD THCA UCEC 
chrX1 4.66E-306 2.13E-141 7.39E-56 1.05E-209 1.48E-262 1.62E-304 0 3.77E-279 2.76e-310 0 0 3.77E-06 0 0 1.38E-187 2.36E-214 6.91E-55 
PIP5K1P1 2.00E-320 1.49E-212 2.40E-188 6.26E-77 5.74E-227 1.40E-249 2.59E-166 1.92E-217 3.93E-231 9.24E-101 1.94E-212 4.12E-300 2.72E-108 3.42E-130 1.20E-28 8.03E-173 7.20E-70 
RAB1A 9.95E-80 0 0 0.304534 6.25E-249 0 0.001966 0 4.05E-92 0.261536 1.98E-25 2.13E-09 0 2.49E-146 0 0.188617 5.89E-44 
M- 5.94E-194 6.42E-252 1 1.50E-55 1.63E-199 7.32E-184 4.07E-154 1 6.42E-146 1.19E-269 1.13E-252 1 1 3.22E-145 1 6.56E-159 8.52E-252 
WDR36 0 0.002656 1.19E-36 2.28E-91 3.78E-263 3.03E-15 0 0 8.77e-315 0.735478 1.27E-49 0 6.77E-05 3.65E-26 2.01E-17 1.60E-68 1.08e-318 
M+ 2.27E-87 2.12E-214 2.84E-253 5.08E-53 2.03E-122 1.35E-73 7.45E-56 0.071903 8.81E-21 9.70E-173 6.56E-146 7.28E-63 5.22E-52 3.38E-14 5.06E-27 7.77E-64 2.99E-173 
chrX2 2.02E-76 1 0.599197 3.31E-25 1.43E-41 9.66E-74 7.05E-39 3.64E-155 2.13E-50 4.97E-38 8.30E-18 0.999679 1 6.52E-05 1.05E-12 5.75E-123 0.838901 
CDKN1C 1.44E-11 1.65E-86 0.036489 2.99E-46 1.98E-37 0.184768 9.40E-308 1.10E-80 0.961771 0.356658 0.381336 2.07E-12 0.999909 1.04E-114 0.121891 2.91E-06 0.054223 
RPL14 1.75E-44 1.51E-51 0.999996 0.938785 1.07E-101 0.243155 2.28E-55 0.37152 0.67232 6.00E-86 6.49E-73 1 6.58E-34 2.99E-46 0.93542 4.61E-80 1 
ABCE1 2.21E-23 3.62E-14 3.46E-07 3.91E-18 8.24E-19 0.034165 7.28E-54 4.80E-35 1 0.999981 9.60E-87 8.33E-94 0.61524 1.14E-35 0.000229 0.359924 0.371768 
SNORD116 7.83E-16 2.24E-23 7.03E-22 2.25E-21 2.04E-27 1 1 0.990651 5.43E-19 1.13E-25 1.12E-21 8.67E-28 2.56E-10 1.38E-20 0.011169 0.000338 2.44E-17 
LINC00937 1 1 5.41E-06 0.439029 0.999926 1 1 1 1.43E-33 0.628745 1 0.24312 2.23E-20 1.45E-28 0.999617 0.036477 0.999987 
 
Table C.3 Significance of Consistency of the miRNA Attractors 
P-Value BLCA BRCA CESC COAD HNSC KIRC KIRP LGG LIHC LUAD LUSC OV PRAD SARC SKCM STAD THCA UCEC 
mir199 0.000198 5.47E-05 3.68E-05 0.002383 8.49E-05 0.000122 0.015315 0.000938 1.47E-05 5.47E-05 4.94E-05 0.000108 0.002016 4.47E-05 4.05E-05 1 0.002943 8.96E-06 
mir514 0.01442 0.001012 0.001212 0.000926 0.002748 0.000122 0.001212 0.330206 0.000489 0.001787 0.001616 0.709871 0.002016 0.001465 0.004581 0.001287 0.00085 0.000264 
mir127 2.19E-07 0.002389 2.43E-06 0.006232 4.14E-05 0.328907 0.027307 0.003651 2.92E-06 1.38E-05 1.13E-09 0.019848 0.310484 0.006592 1.48E-06 0.00014 0.000156 1.41E-07 
mir451 0.000324 0.000405 0.000302 0.000247 0.00056 0.000733 0.000302 0.000375 0.000152 0.000405 0.000375 1 0.012097 0.000348 0.000324 0.000515 0.000231 0.000106 
mir99a 0.00312 0.001587 0.001186 0.002383 0.00056 0.000733 0.001186 1 0.000601 0.000405 0.000375 0.000668 0.003142 0.000348 0.000324 0.004921 1 0.000106 
mir200b 0.000324 0.000405 0.000302 0.000247 0.00056 0.000733 0.000302 0.007317 0.000152 0.000405 0.000375 0.010695 0.000806 0.00335 0.037298 0.000515 0.000231 0.001031 
let7a 0.000324 0.000405 0.000302 0.000247 0.00056 0.006965 0.006342 0.007317 0.000152 0.001587 0.000375 0.000668 0.000806 0.001367 0.000324 0.002014 0.00091 0.000106 
mir194 0.000324 0.007692 0.001186 0.000247 0.00056 0.000733 0.000302 0.007317 0.000152 0.001587 0.000375 0.000668 0.000806 0.000348 0.000324 0.000515 0.005319 0.000418 






































Table C.4 Significance of Consistency of the Genomically Localized Gene-Expression Attractors 
P-Value BLCA BRCA CESC COAD HNSC KIRC KIRP LGG LIHC LUAD LUSC OV PRAD SARC SKCM STAD THCA UCEC 
GIMAP4 3.00E-22 3.00E-22 3.00E-22 3.00E-22 2.10E-21 3.00E-22 3.00E-22 3.00E-22 2.40E-18 3.00E-22 2.10E-21 2.10E-21 3.00E-22 3.00E-22 2.10E-21 3.00E-22 3.00E-22 3.00E-22 
HLA-DPA1 2.40E-33 3.63E-35 3.63E-35 3.63E-35 1.04E-32 6.97E-26 1.60E-29 4.00E-34 4.00E-34 3.63E-35 3.63E-35 4.00E-34 4.96E-23 2.40E-33 1.04E-32 2.91E-31 3.15E-22 2.91E-31 
SLAMF6 2.96E-15 5.41E-24 9.66E-22 5.37E-12 1.11E-18 5.41E-24 5.55E-19 4.59E-09 1.50E-25 5.37E-12 1.61E-15 6.01E-18 1.50E-25 2.58E-22 3.84E-17 1.11E-18 2.58E-22 1.19E-22 
ATP5D 1.16E-47 3.21E-78 4.42E-63 4.18E-18 1.49E-77 6.31E-47 9.97E-60 9.39E-37 2.96E-35 4.93E-27 8.66E-09 2.79E-29 2.35E-68 2.78E-38 1.45E-47 1.99E-18 3.48E-60 1.75E-48 
LILRB4 4.96E-23 3.36E-20 1.20E-21 1.01E-19 8.41E-21 1.20E-21 1.80E-23 1.34E-16 1.20E-21 1.20E-24 1.50E-25 3.36E-20 1 1.01E-19 1.80E-23 1.34E-16 1.50E-25 1.50E-25 
NUBP2 2.35E-29 6.16E-56 1.15E-19 2.99E-35 1.06E-55 1.34E-51 7.51E-43 5.45E-51 8.39E-49 8.23E-47 2.68E-12 1.35E-22 4.69E-57 1.41E-28 1.34E-51 1.41E-28 4.16E-58 3.11E-45 
COPE 3.96E-20 8.31E-28 2.40E-33 6.33E-12 2.18E-31 2.09E-25 1.16E-29 2.18E-34 2.09E-25 2.72E-12 1.29E-09 1 6.54E-31 4.65E-27 2.30E-24 3.33E-18 6.23E-32 4.65E-27 
AURKAIP1 1.39E-19 2.91E-31 1.39E-26 2.41E-09 2.08E-28 1.99E-24 6.43E-06 3.32E-27 2.04E-21 2.56E-25 1.39E-26 1.93E-05 1.35E-08 1.45E-27 4.00E-34 6.20E-24 1.39E-19 4.96E-23 
GPS1 6.97E-26 6.71E-30 6.39E-29 1.52E-11 6.39E-29 2.12E-20 5.81E-28 1.45E-27 1.39E-26 2.96E-15 0.003433 5.55E-19 3.64E-32 4.90E-21 1.06E-13 8.44E-12 5.81E-28 1.11E-15 
SHARPIN 2.15E-20 5.23E-44 1.41E-26 1.65E-38 5.57E-44 1.19E-39 3.70E-24 6.22E-24 4.31E-41 2.82E-38 5.48E-14 2.27E-45 7.16E-42 2.57E-27 1.28E-46 2.63E-21 8.67E-34 7.23E-35 
HIST1H4H 3.80E-27 3.03E-19 1.09E-25 2.46E-09 1.09E-25 1.44E-17 1 1 5.41E-24 6.76E-25 1.09E-25 3.63E-15 1.23E-09 1 8.45E-29 3.03E-16 8.65E-17 1 
SSNA1 6.14E-09 1.90E-15 1.44E-17 0.003058 2.85E-13 2.77E-19 5.04E-17 2.69E-12 1.92E-13 3.03E-16 5.12E-10 3.03E-16 1.05E-14 6.31E-20 1.02E-13 1.64E-06 1.50E-18 2.40E-18 
GADD45GIP1 1 1.19E-22 1.61E-15 5.37E-12 2.52E-19 1.64E-09 3.36E-20 2.52E-19 1.20E-21 8.96E-13 2.52E-19 2.87E-09 5.41E-24 1 1.01E-19 1.64E-09 1.80E-23 1.64E-09 
MRPL2 1.34E-16 3.59E-16 3.36E-20 1 1.20E-24 1 7.56E-21 1 3.36E-20 1.34E-16 1.20E-24 6.88E-09 8.20E-10 5.37E-12 8.07E-16 5.37E-12 1.28E-13 1 
POLR2I 1.55E-27 1.55E-27 1.55E-27 5.29E-17 6.20E-24 4.96E-23 5.29E-17 4.16E-18 6.20E-24 1.55E-27 3.63E-35 2.40E-33 1.39E-26 2.91E-31 4.96E-23 2.91E-31 6.20E-24 1.55E-27 
SIGLEC9 2.52E-20 6.76E-25 6.76E-25 7.61E-28 1 7.61E-28 5.41E-24 6.76E-25 6.76E-25 6.76E-25 8.45E-29 8.45E-29 1 6.76E-25 7.61E-28 1 3.60E-21 3.60E-21 
BUD31 1 7.21E-15 1.90E-15 1 1.50E-18 2.05E-10 1 3.09E-15 8.41E-21 4.22E-12 9.84E-07 0.002622 3.00E-22 2.40E-18 0.004367 4.30E-09 4.22E-12 1 
ZNF28 1 1.19E-22 3.84E-13 1 8.20E-10 1.64E-09 1.01E-19 1 1.79E-12 1 1 5.07E-15 1.61E-15 1 3.59E-16 3.59E-16 1.28E-13 8.20E-10 
PIN1 3.03E-16 1.09E-24 3.80E-27 1.81E-15 1.39E-26 1.01E-19 1.44E-17 5.90E-06 1.39E-26 1 1.01E-19 5.90E-06 1.14E-14 1.23E-09 5.35E-22 1 6.65E-15 1 
DPM2 3.03E-16 4.18E-26 1 6.92E-13 3.62E-22 4.35E-21 1 1 3.60E-21 4.30E-09 1 1 3.03E-16 1.66E-18 4.84E-16 5.41E-24 7.56E-19 1 
ZNHIT1 1 2.06E-15 2.72E-12 1 7.49E-12 1 2.93E-10 8.36E-09 2.75E-14 4.83E-09 3.28E-06 8.24E-14 1.44E-17 2.93E-10 1.73E-16 4.21E-06 1.81E-12 1 
ZNF225 8.11E-23 1.16E-29 1 2.52E-19 1 1 1 1.73E-16 1.90E-26 6.31E-20 5.28E-31 3.78E-29 1 6.05E-16 2.91E-30 6.31E-20 2.52E-19 1.80E-23 
CLTC 2.93E-10 8.65E-17 1.64E-09 1 1 1 3.84E-17 1.02E-09 1 1 1 1.76E-06 1 1 1.15E-12 1 3.84E-13 1.17E-06 
PSMB6 1 4.48E-13 1.61E-12 1 1.44E-17 1 4.48E-13 1 7.21E-15 1 1 1.02E-09 3.09E-15 2.46E-06 7.37E-06 1 1.64E-06 1 
ZNF579 5.43E-16 2.18E-31 2.77E-19 4.18E-26 1.90E-15 1.16E-30 4.65E-27 3.72E-35 2.09E-25 1.19E-22 1.49E-23 5.43E-16 2.56E-28 1.90E-15 1.16E-30 5.35E-22 1.11E-18 1 
INO80E 1.15E-12 1 1 7.37E-06 1 1 3.84E-13 1 1 1 1 1 3.78E-29 1 2.70E-22 1 1 1 
SSSCA1 2.09E-25 7.66E-25 1.90E-15 5.07E-15 2.01E-29 6.54E-27 5.81E-27 2.88E-19 1.39E-23 0.005238 1 1.29E-10 3.55E-31 4.89E-16 1.19E-16 0.005984 5.53E-26 2.72E-12 
ZNF134 2.87E-09 2.58E-22 2.19E-06 1 3.84E-17 0.003495 6.11E-06 5.48E-14 1 4.96E-23 3.36E-20 8.24E-15 1.11E-18 1.28E-13 4.96E-23 1 2.87E-09 1.28E-13 
CYTH4 1 1 5.85E-10 0.001873 1 2.75E-14 1.44E-17 2.75E-14 1 8.24E-14 8.24E-14 4.12E-18 1 2.75E-14 3.84E-17 1 1 2.75E-14 
ZNF420 7.67E-11 8.11E-23 7.37E-06 1 1 1.16E-29 1 8.11E-23 1 2.53E-11 7.43E-22 4.50E-17 7.56E-19 2.09E-25 6.05E-16 1.15E-12 1.76E-09 1 
NOSIP 8.24E-14 1.06E-14 1.02E-09 0.002248 3.84E-13 6.92E-13 1 1.37E-15 5.85E-10 2.75E-14 1 1.76E-06 5.85E-10 7.03E-07 0.002248 1 1.64E-09 1 
TEX264 2.75E-14 3.84E-17 8.24E-14 1.64E-09 6.92E-13 1.68E-11 1.92E-13 1 1 1 1 1 1.02E-09 2.93E-10 3.92E-12 1 4.12E-18 1 
SLC25A46 1 4.81E-15 5.12E-10 0.003495 8.41E-21 5.12E-10 0.003058 1 4.48E-13 1 1 1 6.41E-14 1 1.94E-13 1.79E-09 1 1 
TIMM50 2.87E-09 4.59E-06 1.34E-16 1 1.61E-12 7.37E-06 1 6.14E-09 5.12E-10 4.48E-13 0.004803 0.004367 5.12E-10 1.79E-09 0.003931 8.96E-13 1.79E-09 0.003058 
MXD3 1 4.12E-18 1 1.17E-06 3.84E-17 1.02E-09 4.12E-18 1.92E-13 6.86E-19 1 1 1.02E-09 1.44E-17 0.001873 1 2.93E-10 1.73E-16 2.75E-14 
BAG4 8.24E-14 1.73E-16 1 2.93E-10 2.75E-14 1 1 1 1 3.84E-13 8.65E-17 8.65E-17 4.12E-18 1 1 1 1 1 
APRT 1 2.72E-12 1 1 1.92E-13 0.001499 3.17E-16 1 4.12E-18 1 1 1.76E-06 3.17E-16 6.92E-13 1 1 8.24E-14 1.17E-10 
MRPL51 1 8.65E-17 8.24E-14 1 5.85E-10 1 1 1 1 2.93E-10 1.64E-09 1.92E-13 2.93E-10 1 1 8.24E-14 1 1 
YME1L1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1.17E-06 1 1 1 
KRIT1 1 1 1 2.75E-14 1.44E-17 1 5.85E-10 1 1 1 1.92E-13 2.93E-10 2.93E-11 1 6.92E-13 1.44E-17 1 1 
CD3E 6.86E-19 4.12E-18 6.86E-19 6.86E-19 2.75E-14 1 1 1 1 2.75E-14 4.12E-18 6.86E-19 1 6.86E-19 4.12E-18 6.86E-19 4.12E-18 2.75E-14 
ARHGAP5 1 2.75E-14 1 3.28E-06 1.76E-06 5.85E-10 1 1 1 0.002248 0.002622 1 2.75E-14 1 3.84E-13 1 1 1 
BUB1B 1 1 1 1.17E-06 1 1 1 6.86E-19 1 6.86E-19 6.86E-19 6.86E-19 6.86E-19 6.86E-19 6.86E-19 6.86E-19 1 1 
MRPL38 6.86E-19 8.65E-17 8.65E-17 1 3.84E-17 1.17E-06 2.93E-10 0.001499 3.84E-13 1 5.85E-10 1.73E-16 2.75E-14 8.24E-14 0.001873 1 8.24E-14 1 
TATDN1 1 3.51E-09 1 0.011568 6.86E-19 1 1 1 6.86E-19 1.81E-12 1.15E-12 3.28E-06 1 1 1 1 1 1 
FCGR2A 3.51E-09 1 2.06E-15 1.73E-16 6.43E-09 4.21E-06 1.81E-12 3.84E-17 1 1.73E-16 1.15E-12 2.06E-15 6.86E-19 3.51E-09 1 1 9.12E-06 7.72E-06 
ABCE1 2.75E-14 5.85E-10 1 1.17E-06 1 1 1 0.001873 1 1 1 1 1 1 6.86E-19 1 1 1 
PSMD4 3.51E-09 1.44E-17 6.86E-19 1 6.86E-19 5.49E-15 1 1 4.12E-18 1.81E-12 3.28E-06 1.44E-17 6.86E-19 6.86E-19 0.002996 6.86E-19 1 0.001499 
MT1E 2.75E-14 1 1 2.93E-10 1 6.86E-19 1 1 1.44E-17 2.75E-14 1 1.44E-17 4.12E-18 4.12E-18 1 1 2.93E-10 1 
C11orf83 6.86E-19 5.85E-10 1 1 4.12E-18 1.18E-07 8.24E-14 2.75E-14 6.86E-19 1 1 3.92E-12 2.75E-14 1.31E-11 1 1 3.22E-10 1 







Table D.1 The Single Cell Consensus Gene-Expression Attractors 
Rank Macrophage Score B cell Score T cell Score Endothelium Score  Fibroblast Score Stemness Score Mitosis Score 
1 CSF1R 0.71 MS4A1 0.93 CD2 0.90 ECSCR 0.95 COL3A1 0.64 SPARC 0.97 AURKB 0.53 
2 CD163 0.56 CD79A 0.52 CD3D 0.56 VWF 0.46 LUM 0.61 AEBP1 0.45 ASPM 0.53 
3 CD14 0.54 CD22 0.44 CD3E 0.49 TM4SF18 0.31 ISLR 0.54 CALD1 0.41 BIRC5 0.53 
4 LILRB4 0.52 PAX5 0.39 CD3G 0.34 PLVAP 0.29 COL5A1 0.51 CAV1 0.29 TOP2A 0.50 
5 FCGR1A 0.51 CD79B 0.34 FYB 0.30 ELTD1 0.27 DCN 0.51 FSTL1 0.24 PBK 0.49 
6 MSR1 0.49 IRF8 0.33 ITM2A 0.28 RAMP2 0.26 CDH11 0.46 DLC1 0.24 CDCA8 0.45 
7 C1QA 0.47 BANK1 0.33 CD96 0.28 LDB2 0.25 THY1 0.44 CTSK 0.24 KIF2C 0.45 
8 HCK 0.46 CD19 0.32 TIGIT 0.27 ROBO4 0.24 BGN 0.43 TIMP3 0.23 CKAP2L 0.43 
9 C1QC 0.45 VPREB3 0.31 IL2RG 0.27 MYCT1 0.24 FBN1 0.43 NNMT 0.23 TPX2 0.43 
10 VSIG4 0.45 WDFY4 0.30 ITK 0.25 SDPR 0.23 MFAP4 0.41 NID1 0.22 NCAPG 0.43 
11 MS4A4A 0.44 ADAM28 0.30 SLA 0.25 CALCRL 0.23 PDGFRA 0.41 LAMA4 0.21 MKI67 0.42 
12 FPR1 0.44 FCRL1 0.27 PTPRC 0.24 CCL21 0.23 EFEMP1 0.39 CYBRD1 0.21 CDC20 0.42 
13 CSF3R 0.43 HLA-DRA 0.27 SRGN 0.24 MMRN1 0.23 COL1A1 0.38 DDR2 0.20 CDK1 0.42 
14 SLCO2B1 0.41 TCL1A 0.26 IL32 0.24 CLDN5 0.23 COL14A1 0.36 PTPRS 0.20 KIFC1 0.42 
15 IGSF6 0.40 STAP1 0.25 PRF1 0.23 FABP4 0.22 MXRA8 0.35 A2M 0.20 DLGAP5 0.41 
16 TYROBP 0.40 HLA-DQB1 0.25 GZMA 0.23 CDH5 0.22 PLAC9 0.34 RBMS3 0.19 NUF2 0.41 
17 C3AR1 0.40 CR2 0.24 IL2RB 0.23 ARHGEF15 0.22 DPT 0.33 LRP1 0.19 BUB1 0.39 
18 PLXDC2 0.40 CD74 0.23 PYHIN1 0.22 SHANK3 0.21 FGF7 0.33 COL6A1 0.18 CCNB2 0.39 
19 FPR3 0.39 TCF4 0.22 SH2D1A 0.22 LYVE1 0.21 COL6A3 0.33 CTHRC1 0.18 BUB1B 0.38 


































Figure E.2 Heat map of the associations of the gene expression consensus-attractor signatures. 
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Table E.1 Concordance Indices of the Attractor Signatures in the TCGA PanCanAtlas Data Sets 
Attractor BLCA BRCA CESC COAD HNSC KIRC KIRP LGG LIHC LUAD LUSC PRAD SARC SKCM STAD THCA UCEC 
Leukocyte 0.48 0.45 0.39 0.50 0.45 0.51 0.48 0.61 0.44 0.41 0.51 0.40 0.41 0.40 0.52 0.45 0.42 
Mitosis 0.53 0.58 0.52 0.44 0.50 0.64 0.81 0.71 0.67 0.60 0.48 0.63 0.61 0.57 0.43 0.49 0.60 
MES 0.56 0.50 0.57 0.57 0.50 0.57 0.74 0.66 0.51 0.55 0.51 0.42 0.53 0.53 0.56 0.60 0.51 
END 0.52 0.49 0.51 0.56 0.49 0.41 0.67 0.51 0.40 0.47 0.54 0.36 0.44 0.53 0.59 0.47 0.52 
IFIT 0.50 0.50 0.44 0.53 0.51 0.53 0.57 0.61 0.45 0.49 0.50 0.33 0.41 0.39 0.52 0.41 0.57 
CCNT1 0.53 0.45 0.57 0.42 0.49 0.39 0.53 0.52 0.50 0.52 0.51 0.44 0.53 0.51 0.44 0.51 0.48 
NDUFB7 0.48 0.54 0.45 0.54 0.51 0.59 0.48 0.46 0.46 0.52 0.47 0.60 0.47 0.53 0.48 0.46 0.49 
AHSA2 0.39 0.44 0.49 0.55 0.46 0.55 0.41 0.50 0.46 0.45 0.48 0.79 0.49 0.49 0.50 0.55 0.52 
MP 0.51 0.44 0.44 0.53 0.47 0.56 0.57 0.32 0.49 0.46 0.52 0.42 0.46 0.43 0.50 0.50 0.44 
MM  0.49 0.55 0.56 0.50 0.53 0.45 0.49 0.30 0.52 0.55 0.49 0.58 0.55 0.55 0.48 0.48 0.59 
PIP5K1P1 0.47 0.55 0.49 0.49 0.54 0.59 0.45 0.52 0.47 0.52 0.48 0.35 0.55 0.48 0.50 0.45 0.40 
WDR36 0.50 0.45 0.40 0.62 0.49 0.57 0.58 0.57 0.61 0.47 0.51 0.34 0.50 0.51 0.45 0.58 0.55 
RPL14 0.55 0.44 0.53 0.57 0.51 0.47 0.49 0.48 0.57 0.50 0.52 0.35 0.49 0.48 0.50 0.61 0.57 
SNORD116 0.48 0.54 0.45 0.53 0.47 0.43 0.38 0.57 0.54 0.45 0.49 0.41 0.47 0.45 0.52 0.44 0.47 
ABCE1 0.49 0.56 0.58 0.41 0.50 0.48 0.46 0.42 0.38 0.50 0.51 0.62 0.47 0.48 0.57 0.51 0.47 
LINC00937 0.47 0.51 0.51 0.56 0.54 0.48 0.42 0.28 0.51 0.45 0.51 0.52 0.44 0.51 0.51 0.40 0.54 
RAB1A 0.53 0.43 0.44 0.57 0.48 0.47 0.58 0.54 0.57 0.49 0.52 0.38 0.45 0.47 0.46 0.60 0.52 
CDKN1C 0.46 0.54 0.57 0.57 0.51 0.53 0.50 0.47 0.43 0.50 0.49 0.79 0.50 0.48 0.51 0.47 0.48 
DLK1-DIO3 0.56 0.49 0.50 0.54 0.57 0.47 0.69 0.59 0.52 0.56 0.51 0.31 0.54 0.53 0.54 0.63 0.50 
miR-199a 0.54 0.50 0.44 0.58 0.50 0.53 0.67 0.57 0.46 0.49 0.49 0.40 0.55 0.51 0.56 0.64 0.50 
chrXq27 0.51 0.54 0.47 0.51 0.49 0.38 0.49 0.45 0.47 0.46 0.50 0.52 0.51 0.56 0.51 0.53 0.61 
miR-451  0.47 0.47 0.59 0.41 0.51 0.39 0.36 0.58 0.46 0.50 0.47 0.51 0.47 0.53 0.49 0.34 0.46 
miR-99a 0.56 0.47 0.40 0.57 0.41 0.46 0.35 0.42 0.41 0.42 0.45 0.32 0.43 0.51 0.55 0.48 0.55 
miR-200 0.45 0.50 0.49 0.37 0.46 0.44 0.32 0.65 0.50 0.44 0.46 0.54 0.47 0.51 0.44 0.44 0.43 
Let-7a 0.50 0.43 0.50 0.59 0.53 0.53 0.47 0.43 0.50 0.52 0.53 0.38 0.46 0.42 0.52 0.74 0.35 
miR-194 0.43 0.50 0.47 0.41 0.47 0.37 0.43 0.40 0.45 0.54 0.51 0.60 0.41 0.47 0.43 0.45 0.44 
miR-17 0.47 0.48 0.57 0.41 0.49 0.53 0.52 0.38 0.50 0.53 0.50 0.71 0.57 0.53 0.47 0.46 0.56 
GIMAP4 0.47 0.44 0.39 0.51 0.45 0.39 0.58 0.46 0.38 0.42 0.52 0.39 0.39 0.39 0.53 0.39 0.43 
HLA 0.47 0.45 0.38 0.51 0.47 0.48 0.44 0.66 0.45 0.39 0.51 0.40 0.43 0.38 0.51 0.43 0.42 
SLAMF 0.46 0.39 0.36 0.49 0.43 0.50 0.50 0.62 0.42 0.42 0.49 0.42 0.41 0.39 0.51 0.34 0.40 
ATP5D 0.48 0.54 0.44 0.54 0.50 0.56 0.41 0.45 0.46 0.50 0.47 0.59 0.49 0.54 0.49 0.47 0.46 
LILR 0.50 0.53 0.42 0.50 0.48 0.57 0.47 0.59 0.49 0.46 0.54 0.44 0.45 0.40 0.51 0.39 0.50 
NUBP2 0.48 0.54 0.45 0.51 0.52 0.59 0.49 0.44 0.46 0.51 0.48 0.61 0.47 0.52 0.44 0.55 0.52 
COPE 0.50 0.53 0.43 0.55 0.49 0.60 0.51 0.51 0.52 0.50 0.49 0.66 0.50 0.54 0.48 0.43 0.51 
AURKAIP1 0.51 0.56 0.51 0.47 0.52 0.62 0.44 0.59 0.51 0.50 0.53 0.55 0.55 0.56 0.49 0.54 0.53 
GPS1 0.50 0.50 0.49 0.44 0.53 0.65 0.54 0.50 0.51 0.52 0.49 0.62 0.52 0.55 0.49 0.56 0.56 
SHARPIN 0.49 0.56 0.56 0.51 0.53 0.64 0.59 0.40 0.54 0.52 0.52 0.54 0.56 0.52 0.46 0.58 0.55 
HIST1H4H 0.47 0.49 0.44 0.58 0.51 0.57 0.57 0.62 0.48 0.52 0.50 0.51 0.51 0.54 0.49 0.47 0.50 
SSNA1 0.51 0.57 0.48 0.60 0.51 0.58 0.46 0.48 0.51 0.50 0.51 0.55 0.48 0.53 0.47 0.47 0.45 
GADD45GIP1 0.48 0.51 0.42 0.55 0.50 0.60 0.51 0.44 0.47 0.51 0.47 0.60 0.47 0.52 0.48 0.45 0.52 
MRPL2 0.50 0.55 0.47 0.49 0.52 0.60 0.56 0.43 0.48 0.50 0.48 0.52 0.59 0.54 0.49 0.38 0.56 
POLR2I 0.47 0.54 0.48 0.52 0.50 0.59 0.45 0.50 0.48 0.54 0.49 0.71 0.47 0.54 0.48 0.46 0.56 
SIGLEC 0.52 0.55 0.45 0.49 0.51 0.52 0.47 0.60 0.50 0.45 0.54 0.39 0.46 0.41 0.49 0.45 0.50 
BUD31 0.48 0.56 0.50 0.54 0.54 0.66 0.50 0.61 0.52 0.54 0.48 0.52 0.51 0.50 0.50 0.54 0.52 
ZNF28 0.46 0.49 0.58 0.44 0.47 0.39 0.44 0.60 0.58 0.53 0.52 0.56 0.53 0.51 0.50 0.43 0.51 
PIN1 0.48 0.54 0.48 0.52 0.50 0.63 0.53 0.51 0.49 0.50 0.47 0.71 0.46 0.55 0.43 0.49 0.57 
DPM2 0.54 0.59 0.49 0.56 0.53 0.57 0.38 0.50 0.49 0.49 0.52 0.66 0.46 0.55 0.47 0.45 0.46 
ZNHIT1 0.47 0.56 0.51 0.55 0.53 0.63 0.45 0.52 0.47 0.51 0.49 0.52 0.49 0.53 0.46 0.57 0.54 
ZNF225 0.42 0.42 0.50 0.46 0.47 0.41 0.45 0.58 0.49 0.55 0.44 0.60 0.48 0.50 0.45 0.44 0.50 
CLTC 0.53 0.45 0.56 0.42 0.51 0.43 0.63 0.48 0.55 0.52 0.51 0.40 0.54 0.49 0.46 0.42 0.52 
PSMB6 0.53 0.54 0.44 0.52 0.51 0.57 0.27 0.40 0.43 0.51 0.54 0.47 0.49 0.52 0.52 0.39 0.47 
ZNF579 0.45 0.53 0.54 0.57 0.54 0.61 0.53 0.52 0.51 0.54 0.48 0.71 0.54 0.54 0.48 0.54 0.53 
INO80E 0.48 0.53 0.43 0.50 0.49 0.61 0.50 0.44 0.49 0.49 0.46 0.61 0.43 0.51 0.48 0.58 0.50 
SSSCA1 0.52 0.57 0.48 0.52 0.54 0.64 0.52 0.44 0.51 0.52 0.50 0.57 0.49 0.49 0.47 0.42 0.54 
ZNF134 0.47 0.44 0.63 0.48 0.50 0.36 0.36 0.57 0.51 0.52 0.46 0.67 0.52 0.53 0.52 0.47 0.54 
CYTH4 0.48 0.44 0.42 0.49 0.46 0.55 0.52 0.60 0.47 0.43 0.51 0.41 0.42 0.41 0.51 0.45 0.41 
ZNF420 0.46 0.45 0.51 0.46 0.47 0.38 0.45 0.54 0.51 0.48 0.52 0.47 0.52 0.50 0.52 0.50 0.54 
NOSIP 0.45 0.54 0.48 0.55 0.51 0.61 0.48 0.57 0.51 0.51 0.47 0.74 0.54 0.53 0.49 0.50 0.51 
TEX264 0.48 0.51 0.48 0.44 0.51 0.62 0.35 0.49 0.49 0.45 0.49 0.51 0.48 0.51 0.44 0.52 0.51 
SLC25A46 0.54 0.46 0.57 0.43 0.49 0.35 0.56 0.58 0.47 0.52 0.52 0.29 0.50 0.46 0.52 0.61 0.43 
TIMM50 0.52 0.55 0.52 0.52 0.51 0.66 0.53 0.54 0.53 0.56 0.47 0.59 0.51 0.58 0.49 0.48 0.63 
MXD3 0.48 0.54 0.47 0.51 0.49 0.57 0.57 0.49 0.55 0.52 0.48 0.70 0.48 0.52 0.50 0.56 0.55 
BAG4 0.49 0.48 0.50 0.44 0.46 0.42 0.54 0.43 0.49 0.51 0.42 0.28 0.53 0.49 0.47 0.48 0.52 
APRT 0.49 0.56 0.49 0.55 0.54 0.60 0.41 0.41 0.47 0.50 0.52 0.69 0.49 0.54 0.48 0.52 0.50 
MRPL51 0.52 0.54 0.56 0.51 0.51 0.64 0.56 0.39 0.56 0.55 0.44 0.57 0.57 0.54 0.48 0.53 0.55 
YME1L1 0.50 0.53 0.51 0.49 0.47 0.44 0.60 0.27 0.52 0.51 0.48 0.40 0.52 0.44 0.47 0.47 0.43 
KRIT1 0.49 0.42 0.54 0.46 0.47 0.41 0.39 0.53 0.49 0.50 0.46 0.48 0.49 0.46 0.50 0.58 0.46 
CD3E 0.45 0.40 0.35 0.50 0.43 0.51 0.49 0.62 0.45 0.42 0.51 0.44 0.42 0.39 0.51 0.41 0.37 
ARHGAP5 0.56 0.42 0.53 0.42 0.51 0.39 0.50 0.40 0.50 0.53 0.48 0.42 0.53 0.47 0.52 0.51 0.43 
BUB1B 0.56 0.59 0.51 0.47 0.50 0.59 0.77 0.67 0.61 0.62 0.46 0.64 0.56 0.54 0.45 0.45 0.52 
MRPL38 0.49 0.48 0.45 0.42 0.52 0.64 0.49 0.44 0.51 0.50 0.48 0.71 0.53 0.54 0.45 0.39 0.56 
TATDN1 0.53 0.60 0.53 0.45 0.54 0.65 0.59 0.33 0.54 0.56 0.50 0.59 0.57 0.50 0.46 0.52 0.59 
 129 
FCGR 0.52 0.55 0.44 0.53 0.50 0.59 0.47 0.65 0.50 0.45 0.54 0.39 0.46 0.39 0.51 0.45 0.51 
ABCE1 0.51 0.48 0.56 0.41 0.52 0.44 0.56 0.57 0.52 0.54 0.49 0.62 0.53 0.49 0.47 0.55 0.40 
PSMD4 0.49 0.57 0.50 0.54 0.51 0.67 0.69 0.45 0.60 0.54 0.48 0.59 0.53 0.53 0.51 0.50 0.55 
MT1 0.56 0.50 0.55 0.52 0.56 0.59 0.44 0.59 0.44 0.52 0.53 0.57 0.50 0.47 0.51 0.49 0.57 
C11orf83 0.51 0.53 0.51 0.53 0.54 0.65 0.55 0.36 0.53 0.55 0.49 0.58 0.51 0.51 0.48 0.47 0.52 
ZNF615 0.40 0.49 0.58 0.43 0.47 0.40 0.44 0.55 0.52 0.50 0.49 0.64 0.52 0.51 0.52 0.43 0.47 
 
The values are the concordance index score of the association of the signature with the 
patient’s overall survival. The blue, white, and red colors indicate that the associations are 





Appendix F Cell-Specific Expression of the Single Cell Consensus 
Attractors 
 
Figure F.1 Heat map of the single cell consensus attractors in the melanoma data set. 
 
 




Figure F.3 Heat map of the single cell consensus attractors in the colorectal cancer data set. 
 
 
Figure F.4 Heat map of the single cell consensus attractors in the oligodendroglioma data set. 
 
